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Abstract  
Lithium is currently licensed for the treatment and prophylaxis of recurrent affective 
disorders, treatment of bipolar depression where the use of antidepressants has been 
ineffective, and the treatment of aggressive or self-mutilating behaviour. Lithium requires 
therapeutic drug monitoring (TDM) during treatment and evidence is lacking to support 
the recommended monitoring frequencies of lithium levels. A retrospective analysis of a 
monitoring database was run to establish the association of single and double exposures 
of various lithium levels on renal function. Interviews were also conducted with 
prescribers to establish the factors affecting prescribing decisions related to lithium. 
This study suggests there is a short-term negative association on renal function after 
exposures to single, high lithium levels but due to the small patient groups in the multiple 
exposures analysis the results from this are not statistically reliable. These results did, 
however, raise the considerations that changes in lithium levels may impact on renal 
function. 
This work added to the factors influencing prescribing decisions surrounding knowledge, 
learning and competence of prescribers with concerns around a lack of knowledge of 
older drugs seen in newer doctors. Guidance surrounding at what points during the 
patient’s journey the initial prescribing choice and a decision should be made is also 
needed. This would help overcome the barrier of split services within mental health and 
give clearer roles to the various consultants involved in a patient’s care and aid in the 
involvement of the patient with their treatment.  
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The roll out of a centralised lithium monitoring system with access for all those involved 
in the patients care could be considered to aid in the long-term monitoring of lithium. . 
This sort of system would also allow for all those involved being able to retain oversight 
over patients whether or not they are still directly under their care.  
  
 iv 
 
Contents  
Abstract ........................................................................................................................... ii 
Contents .......................................................................................................................... iv 
List of figures ................................................................................................................ viii 
List of tables .................................................................................................................. ix 
List of Appendices ......................................................................................................... xi 
Glossary ........................................................................................................................ xii 
Acknowledgements ..................................................................................................... xiv 
1: Introduction to lithium ................................................................................................ 2 
1.1 General introduction .................................................................................................................. 2 
1.2 Discovery and the 1800s .......................................................................................................... 4 
1.3 Initial use in psychiatry and the recognition of bipolar disorder ................................................ 5 
1.4 The 1900s to present day ......................................................................................................... 7 
1.5  Main proposed mechanism(s) of action of lithium as a mood stabiliser ................................ 10 
1.5.1 The ionic mechanism ....................................................................................................... 10 
1.5.2 Effects on neurotransmitter signalling.............................................................................. 12 
1.5.3 Effects on the adenyl cyclase system, inositol phosphate and protein kinase C signalling13 
1.5.4 Arachidonic acid metabolism ........................................................................................... 15 
1.5.5 Neuroprotective and neuroproliferative effects through preservation of grey matter ...... 15 
1.6 Pharmacokinetics of lithium .................................................................................................... 17 
1.7 Lithium’s effects on the kidney ................................................................................................ 18 
1.7.1. Effects on tubular function .............................................................................................. 19 
1.7.2. Effects on glomerular function ........................................................................................ 19 
1.8  Therapeutic drug monitoring .................................................................................................. 20 
1.9 Serum lithium analysis ............................................................................................................ 23 
1.10 Diagnosis, treatment and management of bipolar disorder .................................................. 25 
1.11 Decision making in the prescribing of lithium ........................................................................ 27 
1.12 Conclusion ............................................................................................................................ 28 
2: Literature review ....................................................................................................... 31 
2.1 Literature review background.................................................................................................. 31 
2.2 Aims and Objectives ............................................................................................................... 33 
2.3 Methods .................................................................................................................................. 34 
2.4 Included studies ...................................................................................................................... 35 
2.4.1. Development of a therapeutic lithium level ..................................................................... 35 
2.4.2. Development of recommended monitoring frequency for lithium ................................... 36 
2.4.3. Renal effects of lithium.................................................................................................... 36 
2.5 Excluded studies ..................................................................................................................... 38 
 v 
 
2.5.1. Development of a therapeutic lithium level ..................................................................... 38 
2.5.2. Development of recommended monitoring frequency for lithium ................................... 38 
2.5.3. Renal effects of lithium.................................................................................................... 39 
2.6 Results .................................................................................................................................... 40 
2.6.1. Development of therapeutic lithium level ........................................................................ 40 
2.6.2. Development of recommended monitoring frequency for lithium ................................... 45 
2.6.3. Renal effects of lithium.................................................................................................... 48 
2.7 Discussion ............................................................................................................................... 58 
2.7.1. Therapeutic level ............................................................................................................. 58 
2.7.2. Monitoring parameters .................................................................................................... 61 
2.7.3. Renal effects ................................................................................................................... 62 
2.8 Conclusion .............................................................................................................................. 64 
3: An evaluation of the impact of active management of lithium monitoring within 
Norfolk ........................................................................................................................... 67 
3.1 Introduction ............................................................................................................................. 67 
3.2 Standards of lithium monitoring in the UK .............................................................................. 69 
3.3 Patient safety alert .................................................................................................................. 72 
3.4 Implementation of the Norfolk-wide database ........................................................................ 73 
3.5 Aims and Objectives ............................................................................................................... 75 
3.5.1. Aim .................................................................................................................................. 75 
3.5.2. Objectives ....................................................................................................................... 75 
3.6 Methods .................................................................................................................................. 76 
3.6.1. Data extraction ................................................................................................................ 76 
3.7 Service evaluation results ....................................................................................................... 79 
3.7.1.  Rates of testing .............................................................................................................. 79 
3.7.2. Speed of response to lithium levels outside of the recommended range ....................... 81 
3.8 Discussion ............................................................................................................................... 83 
3.8.1. Strengths and Limitations ............................................................................................... 84 
3.9 Conclusion .............................................................................................................................. 85 
4: Factors affecting lithium prescribing ...................................................................... 87 
4.1 Introduction ............................................................................................................................. 87 
4.2 Current beliefs about decision making in prescribing ............................................................. 88 
4.3 Aims and objectives ................................................................................................................ 92 
4.3.1. Aim .................................................................................................................................. 92 
4.3.2. Objectives ....................................................................................................................... 92 
4.4 Interview rationale ................................................................................................................... 93 
4.5 Interviews method ................................................................................................................... 95 
4.5.1. Participant recruitment .................................................................................................... 95 
4.5.2. Participant selection ........................................................................................................ 96 
4.5.3. Topic guide ..................................................................................................................... 98 
 vi 
 
4.6 Data analysis .......................................................................................................................... 99 
4.6.1. Thematic analysis ........................................................................................................... 99 
4.7 Results .................................................................................................................................. 103 
4.7.1. Knowledge and experience of prescribers ................................................................... 104 
4.7.2. Drug factors .................................................................................................................. 107 
4.7.3. Patient factors and patient information ......................................................................... 112 
4.7.4. Setting for initiation and the monitoring process ........................................................... 116 
4.8 Interviews discussion ............................................................................................................ 124 
4.8.1. Strengths and Limitations ............................................................................................. 129 
4.9 Conclusion ............................................................................................................................ 131 
5: An analysis of a management database for the relationship between lithium 
levels and monitoring parameters............................................................................. 134 
5.1 Background ........................................................................................................................... 134 
5.2 Aims and Objectives ............................................................................................................. 136 
5.2.1. Aim ................................................................................................................................ 136 
5.2.2. Objective ....................................................................................................................... 136 
5.3 Methods ................................................................................................................................ 137 
5.3.1. Data modelling .............................................................................................................. 138 
5.3.2. Statistical analysis......................................................................................................... 140 
5.4 Results .................................................................................................................................. 143 
5.4.1. Inclusion and exclusion criteria ..................................................................................... 143 
5.5 Discussion ............................................................................................................................. 147 
5.5.1. Strengths and limitations .............................................................................................. 149 
5.6 Conclusion ............................................................................................................................ 150 
6: A longitudinal analysis of a monitoring database for the relationship of multiple 
lithium levels on estimated glomerular filtration rate. ............................................. 152 
6.1 Background ........................................................................................................................... 152 
6.2 Aims and Objectives ............................................................................................................. 154 
6.2.1. Aim ................................................................................................................................ 154 
6.2.2. Objectives ..................................................................................................................... 154 
6.3 Methods ................................................................................................................................ 155 
6.3.1. Data modelling .............................................................................................................. 155 
6.3.2. Inclusion and exclusion criteria ..................................................................................... 156 
6.3.3. Statistical analysis......................................................................................................... 157 
6.4 Results .................................................................................................................................. 159 
6.4.1. Findings from individual cases ...................................................................................... 161 
6.5 Discussion ............................................................................................................................. 164 
6.5.1. Strengths and limitations .............................................................................................. 165 
6.6 Conclusion ............................................................................................................................ 167 
7: Discussion and Conclusion. .................................................................................. 169 
 vii 
 
7.1 Overall discussion ................................................................................................................. 169 
7.2 Conclusions .......................................................................................................................... 176 
7.3 Publications and conferenced proceedings arising from the thesis ..................................... 179 
7.4 Recommendations for future work ........................................................................................ 181 
8: References .............................................................................................................. 183 
 
  
 viii 
 
List of figures  
Figure 5.1: Process of sample selection for eGFR analysis ................................................144 
 ix 
 
List of tables  
Table 2.1: Results of included studies - Development of therapeutic lithium levels .... 41-43 
Table 2.2: Results of included studies - Recommended monitoring frequency for lithium
 ........................................................................................................................................ 46-47 
Table 2.3: Results of included studies - Renal effects of lithium ................................... 49-55 
Table 3.1: POMH-UK data - Lithium monitoring tests or measures conducted during 
maintenance treatment. ...................................................................................................... 71 
Table 3.2: Lithium level tests conducted on registered patients between Jan 1st –Dec 31st 
2005, Jan 1st –Dec 31st 2009 and Jan 1st –Dec 31st 2012 ...................................................... 79 
Table 3.3: Creatinine tests conducted on all registered patients between Jan 1st –Dec 31st 
2005, Jan 1st –Dec 31st 2009 and Jan 1st –Dec 31st 2012 ...................................................... 80 
Table 3.4: Thyroid function tests conducted on all registered patients between Jan 1st –
Dec 31st 2005, Jan 1st –Dec 31st 2009 and Jan 1st –Dec 31st 2012 ........................................ 80 
Table 3.5: Number of tests recorded as >1.0mmol/L and the times taken for a retest in 
2005, 2009, and 2012. .......................................................................................................... 81 
Table 3.6: Time to next lithium level <1.0mmol/L after a level >1.0mmol/L has been 
reported in 2005, 2009, and 2012... .................................................................................... 82 
Table 4.1: Stages of thematic analysis ...............................................................................101 
Table 4.2: Participant demographics .................................................................................103 
Table 5.1: Detail of control and exposure groups used in this analysis ............................141 
Table 5.2: Single exposure baseline demographics ...........................................................145 
Table 5.3: Single exposure baseline demographics by exposure group ............................145 
Table 5.4: Random effects repeated measures mixed model to predict eGFR, adjusting for 
baseline eGFR. ....................................................................................................................146 
 x 
 
Table 6.1: Double exposure analysis baseline demographics ...........................................159 
Table 6.2: Double exposure analysis baseline demographics by exposure group ............160 
Table 6.3: Random effects repeated measures mixed model to predict eGFR, adjusting for 
baseline eGFR .....................................................................................................................161 
Table 6.4: Individual case data for selection of patients in each pattern group ...............162 
 
  
 xi 
 
List of Appendices  
1 Protocol for: What is the role of lithium monitoring? A retrospective analysis of 
a lithium monitoring database 
2 NHS R&D review outcome for: What is the role of lithium monitoring? A 
retrospective analysis of a lithium monitoring database  
3 NHS R&D review approval for: What is the role of lithium monitoring? A 
retrospective analysis of a lithium monitoring database 
4 Protocol and study documentation for: Factors affecting lithium prescribing: 
views and perceptions of consultants on current practice 
5 NHS R&D review outcome for: Factors affecting lithium prescribing: views and 
perceptions of consultants on current practice 
6 NHS R&D review approval for: Factors affecting lithium prescribing: views and 
perceptions of consultants on current practice 
7 Substantial amendment for: Factors affecting lithium prescribing: views and 
perceptions of consultants on current practice 
8 FMH ethics committee review outcome for: Factors affecting lithium 
prescribing: views and perceptions of consultants on current practice, post 
substantial amendment 
9 FMH ethics committee review approval for: Factors affecting lithium 
prescribing: views and perceptions of consultants on current practice 
10 NHS R&D review approval for: Factors affecting lithium prescribing: views and 
perceptions of consultants on current practice, post substantial amendment 
11 Interviews topic guide (summary version) 
12 Example of coding table 
  
 xii 
 
Glossary  
5HT Serotonin 
51Cr-EDTA 51Cr-EDTA = chromium-51 labeled ethylenediamine tetraacetic acid 
AA Arachidonic acid 
AAS Atomic absorption spectrophotometry 
ACE inhibitor Angiotensin-converting-enzyme inhibitor 
AMI Affective morbidity index 
AMPT Α-methyl-p-tyrosine 
AQP2 Aquaporin-2 
ATPase Adenosinetriphosphatase 
BAP British Association for Psychopharmacology 
Bcl-2 B-cell lymphoma/leukaemia 2-gene 
BNF British National Formulary 
BPRS Brief Psychiatric Rating Scale 
cAMP Cyclic adenosine 3’,5’-monophosphate 
CCG Clinical Commissioning Group 
CKD Chronic Kidney disease 
CNS Central nervous system 
COX-2 Cyclooxygenase-2 
CrCl Creatinine clearance 
DSM Diagnostic and Statistical Manual of Mental Disorders: 
eGFR Estimated glomerular filtration rate 
EPAC Exchange protein activated by cAMP 
FDA Food and Drug Administration 
FES Flame emission spectroscopy 
FSGS Focal global and segmental glomerulosclerosis 
GABA Gamma-aminobutyric-acid 
GFR Glomerular filtration rate 
GP General Practitioner 
GSK3β Glycogen synthase kinase-3, β-isoform 
GTP Guanine triphosphate 
 xiii 
 
ICD International Classification of Diseases 
IMPase Inositol monophosphatase 
Li-ISE Lithium-ion selective electrode technology 
MDRD Modification of Diet in Renal Disease 
mRNA Messenger ribonucleic acid 
NAA N-acetyl-aspartate 
NDI Nephrogenic diabetes insipidus 
NHS National Health Service 
NICE National Institute for Health and Clinical Excellence 
NMDA N-methyl-D-aspartate 
NNUH Norfolk and Norwich University Hospital 
NPSA National Patient Safety Agency 
NRLS National Reporting and Learning System 
NSAID Non-steroidal anti-inflammatory drug 
NSFT Norfolk and Suffolk NHS Foundation Trust 
NTR Narrow therapeutic range 
PCT Primary Care Trust 
PKC Protein kinase C 
PLA2 Phospholipase-A2 
POMH-UK Prescribing Observatory for Mental Health UK 
Primary researcher PhD student 
QIP Quality Improvement Programme 
QOF Quality and Outcomes Framework 
REC Research Ethics Committee 
RPsychCCQI Royal College of Psychiatrists College Centre for Quality 
Improvement 
SIGN Scottish Intercollegiate Guidelines Network 
T4 Thyroxine 
TDM Therapeutic Drug Monitoring 
TSH Thyroid Stimulating hormone 
UMax Urinary concentrating ability 
WMD Weighted mean difference 
 xiv 
 
Acknowledgements   
I’ve always been torn between my love of the arts and my love of science, I wanted to 
find some wonderful quotation which combined the two but nothing seemed quite right. I 
do know however that this would have been a different piece of work without me being 
able to draw on my skills from both of my loves as a part of who you are always goes into 
a piece of research like this. To anyone who is torn between the arts and science, you 
CAN do both! 
 
James thank you supporting me, taking over being my primary supervisor early on and 
letting me progress on my own but still knowing when to give that but of extra time and 
support when needed. You have let me grow as a researcher, person, student and tutor 
at various times over the years. Thank you. 
 
To Michael and Jane, thank you for helping me through the two very different arms of my 
PhD with complicated data analysis and a very different but equally challenging 
qualitative aspect. 
 
Thank you to Steve and Tim for seeing promise in me from the start and supporting me 
clinically through the ups and downs of a constantly evolving clinically focussed PhD in a 
changing health service. 
 
To all the other PhD students who have finished and those just starting within Pharmacy 
Practice – for support and chats about anything other than our various theses! 
 xv 
 
 
To the rest of the pharmacy practice team, thank you for involving me in the provision of 
the pharmacy practice modules throughout my time at UEA, it has been a thoroughly 
enjoyable time. 
 
To all my friends in Norwich and further afield – thanks for putting up with me 
disappearing for months during stages of writing up and research and turning up when 
needed with wine and/or gin! You might get me back for a bit now but you know I’m not 
one for a quiet life…however much I claim I’d like one! 
 
To my parents who have always supported me and been my inspiration in life, hopefully 
I’ve produced a lovely coffee table book for you! I would never have been able to come as 
far as I have without knowing that you have always believed in me. During the statistics 
sections of this thesis I was always reminded of Dad trying to impart his magnificent 
maths and science knowledge to me over the years…well some of it must have sunk in. 
 
And finally to Patrick without who I really don’t think I could have got to the end of my 
PhD with the stresses and upheavals that have happened over the past four years. You’re 
my rock and my safe haven (and of course my source of IT support!). Thank you for all of 
your love and support. 
  
 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter One 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
 
1: Introduction to lithium 
1.1 General introduction 
Lithium was initially discovered in the 5th century AD but it did not become routinely used 
in the field of medicine until 1847, when it was used to treat gout. It had no role in 
psychiatry until the late 1800s (Clouston, 1892). During this time clinical trials were not 
performed in the controlled manner as expected today, but small cohort studies were 
conducted by independent physicians in the various hospitals at which they worked. Since 
the 1800s there have been more clinical studies performed which have led to several 
theories about lithium’s mode of action (Marmol, 2008). 
Lithium is currently licensed for the treatment of mania and hypomania, treatment and 
prophylaxis of recurrent affective disorders, treatment of bipolar depression where the 
use of antidepressants has been ineffective, and for the control of aggressive or self-
mutilating behaviour (Norgine, 2011, Rosemont, 2011, Sanofi-Aventis, 2012). The 
National Centre for Health and Care Excellence (NICE) guidelines do not recommend the 
use of lithium in mania or hypomania as an acute treatment and the manufacturers also 
state that treatment with lithium should be focussed on stabilising bipolar disorder rather 
than used to establish control of acute episodes (Norgine, 2011, Rosemont, 2011, Sanofi-
Aventis, 2012, NICE, 2014a).  
Lithium also requires therapeutic drug monitoring (TDM) during treatment. TDM is used 
to prevent toxicity from high blood levels, and to ensure that the therapeutic level is 
maintained above the minimum effective level for the drug. Lithium is initially prescribed 
at a set dose depending on the condition being treated and the age of the patient, and 
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then this dose is adjusted over the first week of treatment to achieve a serum-lithium 
concentration of generally between 0.4-1.0mmol/L (Joint Formulary Committee, 2015). 
The potential for side effects and toxicity from lithium increases at higher blood levels 
and it is not thought to hold efficacy at lower levels. There remains a level of uncertainty 
over the long-term side effects of various lithium levels, specifically on renal function. As 
lithium is primarily renally excreted this is an area of interest due to the potential for 
accumulation with a declining renal function (McKnight et al., 2012). 
Within Norfolk a county-wide therapeutic drug monitoring database was set up to 
improve the standards of lithium monitoring throughout the area following several 
incidents in primary care surrounding lithium therapy and inadequate monitoring 
(Holmes, 2005). The focus of this research is on the impact of this database on lithium 
testing rates and the relationship of a range of lithium levels on renal function, in addition 
to an exploration of doctors’ perspectives of lithium and the factors that influence their 
prescribing practice. 
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1.2 Discovery and the 1800s 
In the 5th century AD a Roman physician recommended the use of alkaline waters to 
people suffering with mental disorders. The beneficial effect of these waters on their 
mental state was thought to be due to the lithium content but further investigation was 
not undertaken at the time (Marmol, 2008). Lithium as an element was discovered by 
Arfwedson, a student of chemistry, in 1817 while he was analysing petalite ore. What he 
found was a lithium aluminium tectosilicate mineral which appeared to form similar 
compounds to those of sodium and potassium (Hu, 2012). Lithium salts however did not 
become recognised in a clinical capacity until the mid-19th century when they started to 
be used to treat gout due to lithium’s ability to dissolve uric acid (Marmol, 2008). Garrod 
had used lithium carbonate as an internal remedy since 1847 for reducing the formation 
of uric acid deposits in patients that he encountered suffering from gout. He noted that in 
those patients who had been administered lithium carbonate the frequency of gout 
attacks reduced. Lipoeitz and Garrod demonstrated that lithium carbonate, once boiled 
with water and added to uric acid, formed the bi-urate of lithium in vitro. This bi-urate of 
lithium is the same salt formed in the blood and tissues of patients with gout (Garrod, 
1859, Clouston, 1892).  At this time the terms ‘gouty or podagrous insanity or mania’ 
started to be used to describe a type of mental illness associated with gout which 
commonly had symptoms including ‘irritability, incapacity for mental exertion, and 
depression’ (Clouston, 1892). It was also noted by Clouston, that in patients suffering 
from gout, ‘deep melancholia is a common accompaniment of the gouty diathesis’, 
suggesting that there was another side to the insanity, presenting mainly with irritability 
and changes in temper (Clouston, 1892). 
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1.3 Initial use in psychiatry and the recognition of bipolar disorder 
In his 1885 treatise, Carl Lange started to formulate the idea of depression and mania 
existing as a cyclical state, this was 14 years before Kraeplin introduced the concept of 
manisch-depressive irresein (manic-depressive insanity) (Schioldann, 2011, Lange, 1885). 
Before this there had been unpublished personal views of several students, and lesser 
known figures in psychiatry at the time on how ‘melancholia’ and mania may be related 
to each other. In 1854 Jules Baillarger coined the term la floie à double forme, which was 
a disease characterised by separate phases of mania and ‘melancholic depression’ 
occurring in regular periods. Two weeks later, as a response to the publication of 
Baillarger’s theory, Jean-Pierre Falret described a similar condition which he claimed to 
have been discussing for ten years previously under the name la folie circulaire citing his 
publication in 1851 (Jackson, 1986). Such ‘periodicity’ of mental illness was a concept that 
had been discussed prior to Lange’s publication, but more in terms of separate periods of 
depression or melancholy and mania, rather than being part of the same illness 
(Schioldann, 2011). A milder form of a cyclical disorder than the manic depressive illness 
later described by Lange and Kraeplin was introduced by Kahlbaum in 1882, this included 
depressive, hypomanic and mixed hypomanic-depressive disorders (Hecker, 2003). 
Prior to the late 1800s the existence of a cyclical state combining both mania and 
depression had not been considered. However since the 2nd century AD both mania and 
‘melancholia’, the term used at the time for what would now be considered depression, 
had been written about in either the same chapters or adjacent chapters in medicinal 
books as contrasting diseases or conditions. The first accounts which provided significant 
detail were those by Soranus of Ephesus and Aretaeus of Cappadocia whose descriptions 
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can clearly be linked to modern day accounts of mania (Pargeter and Jackson, 1792). Both 
of these authors placed their chapters on ‘melancholia’ and mania adjacent to each other 
demonstrating the belief at the time that the two conditions were somehow linked by 
their contrast. This connection and alignment of chapters was to become a longstanding 
tradition until the concept of a cyclical manic/depressed state came into existence and 
there was a wider understanding of mental illnesses in general (Pargeter and Jackson, 
1792). In 1886 Lange theorised, in his study of emotional illnesses, that an excess of uric 
acid in the body led to what he termed ‘periodical depressions’, linking back to the early 
1800s terms of ‘gouty or podagrous insanity’ and ‘melancholia’ (Lange, 1886). This illness 
was considered to be separate from the long standing diagnosis of ‘melancholia’ since, in 
many cases of these periodic depressions observed by Lange, the particular delusions 
seen in melancholic patients never occurred (Schioldann, 2011, Jackson, 1986). 
The treatise written by Lange in 1886 was later made available with a fuller title 
encompassing his idea of the uric acid diathesis (Lange, 1896). This is the theory that uric 
acid excess led to these depressions, and therefore the breakdown and subsequent 
elimination of the excess uric acid through treatment with lithium was a logical choice 
(Schioldann, 2011). However, by the end of the 1800s the theory of excess uric acid and 
its associations with mania and depression had not been readily accepted by the medical 
community and in the publication of Emil Kraeplin’s milestone textbook of psychiatry in 
1899 was dismissed as a theory (Schioldann, 2011). 
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1.4 The 1900s to present day 
Despite the dismissal of the uric acid diathesis by Kraeplin, in the 1930s a number of 
lithium containing products remained on the market for the control of kidney stones 
utilising lithium’s ability to break down uric acid (Shorter, 2009). There was however 
virtually no reference to lithium being used in psychiatry in the first half of the 20th 
century (Shorter, 2009). The interest in the use of lithium for affective disorders started 
after the 1949 publication by John Cade showing that lithium had a significant effect in a 
case series of ten manic patients presenting with ‘psychotic excitement’ (Cade, 1949). Six 
months before the publication of Cade’s review however, the salt lithium chloride had 
been introduced to the American public as a substitute to the table salt sodium chloride 
(Corcoran and Taylor, 1949). This came after the discovery that a sodium-free diet was 
helpful to patients with a cardiac or hypertensive history (Talbott, 1950). Unfortunately, 
there were reports of poisonings and deaths after the widespread use of this salt 
substitute (Noack and Trautner, 1951, Hanlon et al., 1949, Corcoran and Taylor, 1949). 
Due to this, even though there were positive reports of lithium’s effect in affective 
disorders, it was not speedily taken up by the medical community. However work 
continued to establish the safe and effective use of lithium for the treatment of affective 
disorders. 
In 1951 Noack and Trautner added to the evidence for the anti-manic effect of lithium as 
well as initiating the development of indicators for safe lithium levels and initial signs of 
toxicity (Malhi and Gershon, 2009, Ashburner, 1950, Noack and Trautner, 1951). They saw 
in their small hospital based trial that only some treated patients experienced side effects 
or early signs of toxicity and that these emerged within three to four days of treatment 
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(Noack and Trautner, 1951). These signs of early toxicity included gastric disturbances, 
motor disturbances, blurred vision and dizziness. This range of symptoms were similar to 
those previously documented in case reports by Cleaveland, Corcoran and Hanlon who 
related the similarity of the symptoms described above to those of Addison’s disease or 
sodium depletion (Cleaveland, 1913, Corcoran and Taylor, 1949, Hanlon et al., 1949). That 
lithium owes its effect, at least in part, to the displacement of sodium in the body was 
then suggested due to the similarity of the symptoms of toxicity to disorders of sodium 
dysregulation.  
Small trials throughout the 1950s and 1960s established the efficacy of lithium in both the 
manic and depressed stages of bipolar disorder and by 1972 the evidence was compelling 
for the use of lithium in affective disorders. The USA became the 50th country to register 
and license lithium with the Food and Drug Administration (FDA) approving its use for the 
long-term treatment of bipolar disorder as the lithium carbonate salt in 1980, with 
approval for lithium citrate following close behind (FDA, 2012 (a), FDA, 2012 (b)). By this 
time lithium had already been registered for medicinal use elsewhere, including France 
(1961), UK (1966), Germany (1967) and Italy (1970) (Shorter, 2009). Lithium has since 
been licensed for the treatment and prophylaxis of mania and hypomania, prophylactic 
treatment of recurrent affective disorders, treatment of recurrent bipolar depression 
where the use of alternative antidepressants has been ineffective, and the treatment of 
aggressive or self-mutilating behaviour (Sanofi-Aventis, 2012, Norgine, 2011, Rosemont, 
2011). 
Lithium sits currently in the NICE guidelines as the first line option to be offered to people 
with bipolar disorder as a long-term pharmacological intervention protecting against both 
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depression and mania as well as reducing the risk of suicide and self-harm (NICE, 2014a, 
McKnight et al., 2012). If this is not tolerated or not suitable for the patient, including 
reasons such as they will not agree to routine monitoring, then other options should be 
considered – currently olanzapine or valproate are suggested. However lithium is the 
most effective long-term treatment for bipolar disorder (NICE, 2014a). For bipolar 
depression, although lithium is licensed for this indication, other drugs are suggested as 
first line pharmacological options by NICE, such as olanzapine or lamotrigine.  
As seen in NICE guidelines, anticonvulsants are now also mentioned as alternatives to 
lithium and are also referred to as mood stabilisers. A systematic review from 2004 noted 
that the vast majority of the high quality evidence published or reported on lithium and 
its use in bipolar disorder has been published since 2000, with the inclusion of placebo 
and lithium arms inn studies. The results from this review support the licensed indications 
of lithium in that it is shown to be more effective than placebo in preventing relapse, 
particularly against manic episodes (Geddes et al., 2004).   
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1.5  Main proposed mechanism(s) of action of lithium as a mood 
stabiliser 
Lithium is a monovalent cation and shares many physico-chemical properties with other 
alkaline metals, including sodium and potassium, and it is handled in a similar way in the 
body to these other metals (Amari et al., 1999). These similarities to other commonly 
found bodily metals is, in part, why it has been so difficult to ascertain the key 
mechanism(s) of action when used as a mood stabiliser (Taylor, 2012, Mitchell, 2000). 
There are several main areas of interest for the mechanism of action of lithium, however 
the exact mechanisms by which lithium exerts its therapeutic effects are not completely 
understood (Marmol, 2008, Malhi et al., 2013, Brown and Tracy, 2013). 
1.5.1 The ionic mechanism 
Within the body all tissues retain a sodium electrochemical gradient which is needed for 
the transportation functions of electrolytes and ions as well as being key to cell excitation. 
Before lithium became well established in psychiatry clinicians had noted that there were 
alterations in the intracellular sodium levels of psychiatric patients. Shaw reported that in 
patients suffering from affective disorders there appeared to be higher intracellular 
sodium levels in both manic and depressed states with lower potassium levels in 
depressed states (Shaw, 1966). An altered response by lymphocytes has also been shown 
in patients suffering from bipolar disorder. In healthy subjects lymphocytes exposed to 
lithium showed an increase in Na+, K+-A Adenosinetriphosphatase (ATPase) molecules. 
This response was not mimicked in currently euthymic patients with bipolar disorder 
either taking lithium or on no medications (Wood et al., 1991, Wood and Goodwin, 1987).  
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Studies throughout the 1970s to 1990s investigated Na+, K+-ATPase activity in patients at 
various phases of bipolar disorder. Although there were a variety of methods used in 
these studies to measure the activity of the Na+, K+-ATPase pump all intra-study 
comparisons used the same method. El-Mallakh et al reviewed the evidence for the 
altered Na+, K+-ATPase activity. Several studies did not distinguish patients with unipolar 
depression from those with bipolar depression or clarify if patients were acutely ill or 
euthymic at the time of the study. The 12 studies reviewed by El-Mallakh et al indicate 
overall that in patients with bipolar disorder who are acutely unwell, in either manic or 
depressed phases of the illness, the activity of Na+, K+-ATPase is decreased compared to 
euthymic bipolar patients (Scott and Reading, 1978, Naylor et al., 1976, Hokin-Neaverson 
and Jefferson, 1989b, Hokin-Neaverson and Jefferson, 1989a, Naylor et al., 1980, Reddy 
et al., 1992, Reddy et al., 1989, Akagawa et al., 1980, Chio et al., 1977, Hesketh et al., 
1977, Nurnberger et al., 1982, Rybakowski et al., 1981). El-Mallakh et al theorised that 
the decrease in Na+, K+-ATPase activity is therefore a ‘mood-state related’ marker of the 
disease and not a trait marker.  
Due to lithium’s similarity to sodium, in electrically activated cells each sodium ion is 
replaced by one lithium ion. With long-term lithium treatment therefore there is an 
accumulation of lithium in these cells triggering an increase of Na+, K+-ATPase activity 
resulting in a decrease in intracellular calcium and sodium content (Marmol, 2008, Lenox 
and Frazer, 2002). High intracellular sodium levels have been linked to both phases of 
bipolar disorder with recovery similarly linked to decreased intracellular sodium 
concentrations. In addition high intracellular calcium levels have been shown to be 
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significantly elevated in ill, untreated bipolar patients in both phases of the disorder 
compared to both controls and treated bipolar patients (El-Mallakh, 1995).  
1.5.2 Effects on neurotransmitter signalling 
This proposed mechanism of action of lithium is dependent on the monoamine 
hypothesis which states that depression is in part caused alterations in monoamine 
function (including dopamine, serotonin and norepinephrine) in the central nervous 
system. Although studies are still not in agreement of the site of lithium’s action, be it 
post- or pre-synaptic, they are in agreement that there is evidence of lithium’s action at 
multiple sites involved in the modulation of neurotransmission. One of the main 
neurotransmitters implicated in depression is dopamine. A key finding which supports the 
monoamine hypothesis is the reduction of homovanillic acid levels which is a consistent 
finding in depression (Marmol, 2008). More recently studies have shifted to studying the 
catecholamine depletion effects by the tyrosine hydroxylase inhibitor α-methyl-p-tyrosine 
(AMPT) to further explore the roles of both dopamine and noradrenaline related 
substances in bipolar disorder. Anand et al looked at the effects of AMPT administration 
on eight subjects, currently in remission from bipolar disorder who had all been 
prescribed lithium for >3months. In this double blind study subjects were given either 
AMPT or placebo for four days each. Although no noticeable differences in mood were 
shown during treatment with AMPT once it was stopped a significant percentage of 
subjects showed a transient relapse of hypomanic symptoms which did not correlate with 
increases in homovanillic acid levels. These results are thought to be compatible with a 
dysregulated signalling system and compensatory overshoots rather than direct effects of 
one neurotransmitter system (Anand et al., 1999). 
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Another hypothesis for the mechanism of lithium in mood disorders revolves around 
effects on serotonin (5HT). Although 5HT has been extensively studied in unipolar 
depression and its effects are relatively well known in this illness this is not the case for 
bipolar disorder. It has been shown both in vivo and in vitro that lithium can, at a synaptic 
level, cause an increase in 5HT. As well as this biochemical observation, lithium has been 
shown to interact with different 5HT receptors at both molecular and functional levels, in 
particular 5HT1B receptors at low concentrations of lithium (Mori et al., 1996, Glue et al., 
1986, Marmol, 2008).  This effect on 5HT function is thought to be caused by either 
lithium having partial agonist activity or modulatory action on 5HT1B receptors which 
possibly explains the anti-manic effect of lithium (Chenu and Bourin, 2006). 
1.5.3 Effects on the adenyl cyclase system, inositol phosphate and protein 
kinase C signalling 
Cyclic adenosine 3’,5’-monophosphate (cAMP) was the first second messenger identified 
in mammals and has been shown over the past 30 years to have a key role in the cellular 
response to multiple hormones and neurotransmitters (Fimia and Sassone-Corsi, 2001). 
There are three main targets of cAMP: protein kinase A (PKA), the guanine triphosphate 
(GTP) exchange protein activated by cAMP (EPAC) and cyclic-nucleotide-gated ion 
channels (Fimia and Sassone-Corsi, 2001). It is the PKA target that has been of interest in 
relation to lithium’s mechanism of action in mood disorders as it is a main mediator of 
cAMP action in the central nervous system (Marmol, 2008). Back in 1996 Mori et al had 
observed that the administration of lithium reduces the phosphotransferase activity of 
PKA (Mori et al., 1996). This action was thought to be caused by competition between 
lithium and magnesium at a subunit of PKA, due to the similarity in the ionic radii of 
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lithium and magnesium (Mori et al., 1996, Jope, 1999, Gould et al., 2004). It is thought 
that lithium can stabilise the cAMP level fluctuations by increasing the lowest basal levels 
and decreasing the highest stimulated increases, thereby stabilising the system (Jope, 
1999, Marmol, 2008). In laboratory studies in rat cerebral cortex α2D-adrenoceptors are 
related to this effect of lithium on cAMP stabilisation. The recovery of these receptors 
after irreversible inactivation is related to the stabilising effect of lithium on cAMP 
production (Marmol, 2008). Lithium has also been shown to affect cAMP levels outside of 
the CNS. Studies have shown alterations in the bovine thyroid gland, kidney tissues of 
multiple animals and guinea pig ileum (Marmol, 2008). Interestingly this effect of lithium 
on cAMP phosphorylation only appears to occur in bipolar patients. Zanardi et al reported 
that after only 15 days of treatment with lithium in bipolar patients’ cAMP-stimulated 
phosphorylation to Rap1, a small Guanosine-5'-triphosphate -binding protein present in 
different tissues was enhanced. This modifications of cAMP dependent phosphporylation 
was not mirrored in healthy controls (Zanardi, 1997). 
Inositol phospholipids are also important in the receptor mediated signal transduction 
pathways and are involved in neuronal excitability, secretion and cell division. The inositol 
depletion hypothesis states that the therapeutic effect of lithium is due to it depleting the 
neuronal levels of myoinositol. It appears that lithium decreases inositol 
monophosphatase (IMPase) activity and inositol levels in vitro and animal models and 
decreases myoinositol levels in humans however this has been difficult to replicate in 
clinical studies (Marmol, 2008). 
Two primary second messengers produced by the phosphoinositol signal transduction 
system are inositol triphosphate and diacylglycerol which activates protein kinase C. 
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Modulation of protein kinase C (PKC) by lithium and other mood stabilisers has been 
extensively studied. Early studies in the late 80s/early 90s found decreased levels of PKC 
signalling activity in lithium treated tissues and evidence of an activation of PKC in cases 
of mania (Jope, 1999). The inhibition of IMPase may represent an initial action of lithium 
which triggers a cascade of secondary changes in the PKC signalling pathway which may 
be responsible for the therapeutic effects of lithium in bipolar disorder (Marmol, 2008, 
Manji and Lenox, 2000, Quiroz, 2004, Einat et al., 2007, Manji and Chen, 2002). 
1.5.4 Arachidonic acid metabolism 
Arachidonic acid (AA) is an important mediator of second messenger pathways in the 
brain, Chang et al reported that lithium produced am 80% reduction in AA turnover. 
Subsequent trials showed that lithium decreased gene expression and protein levels of an 
AA-specific phospholipase-A2 (PLA2) and the protein levels of cyclooxygenase-2 (COX-2). 
COX-2 production is also stimulated by PLA2 activation (Chang and Jones, 1998, Chang et 
al., 1996). Similar effects to this have also been found for other mood stabilisers including 
valproate and carbamazepine.  
1.5.5 Neuroprotective and neuroproliferative effects through preservation of 
grey matter 
The neuroprotective effects of lithium are thought to involve inactivation of N-methyl-D-
aspartate (NMDA) receptors through multiple mechanisms including the induction of 
neurotrophic/neuroprotective proteins including B-cell lymphoma/leukaemia-2 gene (Bcl-
2) which leads to antiapoptotic mechanisms (Marmol, 2008). Magnetic resonance 
imaging studies have also shown that the volume of grey matter in bipolar patients 
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administered lithium increases. Healthy subjects have also shown increased dorsolateral 
prefrontal cortex and cingulate gray matter volume (Brown and Tracy, 2013). Clinical 
studies have also reported that the administration of therapeutic doses of lithium not 
only led to increased gray matter volume in brain but also increased levels of N-acetyl-
aspartate (NAA) which is a  marker of neuronal viability and function) effects (Moore et 
al., 2000). 
In summary multiple actions of lithium must be considered in the therapeutic response. 
Multiple actions of lithium, rather than a single site, are necessary due to its multiple 
effects in affective disorders as antimanic, antidepressant and prophylactic stabilising 
actions (Jope, 1999). By modulating neurotransmitters, lithium has a regulatory effect on 
their excitatory and inhibitory functions. Its proposed effects on second messenger 
systems, including cyclic adenosine 3’,5’-monophosphate (cAMP) and PKC are thought to 
aid in the neural plasticity needed for its stabilising effect on mood.  
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1.6 Pharmacokinetics of lithium 
Lithium is a naturally occurring ion that does not bind to plasma proteins and is able to 
cross the blood-brain barrier. It is absorbed through the stomach and does not undergo 
metabolism, it is filtered by the glomeruli and eliminated as the free ion by the kidneys 
(Malhi et al., 2012, Cates and Sims, 2005). The clearance of lithium is directly proportional 
to the glomerular filtration rate of the patient and renal blood flow. It is predicted that 
80% of lithium filtered by the glomeruli is reabsorbed in the proximal tubules (by the 
apical epithelial sodium channel) of the kidneys. Of the filtered lithium 60% is reabsorbed 
in the proximal tubule and 20% between the Loop of Henle and the collecting duct. The 
clearance of lithium is about 20% of the patient’s glomerular filtration rate (Cates and 
Sims, 2005, Kishore and Ecelbarger, 2013, Ratkovi-Gusic et al., 2002).  
As lithium is treated by the kidneys as if it were sodium, a decreased sodium balance 
would be expected to result in increased serum lithium concentrations, whereas an 
increased sodium balance would be expected to result in decreased serum lithium 
concentrations (Kishore and Ecelbarger, 2013, Cates and Sims, 2005).  
The half-life of lithium varies depending on the age and renal function of the patient 
taking it from 24 hours in adults, 36 hours in the elderly to 40-50 hours in patients with 
impaired renal function (Cates and Sims, 2005). 
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1.7 Lithium’s effects on the kidney 
There are several ways of measuring kidney function. One commonly quoted method is 
by calculating the glomerular filtration rate (GFR) which is equal to the total of the 
filtration rates of the functioning nephrons in the kidney. This cannot be measured 
directly and so the urinary or plasma clearance of a filtration marker such as inulin is 
used. This is not often done in clinical practice as it is not a simple process and instead 
serum levels of endogenous markers such as creatinine are used to estimate the GFR. 
Serum creatinine alone is known to be a poor measure of renal excretory function as its 
relationship with GFR is not linear and so it only rises outside of what is considered the 
normal laboratory range once substantial loos of renal function has occurred. Mild and 
moderate kidney injury is therefore poorly inferred from serum creatinine alone and so 
clinical laboratories are recommended to report an estimated GFR calculated from serum 
creatinine levels alongside serum creatinine concentrations (Renal Association, 2011).  
 
A stable volume of extracellular fluid as well as a stable composition is needed for normal 
functioning of the body. The kidney is the primary organ responsible for regulating this 
extracellular fluid therefore any loss of kidney function can have severe consequences on 
the body (Schrier, 2006). In addition to the regulation of extracellular fluid the excretory, 
metabolic, and endocrine functions of the kidney mediate essential interactions with 
several organs, sustaining an array of vital functions. These include regulation of body 
water and thirst, blood pressure, cardiac rhythm, ventilation, drug metabolism, potassium 
balance, erythropoiesis, calcium and phosphate metabolism, tissue oxygenation and acid-
base homoeostasis (Eckardt et al., 2013). 
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1.7.1. Effects on tubular function 
One well documented side effect of lithium use is polyuria which is associated with a 
decrease in urinary concentrating ability resistant to arginine vasopressin, otherwise 
known as acquired nephrogenic diabetes insipidus (NDI) (Turan et al., 2002). The 
mechanisms underlying this effect are not completely understood but is thought to be 
associated with the inhibition of glycogen synthase kinase-3, β-isoform (GSK3β), impaired 
cAMP production, dysregulation of renal prostaglandins, altered purinergic signalling, and 
changes in renal architecture and possibly other methods (Kishore and Ecelbarger, 2013). 
Studies have also suggested that the ability of lithium to produce NDI may related to 
decreased aquaporin-2 (AQP2) messenger ribonucleic acid (mRNA) levels therefore 
inhibiting water channel delivery and reducing water permeability.  
1.7.2. Effects on glomerular function 
Lithium-induced nephrotic syndrome is thought to be due to lithium-induced epithelial 
toxicity leading to minimal change disease, meaning it will resolve after discontinuation of 
lithium, or focal global and segmental glomerulosclerosis (FSGS). A higher prevalence of 
glomerular changes correlated with a higher prevalence of proteinuria which is an 
uncommon result of lithium toxicity (Alexander et al., 2008). Chronic interstitial changes 
have also been shown in patients with psychiatric disorders who were not treated with 
lithium so the changes cannot be definitely attributed to treatment with lithium (Gitlin, 
1999). Glomerular function itself seems to remain relatively untouched with a mild to 
moderate decrease in glomerular filtration rate being seen correlated with age (Johnson, 
1998). 
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1.8  Therapeutic drug monitoring 
The practice of therapeutic drug monitoring (TDM) has been around since the early 1970s 
allowing for individual patients to have, where required, their drug therapy tailored to 
their needs and responses (Touw et al., 2005). The principal aim of TDM is to increase the 
effectiveness of drug treatment whilst reducing the risk of serum level related adverse 
effects for those drugs where the concentration of the active drug or its metabolites are a 
better predictor of effect than dose alone. There are several drugs which have the 
potential to be highly toxic if serum levels are not closely monitored in order to obtain the 
desired clinical effects whilst minimising the risk of any avoidable adverse effects and 
these are termed narrow therapeutic range (NTR) drugs (Raebel et al., 2006). Sample 
populations are used to determine therapeutic ranges for medications, so there may be 
variations in these ranges for individual patients (Hitchings, 2012). 
There is no comprehensive and recognised list of drugs with a NTR available, but the 
following are usually considered to be NTR-drugs: aminoglycosides, carbamazepine, 
digoxin, digitoxin, flecainide, lithium, phenytoin, phenobarbital, ciclosporin, rifampicin, 
theophylline, tacrolimus, aminophylline and warfarin (Blix et al., 2010, Benet, 1999, UKMI, 
2011). There are other drugs in use for which TDM is not routine, but can be used when 
adherence is doubted or the response to treatment or side effects experienced are not as 
expected, for example, clozapine and olanzapine (Taylor, 2012).  
The measurement of one single blood serum concentration from a patient sample is not 
the whole process of TDM. Interpretation of the value(s) reported, leading to appropriate 
conclusions and advice on clinically relevant and suitable treatment options, is needed. In 
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order for TDM to be clinically relevant and effective there are three things that need to be 
known about the drug and the illness as defined by McInnes 1989, p. 281: 
1) A definitive therapeutic target range for serum levels of the drug where the 
maximum therapeutic effect is expected with a minimum risk of toxicity, 
2) Dose alterations purely based on serum drug levels diminishes variations 
occurring between individuals, 
3) Altering the dose of a drug based solely on clinical judgement does not lead to 
as great a patient benefit as keeping drug levels within the therapeutic range 
previously determined. 
(McInnes, 1989) 
There is limited to no clinical benefit for TDM of drugs whose toxic or therapeutic benefits 
can be measured directly. However, where this is not the case then plasma concentration 
measurements can help to adjust the dose to within the therapeutic range required 
(Aronson and Hardman, 1992). With drugs where both the parent drug and the 
metabolite have a clinical effect then the concentrations of both in the blood of the 
patient need to be ascertained to give an accurate value for the overall drug plasma level 
responsible for the clinical effect.  
In recent years, analysis and interpretation of results considering all aspects of drug 
therapy has become more prominent, including patient response, adverse effects, dosing 
information, blood sampling times, pharmacokinetic behaviour, drug level interpretation 
and dose optimisation (Touw et al., 2005). For those patients for whom population-
determined therapeutic ranges are not appropriate, this is increasingly important for 
understanding their responses to drugs and adapting their treatments appropriately 
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(McInnes, 1989). There is the potential with TDM that requests for blood levels may be 
inappropriate and therefore lead to results being interpreted incorrectly and doses 
changed inappropriately (Vuille, 1991, Clague et al., 1983).  
As previously mentioned, there may be patients for whom a population-based 
therapeutic range is not appropriate, and there may also be external factors which modify 
the therapeutic range in a particular patient. In light of this, the context of the result 
reported needs to be considered for any therapeutic decisions made, not just the result in 
isolation. For CNS (central nervous system) drugs TDM assumes that blood concentrations 
are proportional at a set ratio to that in the CNS, this may not be necessarily true in all 
patients and therefore toxicity could occur at therapeutic levels (Walbridge and Bazire, 
1985). The serum level of a drug can only be useful when considered alongside the clinical 
picture of the patient and treatment needs to be tailored to the patient’s needs, the 
clinician(s) responsible for the patient need to be able to interpret the plasma level result 
in light of this (Brodie and Feely, 1988, Vestergaard et al., 1982). 
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1.9 Serum lithium analysis 
Both serum (prepared from clotted blood) and plasma (prepared from anticoagulated 
blood), can be used for many TDM measurements. Serum is used routinely for the 
measurement of lithium to avoid any possible interaction with lithium heparin, which is 
used as an anticoagulant (Aronson and Reynolds, 1992). The pharmacokinetics of lithium 
varies from person to person, making it difficult to accurately predict dosage 
requirements. Serum levels of lithium also vary widely between doses and there is a 
diurnal variation in the way the body handles lithium, with it having a longer half-life 
throughout the night than during the day (Aronson and Reynolds, 1992). Due to this 
variation in serum levels between doses it is recommended that the sample is taken 12 
hours after the last dose. Diurnal variation is not currently taken into account as modified 
release formulations go some way to ameliorating these variations (Aronson and 
Reynolds, 1992). Due to the renal elimination of lithium, any adjustments in dose need to 
take into consideration not only the absolute serum lithium level, but also the changes in 
renal function. A change in serum lithium level may be indicative of a change in renal 
function which requires further investigation (Vestergaard et al., 1982). 
There are several methods of monitoring serum lithium levels, which is an important 
variable for the generalisability of population-based therapeutic drug ranges. Difficulties 
in interpretation may also occur if different laboratories use a variety of methods for 
lithium level analyses on the same patient. The main methods of lithium serum level 
analysis are flame emission spectroscopy (FES), atomic absorption spectrophotometry 
(AAS) and lithium-ion selective electrode technology (Li-ISE) (International Group for The 
Study of Lithium Treated Patients, 2010). At pathology laboratories within Norfolk and 
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Suffolk, a spectrophotometric method is used, with a direct colorimetric endpoint 
reaction. (Eastern Pathology Alliance, 2013 (a), Eastern Pathology Alliance, 2013 (b)). 
Lithium found within the serum sample reacts with a lithium-specific chromoionophore in 
an alkaline solution forming a lithium ion complex, changing the absorbance of the 
sample. The concentration of lithium in the sample is proportional to the increase in 
absorbance (Eastern Pathology Alliance, 2013 (b)). As with any chemical reaction there is 
the potential for interfering substances which can cause physiological changes in either 
the serum or plasma analyte concentrations, and results must therefore be interpreted in 
light of these and the clinical presentation of the patient. 
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1.10 Diagnosis, treatment and management of bipolar disorder 
Bipolar disorder is characterised by recurrent changes in mood. There are also however, 
cognitive, psychotic and anxiety symptoms which account for some of the disability 
associated with it (Altamura et al., 2011). It is estimated that the lifetime prevalence of 
bipolar disorder is between 1-5%. Due to the complexities in diagnosis when this is 
expanded to encompass all bipolar spectrum disorders this can vary between 2.8-6.5% 
(Bauer and Pfennig, 2005). There is a suggestion that these estimates possibly 
underestimate the overall prevalence as a consequence of frequent misdiagnoses due to 
an overlap of psychiatric symptoms and comorbid conditions (Bauer and Pfennig, 2005). A 
diagnosis of bipolar disorder is associated with high rates of other medical, psychiatric 
and substance misuse disorders which contribute to a lower life expectancy and overall 
quality of life (Connolly, 2011). 
Bipolar disorder is, in most patients, a chronic and recurrent illness and the main aim of 
treatment is maintenance of euthymia which is best achieved by the long- term 
treatment to prevent future episodes and further functional impairment. The impairment 
seen in patients who have recovered from acute episodes of mood fluctuation and are 
asymptomatic is related to the number of previous episodes experienced (NICE, 2006). 
There are two main diagnostic schemes in use in the field of psychiatry: the International 
Classification of Diseases of the World Health Organisation (10th edition ICD-10) and the 
Diagnostic and Statistical Manual (5th edition DSM-5) of the American Psychiatric 
Association (American Psychiatric Association, 2013, World Health Organisation, 2010). 
There are differences in these two systems for the diagnosis of bipolar disorder, details of 
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which can be found on pages 5 and 6 of the Scottish Intercollegiate Guidelines Network 
(SIGN) Clinical Guideline 82 (SIGN, 2005). 
Current guidance from the National Centre for Health and Care Excellence (NICE) which 
produces guidelines and advice for health services within England and Wales is that 
lithium should be offered first line for the long-term treatment of bipolar disorder. Where 
lithium is not tolerated, or is not considered suitable, then olanzapine or valproate should 
then be considered (NICE, 2014a). If a person develops moderate or severe bipolar 
depression and is not taking a drug to treat their bipolar disorder then lithium is not 
recommended as mono-therapy, with other drugs not currently holding UK marketing 
authorisation for this use also being recommended. If lithium is already prescribed and 
measuring at a maximum serum level, then it can be augmented with other agents such 
as fluoxetine or olanzapine (NICE, 2014a).  
The differences in diagnostic criteria and the complexities of co-morbid conditions impact 
on the ability to effectively treat bipolar disorder. 
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1.11 Decision making in the prescribing of lithium 
Although there is a great deal of evidence in support of lithium as a treatment in affective 
disorders, it does come with safety concerns, and it has had several ‘renaissances’ in its 
long history (Malhi and Gershon, 2009). In some countries, the use of lithium has been 
declining in recent years, particularly in the Americas. This is thought to be in part due to 
the ongoing and recurrent doubts about its efficacy in affective disorders and also 
concerns around its safety as a long-term treatment option. 
Although there have been several studies in recent years on decision-making in 
prescribing these have focussed on the prescribing of newer medications rather than 
well-established drugs such as lithium (Prosser and Walley, 2006, Cutts and Tett, 2003, 
Denig et al., 2002a, Jones et al., 2001, Jaye and Tilyard, 2002). It is not clear if the 
influencing factors on prescribing are the same for older drugs.  
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1.12 Conclusion 
Since its initial discovery, lithium has experienced oscillations between a positive and 
negative reputation within the medical community. It is currently considered the gold 
standard treatment for bipolar disorder and is recommended in the UK as a first line, 
long-term treatment. It does, however, require therapeutic drug monitoring to ensure 
that the risks of toxicity are minimised whilst still maximising its efficacy. There are also 
still unanswered questions about the long-term side effects of lithium, particularly on 
renal function. 
This thesis starts with a comprehensive literature review to firmly establish the evidence 
base before this work, on the development of a therapeutic drug level, monitoring 
parameters and the established effects on renal function of lithium. This then leads into 
the research conducted investigating the gaps in the evidence specifically around the 
effects lithium, and lithium levels on renal function. One complexity inherent in the 
prescribing of lithium is the difficulty in diagnosing the condition it is intended to treat. 
Bipolar disorder is known to be difficult to diagnose with differences in diagnostic criteria 
even existing in the US and European manuals for diagnosis (DSM-5 and ICD-10). One idea 
which is consistent across diagnostic criteria and guidelines surrounding prescribing is 
that bipolar spectrum disorders are long-term, chronic conditions requiring long-term 
treatment with medication to minimise relapses and to maintain a euthymic state. The 
safety and long-term implication of the chosen treatment are a consideration for 
prescribers. 
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With research on prescribing decisions having focussed on new medications it is not clear 
if these complexities of lithium have a different impact on prescribing decisions. In 
association with investigating the relationship of lithium levels on renal function the long-
term prescribing decisions will be investigated for this well-established drug to add to the 
evidence base in this area. 
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 Chapter Two     
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2: Literature review  
2.1 Literature review background 
When lithium was first used in medicine there was no routine monitoring for therapeutic 
effects or toxicity, doses were increased until side effects occurred then reduced until the 
side effects reduced and there was no clear indication of what was causing them (Schou, 
1988). It was not known what lithium level proved the most efficacious in preventing both 
poles of bipolar disorder. In early studies of lithium as a prophylactic medication in 
bipolar disorder, patients were maintained at lithium levels of 0.6-1.3mmol/L and these 
levels were therefore recommended for use in clinical practice (Maj et al., 1986). Since 
then there have been several studies which have tried to narrow down this therapeutic 
range to maximise efficacy of treatment whilst minimising the risk of adverse effects. 
The custom in the late 1980s for determining serum levels at two, four or 12 months was 
based on what was being done in practice (Schou, 1988). Up until 1995, the British 
National Formulary (BNF) advocated monthly monitoring of lithium as routine. There 
have however been several debates in the literature about the merit in regularly checking 
serum lithium concentrations, and so the BNF recommendations were changed to three 
monthly monitoring (Joint Formulary Committee, 1995). 
Current guidelines for lithium monitoring have not veered far from this, with 
recommendations at the time of writing being for serum lithium levels every three 
months (NICE, 2006, SIGN, 2005). Since the background work for this thesis was 
conducted, national guidelines within England and Wales have been updated and now 
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recommend three monthly lithium levels for the first year of treatment and then every six 
months, or every three months for some patient groups (NICE, 2014a). 
Renal function is important for the elimination of lithium as a declining glomerular 
filtration rate (GFR) will increase any risks of lithium toxicity due to accumulation. 
Although there is evidence that lithium is effective in affective disorders, until the 
publication of the McKnight review in 2012 there was no systematic review of the toxicity 
profile of lithium (McKnight et al., 2012). Even after this publication there remain 
uncertainties surrounding the renal toxicity profile of lithium in relation to its potential 
effects on eGFR, urinary concentrating ability and end stage renal failure. There is also no 
background detail in the published guidance for the recommended frequency of lithium 
monitoring, or evidence for effective lithium levels which would further enable risk-
benefit decisions to be made by prescribers. 
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2.2 Aims and Objectives 
2.2.1. Aim 
A literature search was performed to identify published research articles that looked at 
the development of therapeutic lithium level ranges, the rationale behind the frequency 
of monitoring currently recommended and the effects of lithium on renal function.  
2.2.2. Objectives 
To determine the: 
- relative efficacy and toxicity of different lithium levels in the prevention of relapse 
in recurrent mood disorders, 
- evidence behind the current recommendations of the frequency of lithium 
monitoring, 
- association between lithium use and renal function in adults with recurrent mood 
disorders. 
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2.3 Methods 
This review will be separated into three sections running throughout the method and 
results relating to the three areas covered in the objectives. 
The following databases were searched for relevant articles: Embase, Medline, 
PsychINFO, CINAHL, and the Cochrane database. These databases were chosen as they 
are the specialist ones for allied health professionals, nursing and medicine as well as 
being the general literature databases that are likely to have major published articles in 
this field. The research team did not have the facilities to translate articles that were 
published in a foreign language and so these were excluded if an English version could not 
be found. If full texts were readily available these were accessed, where these were not 
immediately available abstracts were checked to see if they made mention of the 
methods in enough detail for the studies to be eliminated, and all others were requested 
in full to be reviewed. The literature search was performed up to and including March 
2014.  
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2.4 Included studies 
2.4.1. Development of a therapeutic lithium level 
To focus on the development of a therapeutic lithium level this section of the literature 
review needed to include articles which reported on the long-term treatment of mood 
disorders where patients were assigned to specified target ranges of lithium levels. The 
Embase search was performed first and bought up a review article which had looked at 
this same issue covering the period from 1966 to March 2006 (Severus et al., 2008) and so 
when the Medline search was performed the same search terms were used as this review 
and the results were limited from 2006 onwards to find new articles which had since been 
published. Original articles included in the 2008 review by Severus et al., were also 
obtained. This was a pragmatic method of searching due to time constraints on the need 
to do multiple literature reviews for the topics covered in the thesis. 
After detailed searching of the abstracts found from the literature review, 12 articles 
were included for further reading in addition to the five original reports mentioned in the 
review found from 2008 (Severus et al., 2008). From reference list reviews of these 
initially selected articles a further nine articles were included for further reading. Of these 
articles ten were subsequently deemed appropriate for inclusion (Jerram and McDonald, 
1978, Waters et al., 1982, Coppen et al., 1983, Maj et al., 1986, Gelenberg et al., 1989, 
Vestergaard et al., 1998, Stokes et al., 1976, Hullin, 1979, Goodnick and Fieve, 1985, 
Lewitzka et al., 2012). Articles were included if they compared at least two different 
lithium level ranges for the treatment of affective disorders. 
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2.4.2. Development of recommended monitoring frequency for lithium 
To explore the rationale for the development of the monitoring frequency for lithium a 
search was carried out for published articles which mentioned both lithium and drug 
monitoring. No controlled trials were found from the literature search in this area so the 
inclusion criteria for all articles found was kept very broad and all articles which included 
guidance or advice on the monitoring frequency of lithium were considered suitable for 
inclusion. After detailed searching of the published abstracts, 57 were included for further 
reading. Two additional articles were found through reference list searching. Of these 
articles ten were subsequently deemed appropriate for inclusion (Dunner, 2000, 
Vestergaard and Licht, 2001, American Psychiatric Association, 2002, Hitchings, 2012, 
Grandjean and Aubry, 2009, Mitchell, 2001, Schou, 1988, Brodie and Feely, 1988, Delva 
and Hawken, 2001, Sachs et al., 2000). 
2.4.3. Renal effects of lithium 
The section of the literature review focussing on the renal effects of lithium needed to 
include articles which reported on the renal effects of lithium treatment in mood 
disorders. During the previous search performed when for the development of a 
therapeutic lithium level, a systematic review and meta-analysis had been found which 
reported the toxicity profile of lithium. This had screened all published articles, textbooks, 
conference abstracts and even contacted pharmaceutical companies for additional data 
up to 2010. A search was performed using a wide range of key words, as the search terms 
used in this review were not available, and only articles from 2010 onwards were 
included for further review. 
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From the previous search run for the development of therapeutic lithium levels a 
comprehensive systematic review and meta-analysis had been found (McKnight et al., 
2012). The results from this literature search were screened to see if any additional 
articles had been published since 2010, which was the date up to which the McKnight 
review had searched. After detailed searching of the abstracts found from the literature 
review 13 articles were included for further reading in addition to the 28 original reports 
mentioned in the McKnight review. Of these articles 32 were subsequently deemed 
appropriate for inclusion (Janowsky, 2011, Preda, 2012, Rej et al., 2013a, Hullin et al., 
1979, Bendz, 1985, Bendz et al., 1996, Bendz et al., 2001, DePaulo et al., 1986, Grof, 1980, 
Hetmar et al., 1987b, Hetmar et al., 1991, Jensen and Rickers, 1984, Johnson et al., 1984, 
Jorkasky et al., 1988, Kallner and Petterson, 1995, Muir et al., 1989, Nilsson and Axelsson, 
1989a, Povlsen et al., 1992, Presne et al., 2003, Schou and Vestergaard, 1988, Smigana et 
al., 1984, Vaamonde et al., 1986, Waller et al., 1988, Åberg-Wistedt et al., 1988, Coşkunol 
et al., 1997, Hetmar and Rafaelsen, 1987c, Turan et al., 2002, Walker et al., 1982a, Walker 
et al., 1982b, Tredget et al., 2010, Vestergaard and Thomsen, 1981, Vestergaard et al., 
1979). Articles were included if they were case-control, cohort or chart reviews 
comparing creatinine clearance, glomerular filtration rate (GFR), estimated GFR (eGFR), 
serum creatinine or urinary concentrating ability at baseline and follow-up, or between 
cases and controls. One study was also included as it looked at the relative risk of renal 
impairment or renal failure. 
Since the original search was done several papers have been published on the effect of 
lithium on GFR which were found by an email alert set up when the initial search was 
done (Clos et al., 2015, Ott et al., 2016, Rodrigo et al., 2014).  
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2.5 Excluded studies 
2.5.1. Development of a therapeutic lithium level 
A number of studies were excluded as they focussed primarily on monitoring parameters 
of lithium or were critical reviews of the evidence for lithium prophylaxis (Nierenberg et 
al., 2009, Severus, 2010, Carney, 2005, Keck, 2003, Maj, 2000, Grandjean and Aubry, 
2009, Schou, 1988, Prien et al., 1972, Goodwin and Goldstein, 2003, Amdisen, 1980). 
Several other studies did not assign patients to precisely specified target ranges of lithium 
levels, or had no differences in lithium levels used in the studies therefore not allowing 
comparisons to be made (Calabrese et al., 2006, Smith et al., 2007, Burgess et al., 2001, 
Stallone et al., 1973, Nilsson and Axelsson, 1989b, Lewitzka et al., 2012). The study by 
McKnight et al., was a clinically informative, systematic toxicity profile of lithium not 
focussing on differing lithium levels (McKnight et al., 2012).  
2.5.2. Development of recommended monitoring frequency for lithium 
Those articles which had no mention of monitoring frequency or were audits on how well 
areas comply with guidelines or the current rates of testing were not included along with 
articles which contained material pertinent to another section of the literature review or 
those which were letters or replies (Paton et al., 2010, Collins et al., 2010, Jefferson, 2010, 
Sharma, 1992, Lewis, 2004, Gupta and Eagles, 2001, Guscott and Taylor, 1993, Kehoe, 
1993, Hullin et al., 1993, Hellewell and Pugh, 1992, Rowlands, 1992, McKean and Vella-
Brincat, 2012, Anderson and Bazire, 2011, Udumaga E., 2010, Shaw, 2004, Butler and 
Taylor, 2000, Brown, 2012, Frings, 1987, Marcus et al., 1999, Kehoe and Mander, 1992, 
Tjia et al., 2010, Schrader, 2002, Myers and Hallworth, 1996, Friedman and Greenblatt, 
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1986). Several articles also focussed on the reliability processes to estimate drug 
concentrations and dosing strategies or the appropriateness of requests for the drug 
monitoring of lithium which were also not included in this review (Hoegberg et al., 2012, 
Ratanajamit et al., 2006, Mann et al., 2006, Aishah and Foo, 1995, Amdisen, 1980).  
2.5.3. Renal effects of lithium 
Any articles which were personal reflections, discussion only, single case studies, 
editorials, letters or reviews of methods of measuring renal function or those with non-
comparable outcomes measured (Jefferson, 2010, Dhavaleshwar and Spencer, 2010, 
Rybakowski et al., 2012, Werneke et al., 2012, Jean-Noel and Lapid, 2011, Pradhan et al., 
2011, Svedlund et al., 2012, Abramowicz et al., 2012, Bendz et al., 2010).  
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2.6 Results 
2.6.1. Development of therapeutic lithium level  
Table 2.1 details the analysis of included studies and their results. 
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Study Method Diagnosis Prior use 
of lithium 
Characteristics 
of participant 
at study entry 
Number of 
cases 
Follow up Specific outcomes 
measured 
Lithium levels used Results 
Stokes, 
Kocsis et 
al., 1976 
Blinded, 
randomised, 
controlled 
trial using 
three 
separate 
lithium level 
ranges* 
 
Manic 
states 
Unknown On-going 
symptoms or 
episodes 
before entry 
68 (42 
completed) 
10 days for 
each lithium 
level range, 40 
days total 
Behavioural 
ratings 
Placebo 
Low dose: 
0.24MEq/Kg/day 
Medium dose: 
0.50mEq/Kg/day 
High dose: 
0.72mEq/Kg/day 
High and medium 
doses more 
efficacious (p<0.01 
and p<0.05 
respectively) 
High dose only 
significant in 
achieving 
euthymia p<0.005) 
 
Jerram and 
McDonald, 
1977 
Randomised 
controlled 
trial using 
three 
separate 
lithium level 
ranges 
 
Definite 
affective 
disorder, 
currently 
in 
remission 
Yes Stability of 
mood on study 
entry 
80 (73 
completed) 
12 months Necessity for 
additional 
psychotropic 
medication and/or 
admission 
Low: <0.49mmol/L 
Medium: 0.50-
0.69mmol/L 
High: >0.70mmol/L 
No significant 
difference in 
outcomes in the 
three groups 
(p=0.98) 
Hullin, R.P., 
1979 
Randomised 
controlled 
trial using 
three 
separate 
lithium level 
ranges 
Definite 
affective 
disorder, 
currently 
in 
remission 
Yes Stability of 
mood on study 
entry 
73 (70 
completed) 
12 months Hospitalisation OR 
relapse 
Low: 0.25-0.39mmol/L 
Medium: 0.40-
0.59mmol/L 
High: 0.60-1.0mmol/L 
Non-significant 
difference in 
relapse rate 
between groups 
(p=0.76) 
*Cross over trial, DSM - Diagnostic & Statistical Manual of Mental Disorders, ICD - International Classification of Diseases, BPRS - brief psychiatric assessment rating scale 
MEq = milliequivalent (For monovalent ions including lithium, 1 MEq = 1 mmol) 
Table 2.1: Results of included studies - development of therapeutic lithium levels, continued on the following pages 
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Study Method Diagnosis Prior use 
of lithium 
Characteristics 
of participant 
at study entry 
Number of 
cases 
Follow up Specific outcomes 
measured 
Lithium levels used Results 
Waters, 
Lapierre 
et al., 
1982 
Blinded, 
randomised, 
controlled 
trial* 
Two lithium 
level ranges 
DSM III 
defined 
bipolar 
disorder 
Yes Residual mood 
swings in 
preceding 24 
months 
36 (29 
completed) 
6 months for 
each stage of 
crossover, 12 
months in total 
Global clinical 
assessment and 
brief psychiatric 
assessment rating 
scale (BPRS) 
Relapses 
Low dose: 0.30-
0.80mEq/L 
High dose: 0.80-
1.4mEq/L 
Significantly more 
relapses in low 
dose phase 
(p<0.01) 
Significantly higher 
BPRS scores in low 
dose phase 
(p<0.01) 
 
Coppen, 
Abou-
Saleh et 
al., 1983 
Blinded, 
randomised, 
controlled 
trial 
Previous 
lithium level 
or 25 or 50% 
reduction. 
 
Unipolar 
or bipolar 
patients 
 
Yes Unknown 88 (72 
completed) 
≥12 months Affective 
morbidity  
Group 1: 0.45-
0.59mmol/L 
Group 2: 0.60-
0.79mmol/L 
Groups 2 and 3: 
≤0.79mmol/L 
Group 4: ≥0.80mmol/L 
Significant 
decrease in 
morbidity for all 
patients with 
lithium level ≤0.79 
mmol/L (p<0.02) 
Goodnick 
and Fieve, 
1985 
Prospective Bipolar 
disorder 
diagnosed 
according 
to 
modified 
Feighner 
et al 
criteria 
Unknown Stability of 
mood on study 
entry 
44 Group 1 = 
42.0±19.5mont
hs 
Group 2 = 
39.1±22.9mont
hs 
Deviation of mood 
from normal (7 
point scale) 
Group 1: 
0.87±0.10mEq/L 
Group 2: 
0.58±0.12mEq/L 
No significant 
differences in 
episodic 
functioning 
between groups 
*Cross over trial, DSM - Diagnostic & Statistical Manual of Mental Disorders, ICD - International Classification of Diseases, BPRS - brief psychiatric assessment rating scale, MEq = 
milliequivalent (For monovalent ions including lithium, 1 MEq = 1 mmol) 
Table 2.1 continued: Results of included studies - development of therapeutic lithium levels 
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Study Method Diagnosis Prior use 
of lithium 
Characteristics 
of participant at 
study entry 
Number of 
cases 
Follow 
up 
Specific 
outcomes 
measured 
Lithium levels used Results 
Maj, 
Starace et 
al 1986 
Controlled 
trial 
Four lithium 
level ranges 
DSM III 
defined 
bipolar 
disorder 
Yes At least one 
affective 
episode in 
preceding 24 
months 
80 (69 
completed) 
24 months Number of 
affective episodes 
and total 
morbidity 
Group A: 0.30-
0.45mEq/L 
Group B: 0.46-
0.60mEq/L 
Group C: 0.61-
0.75mEq/L 
Group D: 0.76-
0.90mEq/L 
Significant 
decrease in mean 
number of 
affective episodes 
and mean total 
morbidity in 
groups B, C and D 
(p<0.002) 
Gelenberg, 
Kane et al 
1989 
Blinded, 
randomised, 
controlled 
trial 
Two lithium 
level ranges 
DSM (or 
equivalent) 
diagnosis for 
bipolar 
disorder 
Yes Stability of 
mood 
94 recruited 
(33 
completed) 
6 
months 
Relapse Low: 0.40-0.60mmol/L 
Standard: 0.80-
1.0mmol/L 
2.6 times 
increased risk of 
relapse for low 
dose group (95% 
CI 1.3-5.2) 
Vestergaard, 
Wentzer Licht 
et al 1998 
Randomised 
controlled 
trial 
Two lithium 
level ranges 
DSM (or 
equivalent) 
diagnosis for 
bipolar 
disorder, 
currently 
hospitalised 
Unknown Unknown 101 recruited 
with 91 
randomised 
(49 
completed) 
24 
months 
Recurrence of 
symptoms 
which required 
hospitalisation 
Low: 0.50-0.80mmol/L 
High: 0.80-1.0mmol/L 
No statistically 
significant 
difference in 
outcome between 
high/low serum 
levels (p=0.83) 
Lewitzka et 
al., 2012,  
Prospective ICD-10 
diagnosed 
recurrent 
unipolar or 
bipolar 
affective 
disorder 
Yes 1 euthymic 
interval during 
observation 
period 
54 2 years Psychopathol-
ogical features 
<0.40mmol/L 
<0.50mmol/L 
Mean level for all 
patients: 
0.72±0.16mmol/L 
No generally 
occurring 
significant 
correlations 
between lithium 
serum levels  
*Cross over trial, DSM - Diagnostic & Statistical Manual of Mental Disorders, ICD - International Classification of Diseases, BPRS - brief psychiatric assessment rating 
scale, MEq = milliequivalent (For monovalent ions including lithium, 1 MEq = 1 mmol) 
Table 2.1 continued: Results of included studies - development of therapeutic lithium levels 
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Seven studies were found dating from the 1970s and 1980s when there was a significant 
amount of research being conducted around lithium treatment for affective disorders; 
the remaining two included studies are more recent from the 1990s and 2000s (Stokes et 
al., 1976, Jerram and McDonald, 1978, Hullin, 1979, Waters et al., 1982, Coppen et al., 
1983, Maj et al., 1986, Gelenberg et al., 1989, Vestergaard et al., 1998, Lewitzka et al., 
2012). 
There was no significant difference seen for the different lithium levels used in patients 
whose mood was stable at study entry or were assessed whilst euthymic apart from 
Gelenberg, Kane et al which did show an increased risk of relapse for those in the low 
dose group (Jerram and McDonald, 1978, Hullin, 1979, Lewitzka et al., 2012, Gelenberg et 
al., 1989). There was also no significant difference seen when the outcome measure 
required relapse or increase in symptoms severe enough to require hospitalisation 
(Vestergaard et al., 1998). There was a majority agreement that levels ≤0.79mmol/L held 
an increased risk of both relapse and symptom increase (Waters et al., 1982, Coppen et 
al., 1983, Gelenberg et al., 1989, Maj et al., 1986, Stokes et al., 1976). With levels 
>0.79MEq/Kg/day or 1mmol/L significant decreases in the mean number of affective 
episodes were seen (Maj et al., 1986, Waters et al., 1982) and between 0.45-0.9mmol/L 
significant decreases in the mean total morbidity were seen (Maj et al., 1986, Coppen et 
al., 1983) and this was the only level at which significance was shown for achieving 
euthymia (Stokes et al., 1976). 
These single studies have ranges of numbers of participants from 36 to 101 and as such 
each will have a different statistical power. Meta-analysis can help to increase the 
statistical power by combining studies however in this case the differences in the 
 45 
 
methods, population characteristics and specific outcomes measured meant that a meta-
analysis would not be beneficial or appropriate to use. 
2.6.2. Development of recommended monitoring frequency for lithium 
Table 2.2 details the analysis of included studies and their results. 
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Study Type of article Recommendations Based on Reasons for frequency 
Schou, 1988 Review For dose adjustment at the start of treatment 
and for control after dose changes 
 
Unclear Nephrotoxic effects 
Brodie and Feely, 
1988 
Review Start of treatment, then twice weekly for a 
week, then weekly for first month then monthly 
for next six. After this should be three monthly, 
repeated after dose changes.  
 
Unclear To anticipate the possibility of gradual 
renal function decline 
Dunner, 2000 Review 1-2 weeks until satisfactory blood level 
achieved, then 2-3 months for first 6 months, at 
least 6-12 months thereafter 
 
Expert consensus 
guidelines  
Side effects 
Sachs et al., 2000 Practice 
guideline 
Periodic Unclear Side effects and early prevention of 
decline in renal and thyroid function 
Vestergaard and 
Licht, 2001 
Review/Mini-
review 
Serum lithium determined at steady state, then 
four times a year  
 
Hospital guidelines 
from a lithium clinic 
Side effects and toxicity 
Mitchell, 2001 Review Once dose stabilised frequency of test depends 
on the individual patient’s clinical situation but 
should be no less frequency than every 6 
months 
 
Expert consensus 
guidelines  
Toxicity potential due to narrow 
therapeutic range 
Delva and Hawken, 
2001 
Continuing 
medical 
education 
article 
5 days after dose change and then one monthly 
later. Routinely every 3 months.  
Unclear Side effects and toxicity 
Table 2.2: Results of included studies - Recommended monitoring frequency for lithium, continued on the following page 
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Study Type of article Recommendations Based on Reasons for frequency 
American 
Psychiatric 
Association, 
2002 
Practice 
guideline 
At steady state (~5 days unless rapid schedule), 
after each dose increase, before the next 
Generally should be no less than every 6 
months for stable patients. The optimal 
frequency of serum level monitoring in an 
individual patient depends on the stability of 
lithium levels over time for that patient and the 
degree to which the patient can be relied upon 
to notice and report symptoms 
 
The decision to recommend a 
test is based on the 
probability of detecting a 
finding that would alter 
treatment as well as the 
expected benefit of such 
alterations in treatment. 
Laboratory measures and other 
diagnostic tests are generally 
recommended on the basis of 
pathophysiological knowledge and 
anticipated clinical decisions rather 
than on empirical evidence of their 
clinical utility. 
Grandjean and 
Aubry, 2009 
Review Recommended interval for routine serum 
concentration checking varies from 6-12 weeks 
to 6 months in stable patients 
At a minimum: after initiation of lithium 
therapy, after any change in dosage, and when 
there has been concurrent disease or any 
change in medication 
 
Previous review articles Narrow therapeutic range 
Hitchings, 
2012 
Practice article Weekly after initiation and dosage changes 
until concentrations are stable, then every 3 
months thereafter 
Unclear Side effects and toxicity 
Table 2.2 continued: Results of included studies - Recommended monitoring frequency for lithium 
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No controlled clinical trials or high quality evidence was found to support the 
recommendations for the frequency of lithium level testing. The most widely known 
frequency, and that currently recommended in UK national guidelines is based on expert 
consensus taking into consideration the clinical state of the patient and the expected 
utility of the results. The consensus guidelines do comment on the lack of empirical 
evidence of the clinical utility of laboratory tests for lithium treatment and emphasise 
that these recommendations should be adjusted to each individual patient: 
“The optimal frequency of serum level monitoring in an individual patient depends 
on the stability of lithium levels over time for that patient and the degree to which 
the patient can be relied upon to notice and report symptoms” 
 (American Psychiatric Association, 2002). 
Other recommendations, such as the increased frequency of monitoring at the start of 
treatment are based on what happens in practice. 
2.6.3. Renal effects of lithium 
Table 2.3 details the analysis of included studies and their results. 
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Study Method Diagnosis Characteristics 
of controls 
Number of 
cases OR 
participants 
Number 
of 
controls 
Specific 
outcomes 
measured 
Follow 
up 
Results 
Hullin et al., 
1979,  
Comparative study: 
Patients admitted 
overnight and 
measurements taken 
from 18hour urine 
collection 
Affective 
disorders 
Affective 
disorders, 
patients matched 
for age, sex and 
diagnosis not on 
lithium 
30 30 Compared GFR 
and Umax 
between cases 
and controls 
- Non-significant 
reduction in GFR. WMD -
20.20 (CI -41.72-1.32 ) 
Non-significant decrease 
in Umax. WMD -70.00 
(CI -171-31.27) 
Vestergaard 
et al., 1979 
Prospective cohort: 
Determination of 24-
hour creatinine 
clearance and serum 
creatinine 
Unipolar 
depression, 
bipolar 
disorder 
- 184 - Measured GFR 
at baseline and 
follow-up 
15 
months 
Significant decrease in 
GFR 
Significant reduction in 
Umax 
 
Grof, 1980,  Retrospective chart 
review: Measuring 
creatinine clearance, 
maximum urinary 
osmolality and 24 hour 
urine volume 
Affective 
disorders 
- 50  Measured GFR 
at baseline and 
follow-up 
 
68 
months 
Non-significant decrease 
in GFR 
Walker et 
al., 1982a,  
Case-control study: 
studied the renal 
histology and the renal 
function measured by 
biopsy and urinary 
concentrating ability 
Unipolar 
depression, 
bipolar 
depression, 
Schizoaffective 
disorder 
Affective 
disorders patient 
matched for age 
and sex 
47 32 Compared GFR 
and Umax 
between cases 
and controls 
 
- Excluded from analysis 
as no standard 
deviations available 
from any source 
Walker et 
al., 1982b,  
Case-control study: 
biopsies of lithium 
treated patients when 
compared with cadaveric 
donor kidneys 
Unipolar 
depression, 
bipolar 
depression 
Bipolar 
disorder/unipolar 
depression not 
taking lithium 
25 19 Compared GFR 
and Umax 
between cases 
and controls 
- Excluded from analysis 
as no standard 
deviations available 
from any source 
GFR = glomerular filtration rate, eGFR = estimated glomerular filtration rate, CrCl = creatinine clearance, Umax = urinary concentrating ability, WMD = weighted 
mean difference 
Table 2.3: Results of included studies - Renal effects of lithium, continued on following pages 
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Study Method Diagnosis Characteristics 
of controls 
Number of 
cases OR 
participants 
Number 
of 
controls 
Specific 
outcomes 
measured 
Follow 
up 
Results 
Jensen and 
Rickers, 
1984,  
Prospective cohort: 
longitudinal GFR 
measurements by 
51
Cr-EDTA plasma 
clearance 
Unknown - 13 - Measured GFR 
and Umax at 
baseline and 
follow-up 
16.5 
months 
Significant decrease in 
GFR 
Johnson et 
al., 1984b,  
Prospective cohort: 
repeated renal 
function tests  
DSM III 
diagnosed 
bipolar disorder 
- 61 - Measured GFR 
and Umax at 
baseline and 
follow-up 
 
24 
months 
Significant increase in 
GFR 
Smigana et 
al., 1984,  
Prospective cohort: 
tubular function 
studied by the 
desmopressin test and 
the GFR measured by 
creatinine clearance 
Unipolar 
depression, 
bipolar 
depression, 
Schizoaffective 
disorder 
- 53 - Measured GFR 
and Umax at 
baseline and 
follow-up 
 
12 
months 
Significant decrease in 
GFR, significant 
reduction in Umax 
Bendz, 
1985,  
Case-control study: 
longitudinal GFR 
measurements by 
51
Cr-EDTA plasma 
clearance, urine 
osmolality and urine 
volume 
Unipolar 
depression, 
bipolar 
depression, 
Schizoaffective 
disorder 
Healthy, 
matched for age 
and sex 
32 32 Compared GFR 
and Umax 
between cases 
and controls 
- Non-significant 
reduction in GFR. WMD 
-4.00 (CI -20.69-12.69). 
Non-significant 
decrease in Umax. 
WMD -68.00 (CI -
162.06-26.06) 
Vaamonde 
et al., 
1986,  
Prospective cohort: 
measurement of 
creatinine clearances 
Bipolar disorder - 7 - Measured GFR 
at baseline 
and follow-up 
90 
months 
Non-significant 
decrease in GFR 
GFR = glomerular filtration rate, eGFR = estimated glomerular filtration rate, CrCl = creatinine clearance, Umax = urinary concentrating ability, WMD = 
weighted mean difference, 
51
Cr-EDTA = chromium-51 labeled ethylenediamine tetraacetic acid 
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Follow 
up 
Results 
DePaulo et 
al., 1986,  
Prospective cohort: 
GFR measured 
creatinine clearance 
from serum 
creatinine levels 
DSM III 
diagnosed 
bipolar 
disorder 
- 40 - Measured GFR 
at baseline and 
follow-up 
 
18 
months 
Non-significant 
increase in GFR 
Hetmar et 
al., 1987b,  
Prospective cohort: 
24 hour urine 
volume,  
51
Cr-EDTA 
plasma clearance 
and 26hr water 
deprivation test 
Affective 
disorders 
- 32 - Measured GFR 
and Umax at 
baseline and 
follow-up 
 
24 
months 
Non-significant 
decrease in GFR, 
significant reduction in 
Umax 
Hetmar 
and 
Rafaelsen, 
1987c,  
Case-control study: 
24 hour urine 
volume,  
51
Cr-EDTA 
plasma clearance 
and 26hr water 
deprivation test 
Affective 
disorders 
Affective 
disorder 
patients not 
taking lithium 
32 53 Compared GFR 
and Umax 
between cases 
and controls 
- Significant decrease in 
GFR. WMD -12.60 (CI-
22.34 - -2.86) 
Excluded from Umax 
analysis as no standard 
deviations available 
from any source 
 
Åberg-
Wistedt et 
al., 1988,  
Case-control study: 
measurement of 
urine osmolality only 
Unipolar 
depression, 
bipolar 
depression, 
Schizoaffective 
disorder 
Unknown 60 30 Compared 
Umax between 
cases and 
controls 
- Excluded from Umax as 
experimental group did 
not fit profile of 
patients in other 
studies 
 
Jorkasky et 
al., 1988,  
Prospective cohort: 
repeated urinalysis, 
repeated serum 
creatinine levels and 
creatinine clearance 
Bipolar 
disorder 
- 65 (18 at 
follow-up) 
- Measured GFR 
and Umax at 
baseline and 
follow-up 
36 
months 
Significant decrease in 
GFR, significant 
reduction in Umax 
GFR = glomerular filtration rate, eGFR = estimated glomerular filtration rate, CrCl = creatinine clearance, Umax = urinary concentrating ability, WMD = 
weighted mean difference 
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of 
controls 
Specific 
outcomes 
measured 
Follow 
up 
Results 
Schou and 
Vestergaard, 
1988,  
Prospective study: 
Measuring creatinine 
clearance, maximum 
urinary osmolality and 
24 hour urine volume 
and desmopressin test 
Unipolar 
depression 
Bipolar 
depression 
-  
 
346 
39 
- Measured CrCl 
at baseline and 
follow-up 
84 
months 
Non-significant 
decrease in GFR, 
significant reduction in 
Umax 
Waller et al., 
1988,  
Prospective cohort: 
GFR, assessed by 
creatinine clearance 
and serum creatinine 
concentrations 
Unknown - 28 - Measured GFR 
and Umax at 
baseline and 
follow-up 
56 
months 
Significant decrease in 
GFR, significant 
reduction in Umax 
Muir et al., 
1989,  
Prospective cohort: 
repeated assessments 
of serum creatinine 
DSM III 
diagnosed 
bipolar 
disorder 
- 18 - Measured GFR 
and Umax at 
baseline and 
follow-up 
7.5 
months 
Non-significant 
decrease in GFR, 
significant reduction in 
Umax 
Nilsson and 
Axelsson, 
1989a,  
Prospective cohort: 
repeated assessments 
of serum creatinine 
Affective 
disorders 
- 37 - Measured 
Umax at 
baseline and 
follow-up 
84 
months 
Significant decrease in 
Umax 
Hetmar et 
al., 1991,  
Prospective cohort: 24 
hour urine volume, 
serum creatinine and  
51
Cr-EDTA plasma 
clearance 
Affective 
disorders 
- 27 - Measured GFR 
and Umax at 
baseline and 
follow-up 
120 
months 
Significant decrease in 
GFR, significant 
reduction in Umax 
GFR = glomerular filtration rate, eGFR = estimated glomerular filtration rate, CrCl = creatinine clearance, Umax = urinary concentrating ability, WMD = 
weighted mean difference 
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controls 
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outcomes 
measured 
Follow 
up 
Results 
Povlsen et 
al., 1992,  
Prospective cohort 
study: endogenous 
creatinine clearance 
from 24hour urine 
collection 
Affective 
disorders 
- 53 (13 at 
follow up) 
- Measured GFR 
and Umax at 
baseline and 
follow-up 
84 
months  
Non-significant change 
in GFR and Umax 
Kallner and 
Petterson, 
1995,  
Retrospective chart 
review: serum 
creatinine,  
51
Cr-EDTA 
plasma clearance and 
desmopressin test 
Unipolar 
depression 
Bipolar 
disorder 
- 207 - Compared 
baseline GFR 
and Umax to 
measurements 
after lithium 
stopped  
186 
months 
Non-significant 
decrease in GFR, 
significant reduction in 
Umax 
Bendz et 
al., 1996,  
Case-control study: 
serum creatinine, 
desmopressin test 
and urine volume 
measurements 
Unipolar 
depression, 
bipolar 
depression, 
Schizoaffective 
disorder 
Healthy, 
matched for age 
and sex 
13 13 Compared GFR 
and Umax 
between cases 
and controls 
- Significant decrease in 
GFR. WMD -9.00 (CI -
12.08—5.92). 
Significant reduction in 
Umax. WMD -211.00 
(CI -254.76- -167.24) 
Coşkunol 
et al., 
1997,  
Case-control study: 
24hour urine 
collection, b -
microglobulin (b -Mg) 
excretion, 
glycosaminoglycan 
levels and serum 
creatinine 
DSM III 
diagnosed 
bipolar 
disorder 
Healthy, 
matched for age 
and sex 
109 109 Compared GFR 
and Umax 
between cases 
and controls 
- Non-significant 
increase in GFR. WMD 
2.60 (CI -36.09 – 41.29). 
Significant reduction in 
Umax. WMD -229.00 
(CI -269.41- -188.59) 
GFR = glomerular filtration rate, eGFR = estimated glomerular filtration rate, CrCl = creatinine clearance, Umax = urinary concentrating ability, WMD = 
weighted mean difference 
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of controls 
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cases OR 
participants 
Numbe
r of 
controls 
Specific 
outcomes 
measured 
Follow 
up 
Results 
Bendz et 
al., 2001,  
Retrospective chart review: 
serum creatinine,  
51
Cr-EDTA 
plasma clearance and 
desmopressin test 
Unipolar 
depression, 
bipolar 
depression, 
Schizoaffective 
disorder 
- 149 - Compared 
CrCl or GFR 
and Umax 
recorded 
prior to 
lithium 
treatment  
180 
months 
Non-significant 
decrease in GFR 
Significant reduction 
in Umax 
Turan et 
al., 2002,  
Case-control study: Serum 
blood urea nitrogen (BUN), 
creatinine, urine creatinine 
and desmopressin test 
DSM IV 
diagnosed 
bipolar 
disorder 
Bipolar patients 
prior to starting 
lithium 
10 10 Compared 
GFR and 
Umax 
between 
cases and 
controls 
- Significant increase in 
GFR. WMD 24.94 CI 
3.29- 46.59) 
Excluded from Umax 
analysis as no 
standard deviations 
available  
Presne et 
al., 2003,  
Prospective cohort: kidney 
biopsy, serum creatinine 
levels and creatinine 
clearance 
Unknown - 74 - Measured 
CrCl at 
baseline and 
follow-up 
120 
months 
Significant decrease in 
GFR 
Tredget 
et al., 
2010,  
Case-control study: creatinine 
levels and calculated eGFR 
Affective 
disorders 
Severe affective 
disorders who 
had not received 
lithium 
61 62 Compared 
eGFR 
between 
cases and 
controls 
Mean 
of 11.5 
years 
Significant decrease in 
eGFR p=0.003 
Janowsky, 
2011,  
Retrospective chart review:  Aggression, 
self-injurious 
behaviours 
Previous cases: 
no indication of 
renal 
insufficiency 
16 36 Serum 
creatinine 
Mean 
of 3.2 
years 
Increases in creatinine 
levels seen 
         
GFR = glomerular filtration rate, eGFR = estimated glomerular filtration rate, CrCl = creatinine clearance, Umax = urinary concentrating ability, WMD = 
weighted mean difference 
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Study Method Diagnosis Characteristics of 
controls 
Number of 
cases OR 
participants 
Number 
of 
controls 
Specific 
outcomes 
measured 
Follow 
up 
Results 
Rej et al., 
2013, 
Retrospective 
Longitudinal Study: 
historic eGFR and 
serum creatinine 
levels 
Unclear - 42 - Change in eGFR 
between baseline 
and follow-up 
2 and 4 
years 
No significant 
correlation of lithium 
levels and change in 
eGFR p>0.57) 
Close et 
al., 2014,  
Retrospective 
cohort study: 
diagnostic codes 
for renal failure or 
renal impairment 
Bipolar 
disorder 
Bipolar disorder, 
no lithium use, 
adjusted for age 
and sex 
2496 lithium 
users 
3864 
non-
users 
Relative risk of 
renal impairment 
or renal failure 
Median 
of 5.4 
years 
Hazard ratio for renal 
failure 2.7 (CI 1.7 - 
4.3), p=0.001 
Rodrigo et 
al., 2014,  
Comparative cross-
sectional study: 
GFR from serum 
creatinine 
ICD-10 
clinical 
diagnosis 
of bipolar 
affective 
disorder  
Matched patients 
without a 
psychiatric 
condition with 
respect to age, 
gender and co-
morbidities 
47  47  Mean eGFR 
compared to 
controls 
- Statistically significant 
impairment in eGFR in 
the group without co-
morbidities (p<0.05) 
Clos et al., 
2015  
Population based 
cohort study: mean 
eGFR levels 
Unclear Patients with 
exposure to other 
first-line drugs  
305 815 Mean annual 
decline in eGFR 
- No effect of stable 
lithium maintenance 
therapy (levels within 
therapeutic range) on 
the rate of change of 
eGFR over time 
Ott ey al., 
2016,  
Population based 
retrospective 
cohort study: 
serum eGFR and 
creatinine levels 
Bipolar 
affective 
disorder 
Bipolar disorder, 
no lithium use, 
adjusted for age 
and sex 
Episodes of 
lithium 
intoxication 
- Creatinine levels 
before, during 
and after lithium 
intoxication 
- No change in renal 
function from baseline  
GFR = glomerular filtration rate, eGFR = estimated glomerular filtration rate, CrCl = creatinine clearance, Umax = urinary concentrating ability, WMD = 
weighted mean difference 
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From the meta-analysis and systematic review of studies published in 2012, a small 
reduction in GFR (0.5ml/min) was seen in lithium-treated patients over a mean 
observation time of one year. This was also reflected in case control studies where the 
GFR of lithium-treated patients was lower than that seen in controls. The maximum 
urinary concentrating ability was also reduced by about 15% in lithium-treated patients 
when compared to controls (McKnight et al., 2012, Hullin et al., 1979, Vestergaard et al., 
1979, Grof, 1980, Walker et al., 1982a, Walker et al., 1982b, Jensen and Rickers, 1984, 
Johnson et al., 1984, Smigana et al., 1984, Bendz, 1985, Vaamonde et al., 1986, DePaulo 
et al., 1986, Hetmar and Rafaelsen, 1987c, Hetmar et al., 1987b, Åberg-Wistedt et al., 
1988, Jorkasky et al., 1988, Schou and Vestergaard, 1988, Waller et al., 1988, Muir et al., 
1989, Nilsson and Axelsson, 1989a, Hetmar et al., 1991, Povlsen et al., 1992, Kallner and 
Petterson, 1995, Bendz et al., 1996, Coşkunol et al., 1997, Bendz et al., 2001, Turan et al., 
2002, Presne et al., 2003). The results found from published studies after the 2012 
systematic review correlate with these results in the main with significant increases in 
creatinine or decreases in eGFR being shown in addition to an increased hazard ratio for 
renal failure (Tredget et al., 2010, Janowsky, 2011, Close et al., 2014, Rodrigo et al., 2014). 
The studies by Rej et al., Clos et al., and Ott et al., which focussed more on different 
lithium levels or intoxication and the variation in effect on renal function, if any, did not 
show a significant correlation between lithium levels and change in eGFR (Rej et al., 
2013b, Clos et al., 2015, Ott et al., 2016). A meta-analysis including the results of studies 
published since the McKnight review was not performed due to the small number of 
additional studies found and their different inclusion and exclusion criteria, and analysis 
methods (McKnight et al., 2012). These studies were collated and a general overview of 
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the results was considered for this thesis, therefore specifics such as the frequency of 
lowered GFR on lithium cannot be determined from these results. However the recently 
included meta-analysis by Rodrigo et al., comments that in an earlier comparative 
analysis by Bolton et al., not included in this thesis, a majority (85%) of patients on long 
term lithium had normal estimated glomerular filtration rates (eGFR), 15% had reduced 
eGFRs (Bolton, 2011, Rodrigo et al., 2014). 
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2.7 Discussion 
2.7.1. Therapeutic level 
The review article by Severus et al., from 2008 highlighted that there was still uncertainty 
about the most effective lithium level for the prophylactic treatment of bipolar disorder 
(Severus et al., 2008). Historically, the serum levels for the manic stage had been 
recommended as between 0.8-1.9mmol/L. The recommendations for the prophylactic 
range used appear to have been extrapolated from the anti-manic range suggested by 
Prien et al., and the idea that the plasma concentration thought to induce toxic effects in 
patients was >2.0mmol/L and so the treatment dose lay just below this (Prien et al., 1973, 
Hullin, 1979, Jerram and McDonald, 1978). Studies conducted in this area started to look 
at both the maximum and minimum effective ranges for the prophylactic use of lithium, 
using a variety of lithium level ranges from 0.24 to 1.4mmol/L. 
Once lithium started to be used longer term as a prophylactic medication, the 
recommended levels for patients to be maintained at had not been clearly established, 
hence the number of research studies focussing on this at the time. The long-term side 
effects of lithium had also not yet been studied and concerns were raised in the design of 
these studies around what would happen to patients whose blood levels were held just 
below the toxic level. Evidence was needed to show the lowest lithium level which was 
effective in preventing relapses and lowering overall morbidity.  
Stokes et al., showed that a low dose of lithium (0.24 mEq/kg/day) was not found to be 
more efficacious than placebo, but the proportion of patients with improved manic 
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ratings did increase markedly as a function of an increased steady-state serum lithium 
level (Stokes et al., 1976). As there was no difference seen between the lithium level 
groups in the study by Jerram and McDonald, they were the first authors to suggest that 
in some patients, lithium levels below 0.49mmol/L had the potential to still be effective 
(Jerram and McDonald, 1978). With a longer-term follow-up of these same patients by 
Hullin, with a further breakdown of the low levels used, a minimum effective serum 
lithium level of 0.4mmol/L is suggested. A higher relapse was rate seen in patients whose 
lithium levels were maintained between 0.25-0.39mmol/L (Hullin, 1979). This is further 
supported by Waters et al., and Vestergaard et al., who used lithium levels down to 
0.3mmol/L and showed no significant difference between groups (Waters et al., 1982, 
Vestergaard et al., 1998). Abrupt changes in lithium level, seen in the trial designs of the 
cross-over studies, were also associated with relapses (Waters et al., 1982). Waters et al., 
commented that although the lower level lithium group in their study had more relapses 
they thought that this was due to the change in lithium level rather than the lower level 
itself. This is because there was a trend for relapse to occur within two months of an 
abrupt drop in plasma lithium level (Waters et al., 1982). 
To find the evidence for the lithium levels above which no further efficacy is gained, 
Coppen et al., first mentioned that at levels >0.8mmol/L the beneficial effect in affective 
morbidity index (AMI) was not seen compared to levels of ≤0.79mmol/L (Coppen et al., 
1983). Although patients held at 0.45-0.59mmol/L and 0.6-0.79mmol/L had a reduction in 
AMI and those at ≥0.80mmol/L had a slight increase in AMI, these changes were not 
significant. This significance seems to be due to the unipolar patients within the group as 
when the two diagnostic groups were analysed separately the unipolar patient groups 
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showed a significant reduction in AMI with a plasma lithium level on ≤0.79mmol/L but for 
the bipolar patients there was no significant difference in AMI for any of the different 
plasma lithium level ranges. This study seems to show that a reduction in lithium level 
from 0.860.2mmol/L to ≤0.79mmol/L in unipolar patients has a significant reduction in 
morbidity but it does not support the same effect in bipolar patients. At odds with the 
findings of the Coppen study, Maj et al., found that in their patients there was a 
numerically marked decrease in manic but not depressive symptoms in the 0.76-
0.9mmol/L group compared to the 0.61-0.75mmol/L group. However evidence for the 
minimum effective plasma level agreed with the earlier studies, showing that reductions 
in morbidity started at levels ≥0.45mmol/L (Maj et al., 1986). 
The only trial to look at the higher end of the lithium level ranges without the 
complicating effect of changing dose, and the potential rebound effect associated with 
this, concluded that doses resulting in serum levels from 0.8-1.0mmol/L were more 
effective than those in the lower range. After adjustment for stratifying variables (length 
of remission before study entry, number of previous episodes and polarity of recent 
episode) the low range group patients had a significantly shorter time to relapse 
according to Cox proportional-hazards regression analysis (Gelenberg et al., 1989). There 
was, however, a higher percentage of side effects such as tremor, dizziness, urinary 
frequency and weight gain in the high dose group, with borderline significance (p values: 
0.05, 0.06, 0.06, 0.07 respectively). 
Overall the optimal lithium level for the maintenance treatment of affective disorders 
appears to be between 0.4-0.79mmol/L. An increase in side effects without a consistent 
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reduction in AMI or reduction in relapses seems to occur at levels ≥0.80mmol/L. Levels 
greater than 0.8mmol/L may be effective in the short term for manic patient but are not 
therefore recommended for longer-term maintenance treatment of unipolar or bipolar 
disorder. 
2.7.2. Monitoring parameters 
No high quality evidence for the frequency of monitoring of lithium levels, either 
historically or currently, could be found in this literature review. The British National 
Formulary used to advocate routine monthly monitoring of serum lithium and currently 
recommends three monthly monitoring of lithium levels (Joint Formulary Committee, 
2015). Current national guidelines recommend three monthly levels for the first year 
reducing to six monthly after that except for patients in the following groups, taken from 
NICE Clinical Guideline number 185, page 37: 
- older people, 
- people taking drugs that interact with lithium, 
- people who are at risk of impaired renal or thyroid function, raised calcium levels 
or other complications, 
- people who have poor symptom control, 
- people with poor adherence, 
- people whose last plasma lithium level was ≥0.8 mmol/L. 
(NICE, 2014a) 
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The changes over time to the recommended frequency of monitoring of lithium comes 
from consensus agreement, behind which there is a lack of an evidence base. The 
concerns raised about the need for lithium monitoring from included studies are based on 
the prevention of side effects and to anticipate the possibility of gradual ‘creeping’ effects 
on renal function. The potential for external effects on lithium levels such as interacting 
medications, fluid intake or concurrent illness is enough to warrant continued monitoring. 
Further evidence, however, is required to confidently recommend any further changes in 
the frequency of monitoring from current guidance.  
2.7.3. Renal effects 
Renal function is important for the elimination of lithium and a declining GFR will increase 
any risks of lithium toxicity due to accumulation. Although some evidence supports the 
theory that lithium is responsible for progressive glomerular damage there is still 
evidence against this idea (McKnight et al., 2012). Most evidence suggests that although 
there is not a definitive correlation between treatment with lithium and glomerular 
function decline, leading to renal failure, there does appear to be some association 
between lithium treatment and urinary concentrating ability. 
Due to the long time period over which the studies included were performed there have 
been changes, not only in diagnostic criteria but also the accuracy of laboratory testing. 
Most of the included studies did not use a patient group which was lithium naïve and the 
duration of follow-up was not always entirely clear, making the time between exposure to 
lithium and the onset of adverse renal effects difficult to define (McKnight et al., 2012). 
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Dose information was also inconsistently recorded, so any correlations between the renal 
side effects of lithium, serum lithium levels, and doses used in practice cannot be made.  
A small reduction in GFR, 0.5ml/min over one year, does seem to be associated with 
lithium treatment. This reduction is, however, not considered clinically significant due to 
overall renal function decline over time in the general population (NICE, 2014b, McKnight 
et al., 2012). Progressive reductions in glomerular function do, however, have the 
potential to lead to end-stage renal disease. In the 1970s cases of chronic 
tubulointerstitial nephropathy were described in patients with lithium-related end-stage 
renal failure (Aurell et al., 1981, Hestbech et al., 1977). Only a small number of patients 
on long-term lithium therapy, however, go on to develop renal insufficiency or end stage 
renal disease thought to be caused by their lithium treatment (Markowitz et al., 2000, 
Coşkunol et al., 1997, Tredget et al., 2010). 
  
  
64 
 
2.8 Conclusion 
The two decades of small trials investigating therapeutic lithium levels suggested that the 
optimal lithium level for the maintenance treatment of affective disorders appears to be 
between 0.4-0.79mmol/L. The association of levels above >0.8mmol/L and a small 
reduction in GFR, unwanted side effects, fluctuations of lithium level and non-compliance 
compared to those below 0.8mmol/L is replicated in modern guidance and contrasts with 
the earlier high level of 1.5mmol/L (Severus et al., 2008). Once these therapeutic ranges 
had been defined, and have since become common practice and are reflected in current 
guidelines, the practice of the routine monitoring was debated (NICE, 2014a, BAP, 2009). 
From the literature search and review conducted for this thesis there was no robust 
evidence to support any previously recommended monitoring frequencies, which have 
ranged from monthly to yearly. 
The effect of lithium on renal function is still under debate and although there is 
increasing evidence of lithium’s effect on urinary concentrating ability, there has only 
been a small effect on GFR seen which is not consistent across all studies. Further 
breakdown of any different impact of the range of lithium levels used in practice on GFR 
has not been clearly evidenced as the studies available do not consistently report doses 
or serum lithium levels. Although the risk of end-stage renal failure is low, lithium is 
primarily renally excreted and decreases in GFR could lead to accumulation, increasing 
serum levels and so this is an area which could warrant further investigation. 
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The current evidence base is not sufficient to draw conclusions on the effect of lithium in 
patients with previous histories of lithium toxicity or the different effects of doses, 
including low-dose lithium. 
A quantitative section is needed to further establish the effects of lithium and lithium 
levels on renal function using the data collected from a lithium register and monitoring 
database in operation throughout Norfolk. Firstly a sense is needed of this data base and 
the type of impact, if any, it has had on lithium monitoring. The robustness of the data 
and a general sense of the data collected is needed in order to see if analysis of the 
database can add to these gaps in the current literature. Secondly, a disparity in the 
prescribing of lithium between the two counties covered by the one Mental Health Trust 
in the area has been shown from prescribing data and it is not yet known what factors are 
behind this disparity (Powell-Smith and Goldacre, 2015).  
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 Chapter Three     
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3: An evaluation of the impact of active management of 
lithium monitoring within Norfolk 
3.1 Introduction 
Lithium is known to have significant side effects and requires close serum level 
monitoring to ensure levels remain within the therapeutic range to minimize the risk of 
serious adverse effects or toxicity. Lithium levels are also affected by the patient’s renal 
function, any changes is this or their fluid balance and some concomitant medications 
that affect kidney function and the excretion of lithium (NPSA and NRLS, 2009). Lithium 
can also cause hypothyroidism, the symptoms of which can overlap with some features of 
bipolar disorder, particularly in the depressed poles of the illness. Without regular and 
specific screening tests being carried out small, but potentially incremental, changes in 
renal function or a new onset of hypothyroidism mimicking symptoms of depression, may 
remain undiagnosed. 
There were no national guidelines for the monitoring of lithium, outside of the 
recommendations in the BNF, until 2003 with the publication of the British Association for 
Psychopharmacology (BAP) guidelines and 2006 with the National Institute for Health and 
Care Excellence (NICE) bipolar guidance (NICE, 2006, BAP, 2009). The BAP guidelines focus 
on the evidence behind the treatment options for bipolar disorder with no mention to 
frequency of monitoring,  
Lithium therapy is thought to be prone to errors occurring in prescribing and audits have 
shown that the monitoring of lithium, even after the release of the guidelines above, was 
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unsatisfactory (NPSA, 2009, Collins et al., 2010). As an aid to help healthcare practitioners 
comply with the frequency of lithium monitoring recommended by NICE, the National 
Patient Safety Agency released a patient safety alert on safer lithium therapy. This alert 
made monitoring and the provision of information to patients prescribed lithium a 
priority for all healthcare organisations where ‘lithium therapy is initiated, prescribed, 
dispensed or monitored’ (NPSA, 2009). 
Within Norfolk a therapeutic drug monitoring database was set up, prior to this NPSA 
safety alert, to improve the standards of lithium monitoring throughout the region. This 
occurred following several incidents in primary care within Norfolk involving lithium 
therapy and inadequate monitoring (Holmes, 2005).This chapter will focus on an 
evaluation of this actively managed database to determine its impact on the monitoring 
of lithium treatment within the county. Currently there has not been an analysis of the 
database and its impact on monitoring of lithium in a way that is comparable to national 
audits and results. 
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3.2 Standards of lithium monitoring in the UK 
In order to improve standards of care received by patients with mental health or 
emotional needs the Royal College of Psychiatrists College Centre for Quality 
Improvement (RCPsychCCQI) exists. The sole aim of this centre is to improve the quality 
of psychiatric care through the use of audit-based Quality Improvement Programmes 
(QIPs) (Collins et al., 2010). The Prescribing Observatory for Mental Health UK (POMH-UK) 
is part of the CCQI and facilitates audit-based QIPs focussing on medications and their use 
and monitoring within psychiatry. In 2009 all National Health Service (NHS) Trusts within 
the UK providing specialist mental health services were invited to participate in a baseline 
audit on the quality of lithium monitoring (Collins et al., 2010). This was the first 
published audit on national lithium prescribing and monitoring within the UK.  
Patient data were submitted from 38 Mental Health Trusts, excluding Norfolk, from 436 
clinical teams and included 3373 patients. The number of Mental Health Trusts in the UK 
at the time is not evident from the report however there are 60 Trusts included in the 
2015-16 POMH-UK programme (Royal College of Psychiatrists, 2016). Having a central 
register of patients prescribed lithium is rare and so Trusts used a variety of methods to 
identify their sample including a census of prescriptions, clinical team caseloads, 
pharmacy and pathology records (Collins et al., 2010). The audit standards were derived 
from the NICE guideline for bipolar disorder published at the time which stated that 
during maintenance treatment with lithium: ‘a serum lithium level should be taken every 3 
months, renal and thyroid function tests should be completed every 6 months (more often 
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if there is evidence of impaired renal function), and weight, BMI or waist circumference 
should be done annually’ (NICE, 2006). 
In addition to NICE recommendations the Quality and Outcomes Framework (QOF) also 
sets targets for the monitoring of patients receiving lithium in primary care in the UK. The 
QOF was initiated in 2004, as part of the General Medical Services Contract as a voluntary 
scheme. Practices in primary care are scored against groups of indicators within this 
incentive scheme, according to their level of achievement (The Information Centre for 
Health and Social Care, 2012). Within the QOF section on mental health practices are 
scored for: ‘the percentage of patients on lithium with a record of serum creatinine and 
thyroid stimulating hormone (TSH) within the preceding 9 months, a record of lithium 
levels in the therapeutic range within the previous 4 months and a BMI recorded in the 
past 15 months’ (The Information Centre for Health and Social Care, 2012).  
There were two groups of patients within the POMH-UK data: patients who had been 
prescribed lithium for less than a year; and those patients who were prescribed lithium 
maintenance treatment and had been on it for over a year. If multiple test results were 
reported in one month these were treated as one data point as they were unlikely to be 
due to routine monitoring (Collins et al., 2010).Table 3.1 shows the frequency of tests for 
patients on maintenance treatment included in this audit. 
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Number of tests in past 
year 
U&Es with 
creatinine 
Thyroid function 
tests 
Serum 
lithium 
n=2976    
0 553 (19) 524 (18) 273 (9) 
1 795 (27)* 976 (33)* 668 (22) 
2 592 (20)# 693 (23)# 572 (19)* 
3 466 (16)# 453 (15)# 561 (19)* 
4 313 (11)# 208 (7)# 503 (17)# 
5 or more 257 (9)# 122 (4)# 399 (13)# 
* meets QOF targets, # meets NICE standards 
Table 3.1: POMH-UK data - Lithium monitoring tests or measures conducted during 
maintenance treatment, all are number (percentage), adapted from Collins et al., 2010. 
This data showed that 19% of patients had no record of renal function tests, including 
creatinine, 18% had no record of thyroid function tests and 9% had no record of lithium 
levels in the preceding year. Only 30% of patients who had been prescribed lithium for 
over a year had received four or more lithium tests in the preceding year and 38% of 
patients had two or three tests. Data for renal function tests recorded within the past 
year, including creatinine, showed that 83% of patients had one or more tests, and 56% 
had two or more tests recorded. For thyroid function tests 82% of patients had one or 
more tests and 49% had two or more tests recorded (Collins et al., 2010).  
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3.3 Patient safety alert 
In December 2009, the National Patient Safety Agency (NPSA) released a patient safety 
alert in an attempt to improve the safety of lithium therapy within the UK (NPSA, 2009). 
The release of this patient safety alert was in part due to the results of the POMH-UK 
audit as well as concerns about patient safety incident reports. In the five years prior to 
this NPSA alert, the National Reporting and Learning System (NRLS) received 567 patient 
safety incidents related to lithium therapy (NPSA and NRLS, 2009). During the same time 
frame in Norfolk there were there were no reported incidents relating to lithium therapy 
monitoring (Cree, 2011). The majority of these incidents resulted in no or low harm. 
However a key theme was inadequate patient monitoring (NPSA, 2009). 
A lack of patient monitoring, and the risks it entails, also holds a risk of litigation. In a ten 
year review the Medical Defence Union found that there were over 100 cases of litigation 
involving lithium prescribing and monitoring. Out of these poor monitoring was cited in 
59 of these cases, 13 of which involved deaths (excluding suicides), and 44 were cases of 
toxicity with various outcomes (Holmes, 2005). No further details were available on 
whether this poor monitoring was related to medication or other monitoring of the 
patient. Between 1995 and 2004 the NHS Litigation Authority dealt with two fatal and 12 
severe harm incidents which involved lithium therapy (NPSA, 2009). The NPSA alert 
highlighted the need for regular monitoring in line with NICE guidance, reliable 
communication systems for blood test results, the provision of appropriate verbal and 
written information to patients and that systems are in place to identify and deal with 
medicines that may adversely interact with lithium therapy (NPSA, 2009). 
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3.4 Implementation of the Norfolk-wide database 
In May 2000, the newly formed clinical liaison prescribing sub-group of the Norfolk 
Mental Health Care Trust (NMHCT1) conceived the idea of a Norfolk wide lithium register 
and database which came to be known as SystemTDM®. A series of clinical incidents had 
occurred involving lithium toxicity and this had raised concerns over a lack of a consistent 
approach in monitoring. Norwich Primary Care Trust (PCT) requested an investigation into 
the standard of lithium monitoring in GP practices, and found a wide variability in 
standards (Holmes, 2005). The pathology lab at the Norfolk and Norwich University 
Hospital (NNUH) also carried out a survey extracting data from their system for any 
lithium levels recorded between October 1999 and October 2000. There were a total of 
1457 lithium patients found on the system and out of these 32.6% had only one test 
recorded, 54.3% had one or two tests, 45.6% had three or more tests, and 29.4% had four 
or more tests. It is not known how many patients had no tests during the year as data 
could only be extracted for those patients who had at least one lithium level recorded on 
the pathology system at the NNUH (Holmes, 2005). 
The main objectives of SystemTDM® are to ensure that all patients prescribed lithium 
have access to adequate information, education and specialist advice and receive regular 
blood tests following an agreed protocol (Norwich Clinical Liaison Group, 2010). Once the 
decision is taken by a prescriber to prescribe a patient lithium, a registration form is 
                                                     
 
1 Norfolk Mental Health Care NHS Trust became Norfolk and Waveney Mental Health Partnership NHS Trust 
in 2004, a Foundation Trust in 2008 and subsequently Norfolk and Suffolk NHS Foundation Trust in 2012. 
  
74 
 
completed. After registration patients receive an information pack and the blood test 
reminder system is set in place. Reminders are automatically sent, by letter, 11 weeks 
after each lithium test, for 12 weekly blood tests, but these can be altered if a different 
frequency of monitoring is required. Follow-up contact is made with both the patient and 
prescriber if no test results are subsequently recorded on the database (Holmes, 2005). 
By May 2012, the database had been in existence for almost ten years across Norfolk 
allowing the on-going effect of the database on rates of testing for lithium levels and 
other monitoring parameters to be evaluated.  
The database is also considered an ‘active management’ database in that it not only sends 
out reminders for blood tests to the relevant people involved in the patients care but it 
also alerts prescribers to any results that are out of the range specified for that patient. 
The time taken for the next test to be taken only shows that a re-test has been done but 
not how long they remain at levels >1.0mmol/L. There is currently no way of predicting 
which patients are at risk of developing histopathological changes after long-term 
treatment with lithium and if this is associated with the time spent at different lithium 
levels. The mechanism(s) behind the histopathological changes are not fully understood, 
nor is the true long-term risk of lithium treatment (Raedler, 2012, Raedler and 
Wiedemann, 2007, McKnight et al., 2012, Joint Formulary Committee, 2012). 
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3.5 Aims and Objectives 
3.5.1. Aim 
The aim of this service evaluation was to determine the impact of an actively managed 
database (SystemTDM®) on the services provided to patients by evaluating the rates of 
testing and responses to lithium levels outside of the recommended ranges from NICE 
(NICE, 2006). 
3.5.2. Objectives 
The objectives of this evaluation were to: 
- Establish the frequency of lithium, creatinine and thyroid function tests for 
patients registered on SystemTDM®, 
- Evaluate the impact of SystemTDM® on these rates of testing, 
- Establish the frequency of lithium levels outside of the recommended ranges and 
the speed of response to lithium levels outside of the recommended ranges, 
- Evaluate the impact of SystemTDM® on the speed of response to these levels. 
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3.6 Methods 
The protocol and supporting documentation for the analyses in chapters three, five and 
six are included in appendices one, two and three respectively. This research was limited 
to secondary use of information previously collected in the course of normal care, 
without an intention to use it for research at the time of collection. It is therefore 
excluded from Research Ethics Committee (REC) review, provided that the patients or 
service users are not identifiable to the research team in carrying out the research. Local 
research governance approval was received from Norfolk and Suffolk NHS Foundation 
Trust (NSFT) Research Governance Committee prior to commencing data extraction. 
3.6.1. Data extraction 
The clinical pharmacy team had access to the full data stored on SystemTDM® and passed 
on the following data to the primary researcher (PhD student) once anonymised: 
database ID, date of test results and results for: lithium, creatinine, and thyroid function 
(thyroxine (T4) and thyroid stimulating hormone (TSH)). The data was checked by the 
clinical team and duplicate entries were removed. For example some patient IDs 
appeared twice in the original data with differing genders or dates of birth with results 
recorded for one of these IDs. The clinical team clarified the correct entry and ensured 
that the correct anonymised entry was passed onto the research team. 
From these anonymised results received, test results for 2005, 2009 and the most recent 
year at the time which was 2012 (Jan 1st –Dec 31st) were used for this evaluation. The 
year 2005 was taken as the first year of the database for the purposes of this analysis to 
  
77 
 
allow time for SystemTDM® to become routine across the whole county as it was fully 
rolled out by mid-2004, and 2009 was used to enable comparisons to the POMH-UK data. 
Multiple tests conducted within the same calendar month were counted as a single test 
as these were likely to have been conducted for a purpose other than routine monitoring. 
If no result was inputted for a recorded test date i.e. a test was logged but had no result 
recorded, these were excluded, and duplicates in terms of all variables were dropped. 
Patients whose database IDs were linked to individualised level ranges outside of the 
nationally recommended range (0.4-1.0mmol/L) were also excluded as it was not known 
from the data available what the reasons were for these individual level ranges being set, 
this related to only one patient registered on the database. Once registered patients with 
individualised level ranges had been excluded there were 1465 patient IDs passed onto 
the primary researcher for analysis for 2005, 1536 for 2009 and 1381 for 2012.  
The number of patients registered and receiving the nationally recommended numbers of 
blood tests for various monitoring parameters was then analysed. Four groups of ranges 
of lithium levels were chosen to be analysed: <0.4mmol/L, 0.41-0.8mmol/L. 0.81-
1.0mmol/L and >1.0mmol/L as these ranges reflect current UK practice and consensus 
agreement (NICE, 2006, BAP, 2009). The time taken for the patient to have another blood 
test after a lithium level result of >1.0mmol/L was calculated. This was done for all results 
of >1.0mmol/L received in 2005, 2009, and 2012 and gave the number of observations, 
the mean, and the median time to the next observation. The number and the percentage 
of recorded tests within seven, 14, 21, 28 and 90 days were calculated. A Kruskal-Wallis 
test was performed on the data, as it could not be confirmed if repeated tests were 
conducted on the same participants at all three years from the way that the data was 
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modelled for the analysis. Therefore the same patients were not necessarily followed 
through at all three years.  
The time to the next lithium level recorded as <1.0mmol/L was then calculated after a 
level was recorded as >1.0mmol/L for the three date ranges of 2005, 2009, and 2012; this 
gave the number of observations, the mean, and median time to the next observation. 
The number and the percentage of recorded tests that were <1.0mmol/L by seven, 14, 
21, 28 and 90 days were calculated. A Kruskal-Wallis test was performed on the data, as it 
could not be confirmed if repeated tests were conducted on the same participants at all 
three years from the way that the data was modelled for the analysis. Therefore the same 
patients were not necessarily followed through at all three years. 
Including only patients who had tests at all three years would significantly reduce the 
sample size available due to patients being added or removed from the database over the 
timeframe from 2005 to 2012. 
STATA SE 12.1 was used for all statistical analysis (StataCorp, 2011).  
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3.7 Service evaluation results 
3.7.1.  Rates of testing 
Table 3.2 shows the number of patients registered on SystemTDM® and the frequency of 
their lithium level tests between Jan 1st –Dec 31st 2005, Jan 1st –Dec 31st 2009 and Jan 1st –
Dec 31st 2012, all are number (percentage). 
Number of tests in the past year 2005 2009 2012 
n= 1465 1536 1381 
0 133 (9.1) 0 (0) 15 (1.1) 
1 704 (48.1) 61 (4.0) 90 (6.5) 
2* 306 (20.9) 105 (6.8) 115 (8.3) 
3* 161 (10.9) 307 (15.2) 233 (16.9) 
4 or more# 161 (10.9) 1063 (69.2) 928 (67.2) 
* meets QOF targets, # meets NICE standards 
Table 3.2: Lithium level tests conducted on registered patients between Jan 1st –Dec 31st 
2005, Jan 1st –Dec 31st 2009 and Jan 1st –Dec 31st 2012  
Table 3.2 shows that in 2005 the majority of patients registered on SystemTDM® were 
receiving fewer than the recommended four serum lithium tests per year (89.0%). A large 
proportion of these patients had one or two tests recorded (69.0%). At the time of the 
POMH-UK audit in 2009 this proportion has noticeably increased, with the majority of 
patients now receiving four or more lithium tests per year (69.2%). By 2012 these figures 
have not altered, with the majority of patients still receiving four or more tests per year 
(67.2%). 
Table 3.3 shows the number of patients and the frequency of their creatinine tests 
between Jan 1st –Dec 31st 2005, Jan 1st –Dec 31st 2009 and Jan 1st –Dec 31st 2012, all are 
number (percentage). 
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Number of tests in 
the past year 
2005 2009 2012 
n= 1465 1536 1381 
0 1242 (84.8) 176 (11.5) 17 (1.2) 
1* 84 (5.7) 116 (7.6) 165 (11.9) 
2 or more# 138 (9.4) 1244 (81.0) 1199 (86.9) 
* meets QOF targets, # meets NICE standards 
Table 3.3: Creatinine tests conducted on all registered patients between Jan 1st –Dec 31st 
2005, Jan 1st –Dec 31st 2009 and Jan 1st –Dec 31st 2012 
This shows that in 2005 the large majority of patients were not receiving two or more 
creatinine level tests per year as a marker of renal function. By 2009 and again by 2012 
there are increases seen in the numbers of patients receiving two or more creatinine level 
tests over each year analysed. 
Table 3.4 shows the number of patients and the frequency of their thyroid function tests 
between Jan 1st –Dec 31st 2005, Jan 1st –Dec 31st 2009 and Jan 1st –Dec 31st 2012, all are 
number (percentage). 
Number 
of tests in 
the past 
year 
T4 TSH 
2005 2009 2012 2005 2009 2012 
n= 1465 1536 1381 1465 1536 1381 
0 1409 (96.2) 498 (32.4) 330 (23.9) 1228 (83.8) 205 (13.3) 36 (2.6) 
1* 28 (1.9) 175 (11.4) 309 (22.4) 117 (8.0) 123 (8.0) 209 (15.1) 
2 or 
more# 
28 (1.9)  863 (56.2) 742 (53.7) 120 (8.2)  1208 (78.6) 1136 (82.3) 
* meets QOF targets, # meets NICE standards 
Table 3.4: Thyroid function tests conducted on all registered patients between Jan 1st –
Dec 31st 2005, Jan 1st –Dec 31st 2009 and Jan 1st –Dec 31st 2012 
In 2005 a small number of patients had two or more tests for T4 and TSH recorded. By 
2009 and again by 2012 there are increases seen in the numbers of patients receiving two 
or more two or more tests for T4 and TSH over each year analysed. 
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3.7.2. Speed of response to lithium levels outside of the recommended range 
Table 3.5 shows the number of tests recorded as >1.0mmol/L and the times taken for a 
retest, figures are number (percentage). 
Time to next lithium level test Year  
2005 2009 2012  
Number of tests recorded as 
>1.0mmol/L 
192  243 222  ANOVA between years 
≤7 days 63 (32.8) 107 (44.0) 132 (59.5) p=<0.05 
8-14 days 13 (6.8) 35 (14.4) 23 (10.4) p=<0.02 
15-21 days 7 (3.6) 22 (9.1) 8 (3.6) p=<0.01 
22-28 days 2 (1.0) 12 (4.9) 5 (2.3) p=<0.01 
29-90 days 58 (30.2) 34 (14.0) 36 (16.2) p=<0.01 
>90 days 49 (25.5) 33 (13.6) 18 (8.1) p=<0.01 
Table 3.5: Number of tests recorded as >1.0mmol/L and the times taken for a retest in 
2005, 2009, and 2012. 
This shows a significant difference between the numbers of patients receiving a retest 
within seven days (p=<0.05), 14 days (p=<0.02), 21 days (p=<0.01), 28 days (p=<0.01) and 
90 days (p=<0.01) in 2005, 2009, and 2012. For the years 2005, 2009, and 2012 after all 
reports of a level of >1.0mmol/L the time taken (in days) for the level to drop back below 
1.0mmol/L was calculated. 
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Table 3.6 shows the time taken for the lithium levels to return to <1.0mmol/L after a level 
of >1.0mmol/L was reported, figures are number (percentage). 
Time to next lithium level 
<1.0mmol/L after a level 
>1.0mmol/L  
Year  
2005 2009 2012  
Number of tests recorded as 
>1.0mmol/L 
192  243 222  ANOVA between years 
≤7 days 37 (19.3) 77 (31.7) 101 (45.5) p=<0.02 
8-14 days 14 (7.3) 38 (13.0) 21 (9.5) p=<0.01 
15-21 days 9 (4.7) 23 (9.5) 8 (3.6) p=<0.01 
22-28 days 1 (0.5) 12 (4.9) 7 (3.2) p=<0.01 
29-90 days 36 (18.8) 36 (14.8) 37 (16.7) p=<0.02 
>90 days 94 (49.0) 54 (22.2) 46 (20.7) p=<0.01 
Missing 1 (0.5) 0 (0.0) 0 (0.0)  
Table 3.6: Time to next lithium level <1.0mmol/L after a level >1.0mmol/L has been 
reported in 2005, 2009, and 2012. 
This showed a statistically significant difference in the time for the level to return to 
<1.0mmol/L within seven days (p=<0.02), 14 days (p=<0.01), 21 days (p=<0.01), 28 days 
(p=<0.01) and 90 days (p=<0.02) between the years 2005, 2009, and 2012 i.e. random 
sampling would not result in a sum of ranks as far apart as shown here. 
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3.8 Discussion 
Since the implementation of SystemTDM® throughout Norfolk there has been a steady 
increase in the number of people receiving lithium, renal and thyroid function tests as 
recommended by NICE (NICE, 2006). The results from this evaluation were from a year 
before the NICE guidance was published for lithium monitoring. However, the results for 
Norfolk from the same year as the POMH-UK audit show that the number of patients 
having all of the required monitoring tests were much higher. There were 69.2% of 
patients within Norfolk having the recommended four or more lithium level tests per year 
compared to 30% nationally (Collins et al., 2010). For the other monitoring parameters 
the same is seen with 81% of patients within Norfolk having the recommended two or 
more tests for creatinine compared with 56% nationally and 67.4% of patients within 
Norfolk having the recommended two or more tests for compared to 49% nationally for 
thyroid function tests (combined) (Collins et al., 2010). These frequencies have continued 
to increase by 2012, albeit at a slower rate. 
These results show that with the use of SystemTDM® NSFT were able to achieve much 
better rates of testing for all monitoring parameters, more in line with national 
guidelines, than other NHS Trusts who took part in the POMH-UK audit. Due to the 
movement of patients within the country, new starters and people stopping lithium as 
well as the potential for end of life patients being included in the analysis it would not be 
expected that 100% of patients would be able to be monitored in line with the guidance. 
As discussed in the literature review the risk-benefit of lithium for treating symptoms 
whilst minimising side effects seems to change at levels above 0.8mmol/L. Levels up to 
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1.0mmol/L still show some additional benefit albeit with the burden of an increased risk 
profile for developing side effects. The long-term effect of lithium treatment at different 
levels on renal function, and the duration of time patients remain at these levels has not 
been established (McKnight et al., 2012).  
3.8.1. Strengths and Limitations 
One limitation of this data is that we were not able to control for other external factors 
that could have impacted on this increase in lithium level monitoring in the years since 
the database implementation. However from an internal audit conducted in 1999 from 
one of local pathology labs similar rates of testing to 2005 were seen suggesting that such 
a noticeable improvement in rates of testing was not just due to the secular trend.  
During the timeframe of the data analysed the POMH-UK audit was conducted and 
reported, additionally the Quality and Outcomes Framework was implemented including 
markers for lithium monitoring. These two external factors may have had a significant 
effect on the rates of testing seen in the data analysed.  
New initiates and people stopping lithium may also be included in the analysis and may 
account for the 0 to 1 levels recorded. This could not be determined from the data 
available to the research team.  
The reasons for levels recorded as >1.0mmol/L and the actions taken by the clinical team 
once these results were reported are also not known from the information on 
SystemTDM®, only the time taken for retests to occur and the levels recorded from them. 
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In this analysis patients did not need to have a reading at all three time points to be 
included in the analysis in a bid to maintain sample size, however if only those patients 
who did have three tests recorded across the three years analysed may ultimately have 
greater power with a much smaller sample size and further work could be undertaken 
with those patients data. 
3.9 Conclusion 
These results suggest that an actively managed database for lithium aids more effective 
monitoring of lithium by improving the response times to high levels. This reduces patient 
exposure to the potentially toxic effects of lithium levels >1.0mmol/L. In addition to the 
increase in the rates of testing and the speed of response to levels >1.0mmol/L, in the five 
years prior to the patient safety alert after the POMH-UK audit, there were no reported 
incidents relating to lithium therapy monitoring within Norfolk compared to the 567 
patient safety incidents reported to the NRLS in the same time frame. This suggests that 
the database has had a direct impact on improving patient safety (NPSA, 2009, Cree, 
2011) however the impact of external factors such as an increase in training and 
awareness of lithium and the introduction of QoF in 2004 cannot be quantified. 
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4: Factors affecting lithium prescribing 
4.1 Introduction 
As discussed previously the short and long-term effects of lithium on the kidneys are still 
not fully understood and it is not known whether there is any impact from having a 
robust monitoring system in place to aid in the therapeutic drug monitoring of lithium on 
prescribing decisions due to the slight unknown around the long-term effects of lithium. 
The process for prescribing lithium is slightly different to many other medications, in part 
due to the level of involvement required for all parties when it is prescribed. Nationally, 
where lithium prescribing is hospital initiated, there are shared care agreements in place 
allowing secondary care initiation and prescribing until patients are stabilised and 
transferred to primary care for continued treatment and monitoring (Collins et al., 2010). 
These sort of shared care agreements have been in place in both Norfolk and Suffolk since 
2002. 
Prescribing information suggests that lithium appears to be prescribed more often in 
Norfolk as in Suffolk per head of population, despite the similarity in their current shared 
care agreements, population size, and age distribution (Anderson, 2012, ONS, 2011, 
Powell-Smith and Goldacre, 2015). There is a lack of research on the factors which 
influence prescribing decisions for established treatments; most focusses on new drugs 
and comparisons between primary and secondary care or comparisons between different 
healthcare professionals (Schumock et al., 2004, Ljungberg et al., 2007). 
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4.2 Current beliefs about decision making in prescribing 
There have been several studies in the last two decades researching various aspects of 
decision making in prescribing, but these have mostly focussed on prescribing in primary 
care or the prescribing of new drugs (Prosser and Walley, 2006, Cutts and Tett, 2003, 
Denig et al., 2002b, Jones et al., 2001, Jaye and Tilyard, 2002). Qualitative studies of the 
influences of prescribing in secondary care are scarce. Those studies that have looked at 
secondary care prescribing have looked at the differences in factors which influence drug 
use between doctors, formulary commikttee members and other prescribers, or the 
schemas that doctors apply to their decision making (Schumock et al., 2004, Higgins and 
Tully, 2005). 
One recent systematic review on non-medical prescribing had also completed a scoping 
literature search which also showed that most research had been conducted in primary 
care where the bulk of prescribing occurs. This scoping literature search showed that 
decisions around prescribing were based on a range of factors both clinical and non-
clinical which included: 
- Patient expectations 
- The doctor-patient relationship 
- Doctors previous prescribing behaviour 
(McIntosh et al., 2016) 
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It is difficult to tell if the influences on the prescribing of new drugs are the same as on 
prescribing in general. Newly marketed drugs are often accompanied by scientific 
literature alongside an intensive marketing campaign from the relevant manufacturers 
(Ljungberg et al., 2007). In the first stage of decision-making around new drug prescribing 
pharmaceutical representatives are thought to be particularly influential as they appear 
to directly increase awareness of a product, or highlight situations where the new drug 
has advantages over drugs currently available (Prosser and Walley, 2006, Jones et al., 
2001, Ljungberg et al., 2007). This impact of advertising or marketing of medications is 
not reflected across all studies, with those investigating schemas used for prescribing 
decisions or the impact of guidelines reporting little to no influence of marketing on the 
choice of what medicines to prescribe (Perlis, 2007, Schumock et al., 2004, Gill et al., 
1999). Although knowledge was needed for the process of prescribing, the source of this 
information and the doctor’s interpretation of this influenced the readiness to prescribe 
certain drugs. The habits of the prescriber and how drugs can be applied in practice to 
specific patients can lead to differing decisions for the same clinical cases (Denig et al., 
2002b, Ljungberg et al., 2007). Where the information was received through personal 
communication this appears to have a greater impact on the prescribing decisions than 
information received through other media (McGettigan et al., 2001). 
Monitoring of drugs for doctors working in rural localities has been shown to be a 
significant factor in the choice of drug to prescribe, so the geographic location of patients 
and their ability to engage with monitoring from a practical perspective is also important 
(Cutts and Tett, 2003). Although the concerns raised by participants in the Cutts and Tett 
study were for general medications this could be an even greater influencing factor for 
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lithium which is known to have a narrow therapeutic range and require close serum level 
monitoring. 
In the study by Higgins and Tully evaluating whether prescribing is viewed as part of a 
holistic treatment or as a separate entity, a difference was shown between consultants 
and junior doctors. Consultants viewed prescribing as part of a more holistic approach to 
treatment whereas junior doctors did not show this thought process. Each prescribing 
decision made by consultants also involves a risk-benefit or cost-benefit analysis for each 
patient and their individual situation (Higgins and Tully, 2005). Jaye and Tilyard looked to 
see if the length of time doctors had been practising for influenced the relative costs of 
drugs they prescribed. Doctors who reported more experience were shown to be lower 
cost prescribers and high cost prescribers reported more concerns about not being able 
to define a clear diagnosis (Jaye and Tilyard, 2002). If prescribers are more familiar with 
certain drugs they have been shown to choose these drugs over others with which they 
are less familiar (Ljungberg et al., 2007). 
Lithium is a well-established drug and it is not clear if the factors influencing decisions 
whether to prescribe it are the same as for newer drugs. It also requires serum level 
monitoring which has been shown to be a negative factor when prescribing general 
medications. With the disparity of prescribing between Norfolk and Suffolk where one 
county has a system designed to aid the engagement and monitoring of lithium it is not 
clear if this is an influencing factor or if there are other reasons for the variation seen. To 
determine the potential reasons for the difference in prescribing rates between Norfolk 
and Suffolk an exploration of the factors which affect the decision to prescribe lithium by 
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interviewing consultants across Norfolk and Suffolk NHS Foundation Trust (NSFT) was 
needed. For those consultants based within Suffolk this was done before the lithium 
monitoring database SystemTDM® becomes normal practice as it currently is within 
Norfolk. 
From these articles found as part of the literature search, covering not only secondary 
care prescribing but also primary care and in areas other than psychiatry there were two 
main domains which recurred in the conclusions about factors influencing prescribing: 
1. Weighing up clinical factors which could include: 
- Patient symptom and severity and diagnosis, 
- Patients past experience with medications, 
- Medication side effects, 
- Concurrent physical health problems, 
- Medication interactions, 
- Prescribers experience with medications, 
- Patient preference and beliefs. 
2. Interacting with the patients (and relatives where relevant) along the journey to 
prescribing in a shared-decision making process. 
(Chow et al., 2014, Hajjaj et al., 2010, Rajendran et al., 2012, Shepherd et al., 2014, Denig 
et al., 2002b, Ljungberg et al., 2007, McGettigan et al., 2001, Tan et al., 2009, Hedenrud 
et al., 2013). 
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4.3 Aims and objectives 
4.3.1. Aim 
The aim of this project is to build on the limited research into established drugs to 
understand the factors affecting lithium prescribing, by eliciting the views and 
perceptions of consultants working within NSFT on their current practice through in-
depth semi-structured interviews. 
4.3.2. Objectives 
The objectives of the in-depth semi-structured interviews will be to: 
- Explore consultants’ views on lithium as a drug, 
- Explore what factors consultants consider as influential in decisions to prescribe 
lithium or another drug in current practice, 
- Describe the effect of current guidance on the prescribing of lithium, 
- Describe the effect of the current shared care agreement and the procedure for 
transfer of prescribing to primary care, 
- Compare the views and perceptions of Norfolk and Suffolk based consultants on 
the prescribing of lithium i.e. comparing the views of those experienced with 
SystemTDM® and those who are not. 
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4.4 Interview rationale 
The focus of this project was on prescribing decisions and the factors influencing these in 
current practice, with a specific interest on lithium. There was anecdotal evidence that 
lithium was prescribed about twice as often in Norfolk than in Suffolk despite the relative 
similarity of the populations of these two counties, supported by prescribing data 
recently accessible (Anderson, 2012, Powell-Smith and Goldacre, 2015). Lithium is 
currently classified as an amber drug by local drugs and therapeutics committees under 
clinical commissioning groups (CCGs). This means that the initiation of lithium is 
recommended to occur within specialist services, with GPs in primary care being invited 
to take over the responsibility for prescribing and monitoring once the patient has been 
stabilised. In Norfolk when a patient is initially prescribed lithium or is transferred into the 
area they should be registered by their GP or consultant with SystemTDM®(Dye and 
Barker, 2010, Norwich Clinical Liaison Group, 2010). 
A qualitative phenomenological perspective was used exploring how prescribers make 
sense of prior experiences and their surroundings and translate this into practice. 
Quantitative research methods would not therefore be appropriate as they would not 
facilitate the in-depth exploration of the different participants’ experiences and how they 
perceive, describe, feel about, remember and make sense of these experiences in relation 
to their current prescribing practices (Patton, 2002). 
Questionnaires and focus groups were considered for this study as both have their 
advantages and disadvantages. Although the use of a questionnaire allows greater 
anonymity for the respondent, there is no control over who actually completes the 
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questions. The design of the questions must be simple so that they are understood by all 
respondents; however, there is no way of probing or clarifying answers or resolving any 
potential misunderstandings. The way the respondents interpret questions cannot be 
predicted with the use of questionnaires, even with the use of a pilot study, so there is a 
risk of gathering unreliable information or for the respondents to answer questions in a 
way that they think the researcher wants (Phellas et al., 2011). 
If focus groups had been chosen then this would have allowed for opinions to be 
gathered from a large number of prescribers and allow for more depth of response than 
questionnaires but they would also provide an environment where the influences of 
other prescribers could affect responses (Tonkiss, 2011). Focus groups would explore a 
range of views expressed within the group and how the participants negotiate these 
whereas for this study the personal reflections and experiences and decision making 
factors for each individual consultant on their current practice were wanted. Interviews 
were therefore chosen because the strengths of this method are well suited to our study. 
They facilitate a depth of focus and understanding of perspectives and experiences of 
individual consultants and provide scope for open, and sometimes complex, questions to 
be asked and explained if needed to the interviewee, as well as allowing the interviewer 
to pick up on non-verbal cues (Ritchie and Lewis, 2003, Phellas et al., 2011). 
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4.5 Interviews method 
The protocol and supporting documentation for this study are included in appendices 
four through ten. This study received UK ethics approval from the Faculty of Medicine and 
Health Sciences Research Ethics Committee and the Norfolk and Suffolk NHS Foundation 
Trust Research and Development Committee in March 2014.  
4.5.1. Participant recruitment 
Lithium is recommended to be initiated in secondary care and the initial prescribing 
decision is likely to be made by a specialist mental health practitioner rather than a GP. If 
shared care protocols are followed then the initial prescribing decision surrounding 
lithium should be made by a consultant psychiatrist and any requests for shared care 
prescribing should then come from them (Dye and Barker, 2010, Norwich Clinical Liaison 
Group, 2010). Recruitment was therefore targeted through NSFT, the local Mental Health 
Trust. Whilst house officers and specialist registrars prescribe medication, consultant 
psychiatrists were purposively recruited as the individuals with ultimate responsibility for 
patients and prescribing, and should be making the initial prescribing decision. 
The work contact details of all consultants working for NSFT were obtained from the Trust 
Research and Development team in order to contact them for this project. A covering 
letter was sent to all 110 listed consultants, including locum consultants, inviting them to 
participate in this study. The letter was accompanied by a participant information sheet, 
an expression of interest form, a decline to participate postcard and a pre-paid envelope 
addressed to the primary researcher who was the PhD student. An e-mail was sent out at 
  
96 
 
the same time as the letter, which had a participant information sheet attached and 
encouraged respondents to reply via e-mail with the information required for the 
expression of interest form. Although there were reminder emails and letters prepared 
the response rate was such that these were not required. In addition, as part of regular 
research meetings involving NSFT consultants, potential participants were alerted to the 
project by the Research and Development team at the Trust. As the attendance of 
consultants in the research meetings varies across localities, contact via letter and email 
was the main method of recruitment. 
To contextualise results, potential participants were asked to detail whether they had 
worked for Norfolk and Waveney Mental Health Trust, the predecessor organisation to 
NSFT in Norfolk, in the previous ten years on their expression of interest form along with 
their age bracket and area of specialism. They were also asked if they had been employed 
in Norfolk or Suffolk for less than a year. This captured those participants who are likely to 
be less experienced with SystemTDM®, if based in Norfolk or those working within Suffolk 
who have had previous interactions with SystemTDM®. The only inclusion criterion for 
the project was that potential participants were consultants currently employed by NSFT 
and there were no specific exclusion criteria. 
4.5.2. Participant selection 
From the consultants who expressed an interest in participating, a purposive sample were 
recruited covering a range of specialities including older adult, forensics, home treatment 
team, youth service and general adult with an even spread from Norfolk and Suffolk. 
Although it was likely that the consultants most likely to encounter lithium in their 
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practice and prescribe it would be based in general adult teams, no exclusions were 
placed on the areas of practice for prescribers during our recruitment stage. All 
consultants would have worked within general adult mental health services as part of 
their training and would have previous experiences surrounding lithium and its 
prescribing either as a consultant or a junior doctor. It is also possible that lithium could 
be prescribed either as a new treatment or for continuation of care in the young, elderly, 
dual diagnosis and learning difficulties patient groups due to its wide range of therapeutic 
effects (Sanofi-Aventis, 2012, Norgine, 2011, Rosemont, 2011, Sanofi-Aventis, 2011). 
One of the objectives of this study was to see if there was any difference in factors 
influencing prescribing between Norfolk and Suffolk consultants, i.e. those who had 
access to a systematic computerised database for lithium and those who did not. We 
initially recruited five participants from each area, also making sure they had diverse 
specialities for maximum variation sampling (Patton, 2002). If more participants were 
required after these initial ten interviews then they would be recruited dependent on 
which areas or demographics required further investigation. 
Once participants agreed to be involved with the research and had suggested times and 
locations that were suitable for them, they were contacted to confirm a time and date for 
the interview. Once this had been agreed an email or letter was sent to them with 
confirmation of the date, time and location of the interview. The remainder of the 
consultants who expressed interest in participating were sent a regret email once data 
saturation had been reached. There was no financial incentive offered for participating in 
this study. 
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4.5.3. Topic guide 
The interviews were conducted over two months in 2014 (May and June). Initially a pilot 
interview was conducted with a consultant who had been involved with the roll-out of 
SystemTDM® into Suffolk. Due to her involvement with SystemTDM® she would have 
added potential bias to the results and so was invited to participate as the pilot 
interviewee. This pilot interview was conducted to not only test the initial topic guide but 
the process of the interview itself. Feedback was received on the pilot interview by a 
supervisor experienced in qualitative research. All consultants interviewed were given 
information about the general topics to be discussed in the participant information sheet 
and were each asked to sign a consent form before the interview began. The final topic 
guide used for the interviews can be found in appendix 11. 
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4.6 Data analysis 
Each interview was audio-recorded, transcribed verbatim by the primary researcher and 
then checked by a supervisor for accuracy once the transcripts were anonymised. The 
transcripts were analysed independently, using the principles of thematic analysis, by the 
primary researcher and a supervisor (Braun and Clarke, 2006). There was continual 
reference made, at all stages, to the original transcripts to help determine the level of 
themes and subthemes and confirm that these are relevant to what was said in the 
transcript and had not been taken out of context during the coding process. Regular 
meetings took place between the primary researcher and supervisor whilst each 
transcript was being transcribed and analysed to discuss developing themes, if there were 
any discrepancies found these were discussed and agreement reached. Once all ten 
transcripts had been analysed the themes were discussed in a final meeting. At this point 
it was discussed whether data saturation had been reached and if the objectives of the 
study had been met. As both of these things had occurred, rejection emails or letters 
were sent out to the remaining nine consultants who had expressed an interest in being 
involved in the study. 
4.6.1. Thematic analysis 
Thematic analysis is often used within the field of psychology and has been described in 
detail by Braun and Clarke in order to standardise the process for researchers (Braun and 
Clarke, 2006). It is often utilised by novice researchers as it not only provides core skills 
for other forms of analysis but is seen as intuitive and straightforward to use (Braun and 
Clarke, 2006, Riessman, 2008). For this study the inductive approach of thematic analysis, 
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underpinned by subjectivist ontology, lets the intricacies in the collected data be 
captured. By letting the themes and assumptions develop from the text, rather than 
searching for pre-defined themes as would be seen in a deductive approach, an 
understanding of how and why things happen can be elucidated for each participant 
(Ryan and Bernard, 2003). The developing themes are inherently linked with the data 
collected during the study rather than the researchers drive or interest in the study topic. 
The impact of the researcher themselves on the coding process cannot be removed 
completely as they are an integral part of the research process (Braun and Clarke, 2006, 
Coghlan and Brannick, 2014). 
The process of thematic analysis as detailed by Braun and Clarke in table 4.1, was 
followed to produce a rich thematic account of the whole data set in order to get a sense 
of the predominant or important themes (Braun and Clarke, 2006). 
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Stage Description 
1. Familiarising yourself with the data Transcribing the data if required then 
reading and re-reading the data, noting 
down initial ideas 
2. Generate initial codes Code features of the data systematically 
across the whole data set, collate data 
relevant to each code 
3. Search for themes Collate codes into potential theme, gather 
all data that is relevant for each theme 
4. Review themes Check if themes make sense in relation to 
the coded extracts and then the entire data 
set. This will create a ‘thematic map’ of the 
analysis 
5. Define and name themes Refine the specifics of each theme and the 
overall story of the analysis. Clear 
definitions and names for each theme are 
defined 
6. Produce the report Selection of appropriate extracts, final 
analysis of these extracts relating back to 
the research questions and the literature 
and production of a scholarly report 
Table 4.1: Stages of thematic analysis adapted from Braun and Clarke, 2006 
The scissors and paste technique of ‘pawing’ was used for the analysis without the aid of 
a computer program. The advantage of this cutting and sorting technique is that the data 
can be used to describe how the themes are distributed across the interviews (Ryan and 
Bernard, 2003). Coding started with the first line of the first transcript and progressed 
through every line of each transcript in chronological order. Some codes covered more 
than one line if they were within a long passage of text, and so not each line was 
individually coded, but an effort was made to code as much as possible. Each transcript 
was coded by the primary researcher and a supervisor independently. Regular meetings 
took place to discuss the developing themes and to ensure that all themes had been 
identified. 
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The primary researcher was a pharmacist with mental health experience who was funded 
by the ‘Lithium database team’, which the participants were aware of at the time of the 
study. The personal experiences and views of the primary researcher may have impacted 
on the process of analysis and the findings. To negate this effect however the supervisor 
involved with analysis and coding was a pharmacist but not a mental health specialist. 
The primary researcher had also attended a course on interviewing skills and received 
training on qualitative data analysis. 
The coding process returned 135 codes in total. These were collated into a coding table, 
an example of which can be found in appendix 12, and then printed off and cut into 
individual strips to be manually arranged to reflect their degree of agreement with others 
e.g. all codes relating to teaching and learning were grouped together. This initially 
produced 17 themes which were subsequently further combined where differences did 
not seem clear or there were aspects which interlinked. The final theme which each code 
fitted into was decided without reference to the original questions asked within the 
interviews. There was constant revisiting of the transcripts throughout the coding and 
analysis to validate these themes. To highlight the similarities and differences between 
the consultants’ views identified in the analysis, selected quotes are presented in the 
results section. 
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4.7 Results 
From the initial 110 recruitment letters and emails sent out ten consultants replied either 
by postcard or email declining to participate and nineteen expressions of interest were 
returned. There were five participants initially recruited from Norfolk (N) and five from 
Suffolk (S) from the nineteen expressions of interest returned. Table 4.2 details the 
demographics of the included participants and their reference for the quotes included. 
Participant 
reference 
Location Age/Gender Type of practice 
7 N 51-65/M Crisis resolution and home treatment team 
101 S 36-50/F Old Age 
66 S 51-65/M Home treatment team Liaison/Private 
8 S 36-50/M Learning Disability 
69 N 36-50/F Old Age 
90 N 51-65/F Forensics 
77 S 36-50/F Adult 
106 N 36-50/M Younger adults 
57 S 36-50/M General Adult 
50 N 36-50/M Adult 
Table 4.2: Participant demographics 
There were four main themes identified in the analysis:  
- Knowledge and experience of prescribers, 
- Drug factors, 
- Patient factors and patient information, 
- The monitoring process and setting for initiation.  
However, the themes identified should not to be seen as individual influences; many of 
them potentially act in combination. 
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4.7.1. Knowledge and experience of prescribers 
There were some differences in opinion over who should initiate and prescribe lithium in 
terms of the grade of doctor and whether it should be a hospital doctor or a GP. The 
majority of participants interviewed did not feel that lithium needed to be initiated by a 
specialist and could be done by any doctor as long as they were deemed competent and if 
junior doctors were supervised. 
“I think juniors should be initiating it but in discussion with more senior colleagues 
so I think they should get the experience of doing it” (90) 
However one participant considered the effect that the status of the prescriber may have 
on the patient and whether this would make a difference to them, 
“so if a consultant prescribes it I guess it’s symbolically going to be more important 
or more powerful than if someone else does” (7) 
Although generally the participants felt that all grades of hospital doctors could, and 
should, prescribe lithium if supervised and most mentioned that a specialist should be 
involved at some point in the initiation process. 
The past experience of doctors involved in prescribing is taken into consideration when 
they are choosing which drugs to prescribe and competence can be seen to be obtained 
from these experiences. Whether they have seen a drug work in the past or not and, 
based on these experiences, how they think the patient in front of them will respond is a 
guiding factor in prescribing decisions. 
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“you’ve seen a number of people and you’ve seen that well in this particular 
situation in this patient this works it might work here” (69) 
There were various sources of information used by the participants which they felt 
influenced their prescribing decisions. The impact that colleagues, pharmacy and the 
scientific literature they had read, and what they understood from this, were the most 
influential.  
“then you also have stuff that your friends say that you meet somewhere you 
know, (INTERVIEWER: yep) you professional colleagues you know and that 
influences” (7) 
The use of other colleagues’ experiences in group discussions was apparent for those 
consultants who worked in a ward based environment. However, for those prescribers 
who were based in clinics, or saw mainly outpatients, there was less of this discussion 
with colleagues and one participant even noted that they were not aware of the 
prescribing practices of their colleagues. 
“when it comes to team meetings our team meetings are joint [between 
consultants covering different specialities on the ward] so I sit there with two 
other consultants so there are three consultants sitting there in the same meeting 
so again if there is a difficult one that comes up there are three heads together 
plus 20 nurses, so you know there is a lot of erm discussion and toing and froing 
and well I tried this and have you tried that, that happens so” (101) 
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Here the collaborative ways of practice seen with an inpatient situation are shown with 
several doctors and nurses available to discuss patients and possible treatment options, 
drawing on each other’s experiences and knowledge. 
A generational difference in prescribing practice was also bought up during the interviews 
by half of the participants, 
“from the newer generation the junior doctors who haven’t seen it or used it think 
well there are better drugs so they will say why can’t we use the lamotrigine, why 
can’t we use the quetiapine so they will try and sort of tend to erm go to the drugs 
that have come into the market more recently” (101) 
This introduced an idea that the participants interviewed thought that newer doctors 
were more likely to go for drugs that have been launched onto the market more recently 
and not prescribe the older drugs such as lithium. This feeling about generational 
differences, and possibly a lack of knowledge about older drugs, was expanded upon 
when participants were discussing teaching and learning of junior doctors and around the 
promotion of drugs. 
“I just think the drugs that are viewed by our trainees as often being off the ark 
there’s almost a responsibility really amongst the consultant body to just be 
explicit with their trainees about the drugs that they use any why and keep talking 
about them” (77) 
Older drugs such as lithium are not marketed by anyone so there is no promotional 
material or other forms of marketing for these drugs. An increased emphasis on older 
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drugs, which may not be marketed, was mentioned by half of the participants in terms of 
the training and on-going teaching of junior doctors. 
When questions about guidelines were asked, most participants felt that they did not use 
guidelines as a step-by-step "prescribing manual”, but just as a background guide, where 
the diagnosis was clear and the participants were confident that the diagnosis was correct 
and reassessed regularly. 
“at the end of the day it’s you know you’re fitting the patient to the guidelines as 
well yeah so depends on who is in front of you” (69) 
The impact of the patient and their condition was much more prominent and participants 
gave more weight to their learnt knowledge and experience rather than using guidelines 
as a strict prescribing schema. Prescriber’s personal preferences and knowledge about 
medicines they had used, seen used or had experience with were strong influences on 
prescribing decisions. 
4.7.2. Drug factors 
The participants all had positive thoughts about lithium as a drug noting its efficacy in a 
wide range of affective disorders.  
“entirely positive I often describe it as psychiatric dettol erm because of its utility 
and incredibly well tolerated by the vast majority of patients” (66) 
The term ‘psychiatric dettol’ could be perceived as a rather negative turn of phrase with 
its antiseptic associations, this participant uses it to describe how useful he finds lithium 
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to be in a wide variety of situations. Although the participants note that lithium is a highly 
efficacious drug, it is by no means ‘perfect’, but its efficacy and utility was still an 
underlying element of consideration when consultants thought about which drugs to 
prescribe. The ease of prescribing a drug was a factor for the majority of the participants 
interviewed, with them commenting that the complexity of prescribing lithium and the 
work this entails may influence their decision over which drug to prescribe.  
“you know it requires a bit more work to give someone lithium” (50) 
“sometimes that hinders your wanting to prescribe” (69) 
As there are several drugs to choose from for the treatment of affective disorders, and 
the fact that patients respond in varying degrees to each of these options, the fact that 
lithium requires more effort to initiate and prescribe may result in other, easier drug 
options being favoured having a negative impact on prescribing practices.  
“I’ve started using it [lithium] less and less and it’s often for fairly practical 
reasons” (50) 
“I think I think it it’s an underused drug I’m sure of yeah…erm because of its you 
know because of the ease of of monitoring it and everything else you know 
compared to all the other drugs we use it’s one of the few drugs we can actually 
say we know what level is going to help most people” (66) 
These participants felt that the prescribing of lithium had reduced and it isn’t used as 
much as it should be in part due to the difficulties surrounding initiation and monitoring 
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when compared to the newer, and somewhat easier to prescribe drugs for affective 
disorders. 
The generational differences in prescribing as discussed earlier were also mentioned 
again, with reference to the newer generation(s) of doctors not using it either due to a 
lack of education, experience or the inherent complexities of prescribing. The fact that 
lithium needs monitoring may negatively impact on the decision to prescribe it can be 
countered with the fact that prescribers know what level to aim for to treat a patient and 
get them well and how to monitor this. 
When choosing what drug to prescribe for a patient, all the participants mentioned that 
they consider the side effect profile of the drugs on offer and the consultant’s ability to 
explain this to patients. 
“at least you could tell people what the side effects were going to be [with 
lithium]” (66) 
In this case participant 66 felt that he was likely to prescribe older drugs for which the 
side effect profile was clear and easily explained to patients than newer drugs whose side 
effects were maybe slightly more unpredictable on a patient by patient basis. If there is 
some confusion over what is likely to happen to a patient or a lack of complete 
understanding of the side effect profile from the prescriber’s perspective then this will 
negatively affect their thoughts about prescribing that particular drug. Although all 
participants had positive comments about lithium as a drug, they commented on its side 
  
110 
 
effect and toxicity profile negatively whilst also highlighting an area of confusion or lack of 
complete understanding of these effects of lithium. 
“actually I think there’s some misunderstandings around it as to its what long-term 
effects it does and doesn’t cause to the kidneys I get confused as to what’s going 
on there” (106) 
Following on from the prescriber understanding of the side effect profile is the added 
difficulties and required monitoring which goes alongside drugs with a narrow 
therapeutic range, such as lithium. 
“if you’ve got too little it won’t do anything if you’ve got too much you might kill 
somebody so you need it in the right sort of range” (77) 
“the main monitoring is about first of all making sure that it’s in the therapeutic 
range” (50) 
As picked up by participant 77 the risks associated with lithium when outside of its 
therapeutic range can be life threatening and there is a serious overdose risk which needs 
to be considered. 
“patients might overdose on it and that’s a really messy overdose and I say that 
not just as a psychiatrist but as someone who used to be a medical registrar erm a 
lithium overdose is a really difficult thing to sort out, it makes people very ill and is 
not easily amenable” (8) 
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The participants are notably considering one major hazard of lithium, which is its impact if 
taken in an overdose. It is variously described as messy and difficult and the potential for 
this to be lethal is clearly a factor when deciding what drug to prescribe for their patients. 
In addition to the risk-benefit considerations prescribers think about when deciding 
whether or not to prescribe lithium, there was a clear consideration of particular 
circumstances when lithium would just not be considered as an option. 
“people with existing renal damage or thyroid problems, people with perhaps with 
cardiac problems” (7) 
The physical health of the patient and the effect that any drug may have on this is a factor 
in their decision-making process. There are certain conditions or circumstances under 
which prescribers would not consider lithium and would choose a drug which would not 
have an impact on the patient’s physical health or interact with any other drugs being 
taken. 
“I would look at the interactions, what else they might be on, how it’s going to 
work, erm you know it’s not unusual again for my lot to be on diuretic, to be on 
anti-hypertensive, to be on enalaprils or you name it and it’s there, all that other 
bits come into it as well so erm what else they’re taking would sort of make a 
difference” (101) 
This was mainly a consideration for those prescribers dealing with the elderly as the 
potential for polypharmacy is much greater in this group of patients due to the increase in 
comorbidities with age. 
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4.7.3. Patient factors and patient information 
The participants commented that the presentation of the patient in front of them was a 
major factor when choosing what drugs to prescribe, regarding their specific set of 
symptoms and mental and physical health condition(s). However the previous response 
of the patient treatments is a factor in the choice of drug to prescribe. If they have had 
something before that had worked for their illness and symptoms then that drug was 
more likely to be tried as a first choice. 
The majority of participants mentioned the potential for misunderstanding of provided 
information and finding a way to expand on the provision of written information to more 
of an education process. However participant seven mentions that this is a difficult 
process and that there is still the potential for misunderstanding from the patient’s 
perspective. 
“it’s kind of hard really hard to get that right so you give people all the information 
they want and in a way that they really do understand it” (7) 
Although there is an emphasis placed on providing information, this is no guarantee that 
this information is understood or interpreted by the receiver in the same way as the 
giver. The provision of information and patient education has another facet to it, which is 
the protection of the prescriber from legal issues surrounding information and 
development of side effects or more serious problems from treatment. 
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“medico-legal because if you prescribe something and you fail to inform the 
patient of risk X,Y,Z and they then develop a complete heart block or whatever in 
theory then they can sue you because you didn’t give them the information” (7) 
“I don’t want them to come back later to say to me you never told me something” 
(101) 
This is something that doctors consider when choosing what to prescribe and there were 
some thoughts that doctors may choose what they consider to be a ‘safer’ drug in terms 
of medico-legal issues. 
“people are far more aware of it, patients are rightly erm you know complaining 
when things go wrong” (90) 
There is an acknowledgement that patients are much more aware of their rights than 
previously and are willing to complain if things go wrong in their treatment and have 
become less passive and more engaged in their treatment and treatment choices. 
With more of a focus on the patient side of the prescribing, adherence to drug treatment 
was discussed. There were two subcategories discussed within this area. The first 
covering the need for patients to take drugs and the fact that with lithium there is a 
serious risk of rebound symptoms if the drug is stopped abruptly. 
“I would want to prescribe it for someone who I thought would be reasonably likely 
to take it and umm you know do the tests and and stuff and if I thought someone 
was unreliable and they wouldn’t do it then I probably wouldn’t prescribe it 
because that’s not going to help anyone” (7) 
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“the discontinuation, the rebound mania that occurs with discontinuation is a big 
concern” (50) 
There are risks involved with patients not taking lithium as prescribed, not only that they 
will not be effectively treated, so it is in effect prescribing a drug that is not going to be 
taken, but lithium comes with a risk of rebound mania if abruptly stopped. The second 
subtheme bought in concerns about insight and the capacity to consent to treatment. 
There is a need for patients to understand their treatment and have the insight to agree 
to a drug such as lithium which requires a long-term commitment to blood tests for 
monitoring. 
“I’ve got a clear view as to whether the person has got capacity to make the 
decision erm and also how how committed they are to that form of treatment” 
(66) 
For those patients who do not have the insight and capacity to agree to a form of 
treatment there are processes in place recognised by the participants of either a “best 
interest decision” or treating immediately with the constant reassessment for capacity. 
“there have been occasions where I’ve given people, inpatients, antipsychotics and 
given them the information leaflet quite a lot later” (90) 
“of course I’m assessing capacity all the time” (66) 
This assessment of capacity is an ongoing process with some patients being given 
information about their drugs at a later date when they are able to take this information 
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on board and make decisions for themselves when perhaps a “best interest decision” had 
been made at the initial time of prescribing. 
Over half the participants also raised the involvement of the patient in the choice of drug 
to prescribe. The participants acknowledged that it was not them who would be taking 
the drug and so the thoughts and feelings of the patient on their options of drugs were 
strongly considered. 
“at the end of the day it’s their care and they’re going to be taking the tablets and 
you know having the side effects not you” (69) 
“or if there’s huge patient preference I try go down that line first” (90) 
However they also acknowledged that if drug treatment was necessary there is still a 
limited amount of choice available and although they may be giving the patient a choice, 
it is a shortlist choice of drugs from which the patient can express a preference. 
“what I tend to say is you’re taking one of these but you can choose which one” 
(90) 
“I’d offer a choice of the options I wouldn’t just say I’d tell them what the options 
were” (106) 
The second aspect of this category was what the patient was expecting to achieve from 
their treatment and what they are able or willing to accept in terms of side effects. 
“what the person want to get out of it i.e. if somebody’s saying I just want to feel 
better, enough to you know live around my own house or I’m going fully back to 
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work and you know I want my whole life, active life back so what what do they 
really want what are they trying to achieve” (101) 
What each patient is willing to tolerate in terms of side effects is influenced by what they 
expect to gain from their treatment and the relative effects of untreated illness or side 
effects on their life. 
All participants acknowledged that patients need time to make an informed decision 
about their treatment options. For some the provision of written information is assumed 
enough to allow this process to happen, but other participants felt that this process was 
more about educating the patient with more than just the provision of written 
information about the treatment so that they are more able to come to an informed 
decision. 
4.7.4. Setting for initiation and the monitoring process 
This was the only area in the analysis where there was a difference seen in the responses 
from participants based in Norfolk and those based within Suffolk. 
One area which had a negative impact on the prescribing of drugs, such as lithium, was 
the duration of contact with inpatient services. The participants felt that there was a push 
to get patients out of hospital quickly, with the long-term care moving to an outpatient 
setting and then primary care. Without a lengthy contact period some participants felt 
that lithium was not an ideal drug in these situations, and did not want to initiate it as 
they would not be taking on the long-term management of those patients, their 
colleagues would. 
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“this is part of the problem with the model, that you’re committing your colleagues 
to a course of action that they might not well not proceed on erm …so I think it 
does it does make a difference and that and that’s probably the reason why 
because my contact with patients is anything from two days to six weeks I 
wouldn’t make the decision about lithium because I think it should be the treating 
consultant who has longer term responsibility” (66) 
Only the presenting symptoms were dealt with by the inpatient consultant in the short 
term for the patient to then be discharged for the outpatient consultant for a long term 
treatment plan to be formulated with the patient for the continued management of their 
symptoms. 
“they’ve been manic three times which surprises me they get the symptoms 
squashed with valproate and olanzapine and sent back out again” (106) 
Leading on from this, however, there were differences in opinion on where lithium should 
be initiated with several participants having had experience of starting lithium in both 
outpatients and inpatients and not feeling that the setting of the patient should make any 
difference to the choice of drug to prescribe. Other participants felt that lithium may be 
easier to start in inpatients, due to the ease of access to patients and results, but others 
commented that patients are generally more unwell as inpatients and starting lithium in 
the community may be easier. 
However there were concerns raised by participants about the robustness of processes 
outside of secondary care, for monitoring patients and the ease of access to blood tests. 
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This highlighted some concerns that patients should not necessarily be discharged from 
secondary care services unless these processes were strong and secure. In some cases 
participants would check their patients’ blood tests if they had access to a pathology lab 
system because they did not feel confident that these checks were going to be performed 
if they did not do this personally. 
“I think there are sometimes difficulties in in getting the results but we, most 
people in Suffolk, the bloods at the moment are done at the -------- so we can find 
someone who can access their computer system” (66)  
“It felt quite ad hoc and you sort of set things up and you write please can this 
person do, I do the bloods and who looks at them and it was all it wasn’t it seemed 
it was easier to do it yourself often” (106) 
For those participants who did not have access to a computerised system which collated 
all blood results for patients and sent reminders and alerts to prescribers, there was 
repeated mention of creating their own version of this system on a smaller scale for each 
patient. The idea that it is negligent on the part of the prescriber to not do these tests and 
know what is happening with their patients was also discussed and has links to the 
medico-legal issues raised earlier. 
“if you don’t do that regularly you would be negligent, not doing your job” (77) 
“it’s irresponsible as well it’s actually irresponsible not to know when you are 
prescribing something” (69)  
  
119 
 
However, this role of monitoring the patient varied between participants with several 
feeling, as described above, that it was the prescriber’s role to ensure that all monitoring 
was being performed and to know what was happening with the test results, but the 
practicalities of this raised other concerns and thoughts discussed later. 
Several participants, who had experience of using SystemTDM®, raised the idea that such 
systems were an aid to practice, and had the ability to improve the quality of care and 
reduce the numbers of incidents due to adverse effects. 
“So I think the lithium database has been a fantastic thing to have happened and I 
think it’s hugely improved the quality of care and I suspect that’s measurable and 
demonstrable possibly even including the number of side effects and so on that we 
have seen I would expect has probably reduced as a result of the database” (7) 
“at Norfolk I loved the lithium database it made the whole thing feel so much safer 
and er coming back to Suffolk felt like a return to the dark ages” (8) 
They also highlighted that computerised systems gave prescribers the ability to oversee a 
large cohort of patients, and see any trends emerging in the data recorded for groups or 
individual patients over time. 
“with the lithium database you’re still having a system that is overseeing” (50) 
“also the trends for the individual patient…cause you can see if something’s slowly 
slipping even though it’s in the normal range” (90) 
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The computerised system as described here allows for slow changes in individual 
patient’s blood test results to be picked up and show any trends occurring in the wider 
lithium-treated population. Those participants who used a computerised system felt that 
more than one person, the prescriber, getting the blood results was a good system, 
allowing for a second person for whom that is a particular part of their job to get notified 
of test results. 
“I think it’s fantastic that someone else looks at them for whom that is their job or 
at least is a par.., sort of their day” (8) 
“think actually it’s quite a good system that it goes to the prescriber and the 
person who keeps the database” (90) 
This was discussed alongside the idea that sometimes front line staff and prescribers are 
not always best placed to receive such results as they often have their attention or time 
pulled in multiple directions. 
“someone else needs to be a step back from that taking the longer-term view and I 
think that all of those roles are important in the NHS, front line staff are often 
battered around too much” (8) 
The participants also raised the question of whether GPs or primary care, who are 
conducting the ongoing monitoring, are the most appropriate people to receive test 
results and act upon them. The participants commented that if they had their attention or 
time diverted, within a specialist area, then a GP is likely to suffer this effect even more. 
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Although the need for strict monitoring systems was important, the participants also 
highlighted the need for someone to look at and respond to the results. 
“I think there’s been a focus on doing the bloods rather than looking at the bloods” 
(8) 
“I mean there is no point taking you know looking, having blood results around if 
you’re not going to look at them and act on them you might as well not of 
bothered” (90) 
Without the results of the blood tests being looked at, the responsible clinician for those 
patients will not be able to act on them. Changes in patients’ physical health may not be 
picked up on and the slower, creeping changes may not be seen. 
Some participants suggested that the long-term monitoring and prescribing of lithium 
would be suited to an outpatient clinic, in particular for patients who were mentally 
stable and may not have much other contact with specialist services. In current practice 
once patients are stable, prescribing responsibility for lithium passes to primary care 
under a shared care agreement. If their treatment maintains their mental stability they 
could be discharged from mental health services completely. 
“When perhaps the psychiatric spotlight has come off that patient because they’re 
not unwell, which is of course another consequence of lithium treatment” (8) 
“so I don’t know that erm gap can be breached or instead have a lithium 
monitoring clinic, like you know like clozapine monitoring clinic” (69) 
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The consequence of patients being well treated and maintaining mental stability is that 
they do not have such a high intensity of psychiatric help readily available and this could 
be an area where the use of a specialist clinic could allow for ongoing monitoring as well 
as links to secondary care for easy access back into specialist services if required. With a 
good link between primary and secondary care, or the use of a lithium database, 
participants commented that they were happy discharging patients back to primary care 
and for GPs to continue with lithium monitoring. 
“in terms of monitoring if they have been stable for a long and because we have 
the lithium database so we’re actually quite happy to have that monitored by the 
GPs” (50) 
“combination of a lithium database plus link, good solid link workers could mean 
that you could discharge people from secondary care” (8) 
However, in some cases this did still rely on primary care being open to discussing the 
patient with secondary care if needed. There were some cases where communication 
between primary and secondary care, particularly surrounding the reporting of ongoing 
monitoring results, was not as robust as the participants felt it could be with a knock-on 
negative impact on clinic times and resources. 
“and not only does it [lithium monitoring] not always happen and we don’t always 
know if it’s happened or not I also think it also leads to so many wasted clinics” (8) 
“when it’s done [lithium monitoring] they don’t let you know they don’t tell you 
anything so you know communication can be a bit of a problem” (69) 
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Some areas of practice required the patient to have links with both primary and 
secondary care with one doing the monitoring and prescribing, and the other providing 
ongoing advice on treatment, communication between the two is needed for this process 
to work. Any lack of communication about what is happening with patients can lead to 
clinics which cannot perform as needed due to incomplete knowledge surrounding the 
monitoring and results or the fact that no monitoring had occurred. Those consultants 
who had a good relationship and communication between primary and secondary care or 
were used to using a lithium database were comfortable discharging patients back to 
primary care and for GPs to continue with lithium monitoring. This suggests that the need 
for an outpatient clinic or the patient remaining under secondary care services is negated 
by the use of robust monitoring systems. This allows for patients to be discharged from 
secondary care services and managed within primary care with the consultant and other 
selected healthcare professionals retaining oversight to monitor levels. 
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4.8 Interviews discussion 
This is the first study eliciting the views and perceptions of consultants working within a 
Mental Health Trust on the factors affecting their prescribing decisions with a particular 
focus on lithium. Although this has had many other types of research conducted around 
it, is still an old drug and there has not been a focus on whether the same factors as for 
other drugs are influential when it comes prescribing decisions. 
The two main domains and factors influencing prescribing decisions pulled out from the 
literature review for this chapter were all reiterated in our results along with some other 
factors such as the setting for initiation and the monitoring process which is more specific 
to drugs such as lithium which require therapeutic drug monitoring. 
Although the scientific literature is important in providing further knowledge about 
medications and clinical cases, the application of this knowledge and discussions with 
colleagues or pharmacy are much more influential when choosing which drugs to 
prescribe. This echoes the findings from previous studies (Perlis, 2007, Schumock et al., 
2004, Gill et al., 1999, McGettigan et al., 2001, Ljungberg et al., 2007, Prosser and Walley, 
2006, Denig et al., 2002b). It has been shown previously that habitual prescribing 
practices are relatively common, particularly in primary care (Denig et al., 2002b). Denig 
et al., noted that general practitioners, who were the focus of their study, did not have a 
wide range of decision behaviours with almost 40% of the transcripts showing habitual 
behaviour when prescribing. This is reflected by the multiple papers referenced in the 
literature review for this chapter expanding on the familiarity with certain drugs and 
previous practical experience with them being influential factors in decisions to prescribe 
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these drugs (Chow et al., 2014, Hajjaj et al., 2010, Rajendran et al., 2012, Shepherd et al., 
2014, Denig et al., 2002b, Ljungberg et al., 2007, McGettigan et al., 2001, Tan et al., 2009, 
Hedenrud et al., 2013, McIntosh et al., 2016). This was also reflected in our research with 
a familiarity with particular drugs and whether they had been seen to work before in 
similar situations leading our participants to be more likely to choose those drugs before. 
These experiences also influenced prescribing decisions in another way, with the 
competence of the prescriber being raised, and with the thought that there should not 
necessarily be any restrictions on the grade or type of doctor who could prescribe 
complex drugs such as lithium, as long as a specialist is involved and the initial prescriber 
is deemed competent. Where collaboration with other colleagues is available such as in 
ward-based environments discussions were considered influential for making prescribing 
decisions where there are perhaps slightly more complex cases. This expands from 
previous research which has not picked up on this facet before, with most focussing on 
primary care where this sort of knowledge exchange is not as readily available. 
The fact that the older drugs are not marketed or ‘pushed’ to prescribers in the same way 
as the newer drugs, was considered detrimental to drugs such as lithium. The influence of 
pharmaceutical representatives and their marketing material has been shown to have an 
impact on the first stages of decision making around new drug prescribing or for the use 
of specific drugs in situations where an advantage may be perceived over others (Prosser 
and Walley, 2006, Jones et al., 2001, Ljungberg et al., 2007). The consultants interviewed 
felt that this impact of marketing, or a lack thereof, was apparent in a generational 
difference in prescribing practices. They felt that newer doctors were more likely to 
prescribe newer drugs that had come onto the market more recently, with older drugs 
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being somewhat underused. It was felt that there needed to be an increased emphasis on 
these drugs which are not actively marketed, such as lithium, to ensure that they are not 
underused due to a lack of knowledge. However, the lack of influence of guidelines on 
prescribing decisions was echoed in this study as had been picked up previously in studies 
investigating prescribing schema. Guidelines are used as just that, a base to be used 
initially to guide treatment choices, but other factors are more influential in making 
prescribing decisions (Perlis, 2007, Schumock et al., 2004, Gill et al., 1999). As guidelines 
are not really used by this group of specialists in their day-to-day practice this may mean 
that juniors, who do not have the older drugs marketed to them, may be unaware of their 
place in treatment.  
There was also no mention of costs raised by the consultants in this study which has been 
previously seen as an influencing factor in previous studies, with prescribers conducting 
cost-benefit analysis (Higgins and Tully, 2005). However the costs of a service such as 
SystemTDM® has been raised as an issue by funding bodies who feel that if monitoring is 
done in line with the Quality and Outcomes Framework, see chapter three, this is 
sufficient and the finances required to implement SystemTDM® are not in line with any 
additional advantages it would add to practice (Anderson, 2015). 
Where drugs need therapeutic monitoring the ability of the patient to engage with this 
has previously been a concern and a key factor in deciding what drugs to prescribe, 
particularly for rural communities (Cutts and Tett, 2003). This is also reflected in several 
ways when the decision to prescribe lithium or another drug is made. The risks associated 
with prescribing lithium, which has a narrow therapeutic range and the potential for 
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toxicity, were raised and linked to the needs for rigorous monitoring processes. There 
were variations in confidence that these monitoring processes could be done in primary 
care, without any link to secondary care specialist services. In cases where the robustness 
of this service was not clear, other drugs were more likely to be chosen which did not 
require this level of monitoring. This complex process was also a negative factor on the 
prescribing of lithium with decisions being made sometimes to prescribe ‘easier’ drugs. 
Computerised systems were seen as a positive factor and if these were in place alongside 
good communication between sectors of practice, the negative factors on decisions to 
prescribe complex drugs or drugs which require monitoring were negated. 
Computerised systems can allow changes in individual patients monitoring results to be 
seen, as well as any trends in the data for the whole treated population which may 
require further investigation. These individual changes could be large or small creeping 
changes that may be important in terms of ongoing side effects and potential toxicity for 
drugs such as lithium. The fact that more than one person gets to see the results for all 
patients is thought to help in the long-term monitoring of patients as prescribers and 
front line staff have their attention drawn in multiple directions over the course of a 
working day and following up on monitoring on their own may be an area of practice that 
gets missed. This sort of centralised results and reporting system for blood test 
monitoring has been in place for other complex drugs such as clozapine and warfarin in 
order to improve the quality and outcomes of the drug monitoring conducted (Steinman 
et al., 2011, Hickey et al., 2014, Luchins et al., 1998). The dynamic process of actively 
monitoring the benefits and harms of the prescribed drugs over time, not only focussing 
on the initial prescribing decision is essential and this process comes across in the 
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concerns about the ownership of the prescribing decision and the long-term follow-up of 
patients raised by our participants. 
Appropriate prescribing requires some form of risk-benefit analysis encompassing the 
effects of any untreated illness and the side effect profile of the drug for each particular 
patient and their lifestyle, as well as risks posed by drugs with a narrow therapeutic range 
as mentioned above. This was discussed by Higgins and Tully who commented that 
consultants in previous studies have shown a more holistic view of appropriate 
prescribing with this encompassing the need for some form of risk-benefit analysis taking 
into account the patient as an individual (Higgins and Tully, 2005), supported by the 
results from this study.  
This is a complex process and Zetin coined the phrase psychopharmacohazardology in an 
attempt to encompass this all (Zetin, 2004). The prescribing of multiple drugs, known as 
polypharmacy, is becoming more of an issue, not only with an aging population but the 
increasing prevalence of chronic diseases (Linjakumpu et al., 2002, Wise, 2013). Mental 
health patients will not only present with their psychiatric condition which needs treating 
but may also have chronic physical health conditions for which they are required to take 
drug treatment. Interactions of the drug to be prescribed with not only other conditions 
but any drugs being used to treat these conditions was considered when choosing a 
treatment option. Adherence, consent and the ability to make an informed decision were 
new factors in the prescribing decisions raised in this study, particularly in relation to 
lithium itself due to the long-term monitoring and severe rebound effects if abruptly 
stopped (NICE, 2014a, Moncrieff, 1995). 
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Several participants expressed frustration around the service configuration where they 
are treating patients without being able to see them through to successful treatment 
conclusions, merely getting them well enough to be managed in the community. 
Nationally within mental health services there is an inpatient/outpatient functional split 
model of consultant psychiatrist care. This represents a change over the past decade from 
the sectorised model in which a single consultant was responsible for the patient’s whole 
journey of care (Begum et al., 2013). In the current model of care a patient will see 
patients may well see four or five different consultants throughout one episode of illness 
and they may even be in separate geographical locations (Tyrer, 2013). This goes some 
way to explain the reluctance by the inpatient consultant to make a long-term treatment 
choice as they will not be looking after the patient in the longer-term. They are therefore 
less likely to initiate the drugs used for long-term treatments as the initiating doctor will 
not be the one who continues to see the patient. This had an impact on the prescribing of 
lithium in that, once again, the consultants interviewed were not likely to initiate it as 
often as they maybe would have liked if they were based in acute or inpatient services. 
4.8.1. Strengths and Limitations 
This study focusses on the views and perceptions of ten consultants working within NSFT 
on factors that influence their prescribing. The response rate for the study allowed for a 
sample size to reach data saturation, with more consultants expressing an interest to 
participate than was needed for the interviews to reach data saturation with consultants 
working within a wide variety of areas of specialism replying. The option of a ‘decline to 
participate postcard’ may have increased nonresponse by making prominent the option 
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to refuse (Abi-Habib et al., 2004, VanGeest et al., 2007). From the 110 consultants invited 
to participate in the research only 19 replied with an expression of interest, a response 
rate of only 17%.  
The consultants who responded expressing an interest in being involved in the study may 
have been those who had stronger opinions on either lithium or prescribing practices and 
may not reflect the views of those consultants who maybe do not have such strong views. 
Although not specified during recruitment, only prescribers of lithium ended up being 
interviewed and all had very positive comments on lithium as a drug. Gaining the views of 
consultants who actively did not prescribe lithium or did not feel positively about it may 
have added further to the analysis, gaining additional insight into reasons why they did 
not prescribe it and the impact of negative feelings about the drug on their practice. 
However, the objectives of this study were achieved. 
The interviews were conducted by a pharmacist and the participants were aware of this 
from the outset. This may have influenced the way that they felt they could talk about 
prescribing decisions for their patients. It was made clear in the participant information 
sheet and at the start of the interview that they were free to say anything and decline to 
answer questions if they wished, and that nothing would leave the room afterwards 
unless an issue raising a concern of professional misconduct or negligence was disclosed. 
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4.9 Conclusion 
This study supports some current beliefs about prescribing decisions surrounding the 
familiarity of prescribers with certain drugs, the implications of the practicalities of 
therapeutic drug monitoring (TDM) monitoring when required and the impact of 
promotion and marketing. This study also adds detail to prescribing decisions for older 
drugs and those within a specialist area, with some restrictions on their prescribing. 
There is a continual process of reassessment and confirming a diagnosis for the types of 
patients seen by our participants, which may not be seen in other areas of practice, 
leading to less of a reliance on guidelines for treatment choices. The idea of an outpatient 
clinic for the ongoing prescribing and monitoring of lithium was raised and would seem to 
alleviate some concerns as well as aiding the monitoring process. The link with specialist 
services, if needed for reassessment and a continual risk-benefit analysis of the current 
treatment, could be achieved in an outpatient clinic setting. 
Although there are current shared care guidelines for the prescribing and monitoring of 
lithium, the participants interviewed did not convey complete confidence in the processes 
in place once patients were discharged from hospital to community services. Within 
Norfolk, where SystemTDM® is in operation, these concerns were allayed as the 
participants commented that they knew that all of the relevant people involved in that 
patients care, as well as someone managing the database, would be kept informed of 
blood test results.  
  
132 
 
The prescribers within our study were very focussed on patient information and 
education and their involvement with treatment than has been highlighted in previous 
studies. Concerns were raised about the way that older drugs are treated within the 
training program for doctors and psychiatrists and this is something that will need 
addressing. Due to this a lack of knowledge surrounding drugs negatively affects the 
prescribing of these drugs due to prescribers’ tendencies to primarily select drugs with 
which they are more familiar. 
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 Chapter Five   
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5: An analysis of a management database for the 
relationship between lithium levels and monitoring 
parameters. 
5.1 Background 
Lithium has been proven to have efficacy against both the manic and depressed poles of 
the illness (Malhi et al., 2011). Despite its effectiveness there are disadvantages to its use 
including its narrow therapeutic range (NTR) and its potential detrimental effects on the 
kidneys and thyroid. Lithium is mainly excreted unchanged by the kidneys and any decline 
in renal filtration rates can lead to an accumulation of lithium, which will subsequently 
increase serum levels. This is of particular concern if lithium is taken by older people who 
have a general age-related decline in renal filtration rates (NICE, 2014b, Zhang and 
Rothenbacher, 2008). Until the fourth decade of life, glomerular function remains well 
maintained, but after this, it is expected to decline by about 8ml/min/1.73m2 body 
surface area per decade. However, using glomerular filtration rate (GFR) estimates some 
population-based studies suggest that this decline may begin after the second decade of 
life (Weinstein and Anderson, 2010). 
Potential renal adverse effects of lithium include a decline in urinary concentrating ability, 
diabetes insipidus, chronic kidney disease (including renal failure), nephrotic syndrome, 
hypercalcaemia, hyperparathyroidism and distal tubular acidosis. In a small proportion of 
patients GFR gradually declines, with some subsequently developing chronic renal 
insufficiency or renal failure, 0.2-0.5% of the populations studied (Gitlin, 1999, McKnight 
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et al., 2012). Abnormal renal function or structure is included under the umbrella term 
Chronic Kidney Disease (CKD) and commonly occurs alongside other conditions such as 
diabetes mellitus and cardiovascular conditions, although it is frequently unrecognised. 
The cost of CKD has an impact on the NHS spend within England with this estimated to be 
£1.44-£1.45 billion in 2009-10, which was approximately 1.3% of all NHS spend in that 
year (NICE, 2014b). Previous studies on the renal adverse effects of lithium have not 
included patients with a history of lithium toxicity or included details about the number of 
episodes of lithium toxicity, or out-of-range levels (Zhang and Rothenbacher, 2008). This 
study was an aim to use data already collected in routine care patients prescribed lithium 
to see real life effects on calculated eGFR of levels used for treatment.  
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5.2 Aims and Objectives 
5.2.1. Aim 
The aim of this analysis was to determine if there is an association between lithium levels 
and renal function. 
5.2.2. Objective 
The objective was to: 
- Establish the relationship between estimated glomerular filtration rate (eGFR) 
after ≤3months and 6 months (±3 months) and one year (±3 months) after 
exposure to one lithium level within specified ranges. 
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5.3 Methods 
This study was limited to secondary use of information previously collected in the course 
of normal care, without an intention to use it for research at the time of collection. It is 
therefore excluded from Research Ethics Committee (REC) review, provided that the 
patients or service users are not identifiable to the research team in carrying out the 
research. Local research governance approval was received from Norfolk and Suffolk NHS 
Foundation Trust Research Governance Committee prior to commencing data extraction. 
The protocol and supporting documentation is included in appendix one. 
SystemTDM® currently holds the following information about the patients registered with 
the service: 
- Database ID, NHS number, alternative ID, full name, address and registered GP 
practice of each patient, 
- Date of registration, 
- Date of and test results: lithium, urea, creatinine, eGFR (2006 onwards), TSH, T4, 
- Risk factors: Age >70, Impaired renal function, taking a non-steroidal anti-
inflammatory drug (NSAID), angiotensin-converting-enzyme (ACE) inhibitor or 
Diuretic 2 
- Patient’s date of birth, 
                                                     
 
2 Tick box system reliant on primary care to initially provide the data upon patient registration and update 
for any change in or new diagnoses 
  
138 
 
- Gender, 
- Psychiatric diagnosis/diagnoses, 
- Current and past addresses, 
- Copies of SystemTDM® letters sent, 
- Any notes relating to the patient, 
- Uploaded documents, 
- Any alerts relating to the patient such as reduced renal function/co-
morbidities/prescribed interacting medications. 
The clinical pharmacy team had access to the full data stored on SystemTDM® and passed 
on the following data to the primary researcher once anonymised: database ID, date of 
registration, date of test results, and results for: lithium and creatinine, patient’s year of 
birth and gender. Any duplicate entries were removed by the clinical team. 
5.3.1. Data modelling 
Data modelling was done by a statistician used to working with STATA, with clinical input 
on the required model from the primary researcher. Statistical analysis was then 
performed by the primary researcher.  
Three ranges of lithium levels were chosen to be analysed to reflect current practice and 
consensus agreement: patients who had all lithium levels ≤0.8mmol/L (reference group) 
and a single exposure to lithium levels between 0.81-1.0mmol/L (group two), 1.01-
1.2mmol/L (group three) or 1.21-2.0mmol/L (group four). Patients with multiple 
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exposures to the levels for groups two, three and four were excluded for the purpose of 
this analysis. 
The term exposure is used to indicate that at the time the blood test was taken for the 
lithium level the body of the patient had for that moment been exposed to that level of 
lithium. The timings of lithium level testing is recommended to be 12 hours post dose for 
routine monitoring, if however a patient had taken their dose of lithium less than the 
recommended 12 hours before the blood test the lithium level reading recorded would 
show a slightly high level for that patient. It is not possible to tell from the data received 
by the research team if any of the high readings were due to dose timing issues. 
The reference group (≤0.8mmol/L) reflects recommendations from the National Institute 
for Health and Care Excellence Guidelines (NICE) for patients prescribed lithium for the 
first time and the level to aim for in prophylaxis of bipolar disorder (0.6-0.8mmol/L). NICE 
guidelines also recognise that the elderly, and any patients with reduced renal function, 
are more susceptible to the adverse effects of lithium and may respond to lower levels, 
hence the lower part of this range reaching below 0.6mmol/L (NICE, 2006, BAP, 2009). 
Groups two and three acknowledge the differing levels from the British Association for 
Psychopharmacology Guidelines (BAP) and the NICE guidelines. Levels up to 1.0mmol/L 
are recommended by BAP for all patients requiring prophylaxis if needed and in NICE this 
is reserved for ‘people who have relapsed previously while taking lithium or who still have 
sub-threshold symptoms with functional impairment while receiving lithium’ or those who 
present with acute mania (NICE, 2006). The BAP guidelines acknowledge that higher 
levels may be used in acute mania, from 1.0-1.2mmol/L, covering group three (BAP, 
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2009). Group four was chosen as this is a range of lithium levels not routinely used for the 
longer term treatment of bipolar disorder within the UK and would be generally 
considered to be an out-of-range or ‘high’ level. 
Estimated glomerular filtration rate (eGFR) was manually calculated using the creatinine 
levels recorded on SystemTDM® and the simplified Modification of Diet in Renal Disease 
(MDRD) equation. The MDRD Study equation is the most thoroughly validated equation 
for approximating GFR (Myers et al., 2006). Race was not recorded on the database so no 
corrections could be applied for African-American patients. However within Norfolk there 
is a predominantly Caucasian population (ONS, 2011 (b)) and so not making this 
correction is unlikely to have any significant influence. 
5.3.2. Statistical analysis 
The start of the follow-up for patients in the reference group was determined by creating 
a pseudo-exposure date. This was done by adding the median duration that exposed 
patients had been registered on the database prior to their exposure event to the 
registration date for patients in the reference group. The median duration that patients 
had been registered on the database was calculated by working out the time between 
teach patients registration and the first exposure event (a lithium level >1.0mmol/L). The 
average time of being registered on the database before an exposure event took place 
was then calculated and this figure was then used as the time to use from database 
registration to the pseudo-exposure event for the control group patient i.e. when to ‘start 
the clock’ for the follow up period. This process is detailed in table 5.1. 
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Control group* Follow up period 
 Baseline 3 months 6 months (±3 months) 
Database  
registration 
Same length of time as  
the mean time of 
registration as exposure 
groups e.g. registered in 
2007 pseudo exposure in 
2009  
- Li 
- Renal 
2nd result 
 
- Li 
Follow up test 
 
- Renal 
(Li data not 
extracted for this 
model) 
Exposure groups    
Database  
registration 
1st high (H) since  
database registration 
- Li 
- Renal 
2nd result 
 
- Li 
Follow up test 
 
- Renal 
(Li data not 
extracted for this 
model) 
*Control group never has a high reading 
Table 5.1: Detail of control and exposure groups used in this analysis. 
The follow-up periods of ≤3 and six months (±3 months) are in line with the UK guidance 
from 2006 for three monthly monitoring (NICE, 2006). By one year (±3 months) follow-up 
post-exposure all results had returned to within range and so this was used as the 
reference group for time. 
A random effects repeated measures mixed model with an interaction with time was run 
using STATA SE 12.1 to ascertain the significance of the exposure groups and time-
periods, adjusting for baseline eGFR (StataCorp, 2011). Initially time-series analysis was 
considered for this analysis but due to the naturalistic data, the time points for blood 
tests were not as regimented as are needed for this approach so the repeated measures 
model was chosen. There are several commands in STATA to build a random effects 
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model including xtreg, anova and xtmixed. The reference and treatment groups in this 
analysis are made up of different patients. However, by using a repeat-measures design 
for the analysis each subject serves as their own control. This means that the variability 
between subjects is isolated and the analysis can focus on treatment or intervention 
effects which may otherwise have been masked by subject variability. As eGFR was 
normally distributed there was no need to perform any transformations on the data. 
Using the simplified MDRD equation gender and age are taken into consideration when 
calculating eGFR so no further adjustments were required.  
The Wald Chi2statistic is used to test the hypothesis that at least one of the predictors' 
regression coefficients is not equal to zero. The number in the brackets indicates the 
degrees of freedom of the Chi2 distribution used to test the Wald Chi2 statistic and is 
defined by the number of predictors in the model (12). 
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5.4 Results 
5.4.1. Inclusion and exclusion criteria 
Patients were included for analysis if they were registered on SystemTDM® between 2002 
and the end of January 2013 and had had at least one lithium and one creatinine reading 
recorded. The reference group was made up from patients whose lithium levels never 
exceeded 0.8mmol/L in the time they were registered on the database. Lithium levels 
remaining in the same range for the three months after the initial test result were classed 
as the same exposure. The first instance of a level within the highest group recorded was 
classed as the point of exposure and the start of the follow-up period. After any of the 
exposure events patients remained prescribed lithium for the duration of the follow-up 
period in which they were included. If lithium levels over the follow-up period were 
recorded as >0.8mmol/L, only eGFR levels up to the last known lithium reading of 
≤0.8mmol/L were used and after that the patient was not included in the analysis.  
Levels above 5.0mmol/L were not included for analysis as these were likely to have been 
erroneous levels, either from mistimed sample collection, overdose or collection of blood 
samples in lithium-heparin containers (Wills et al., 2006). Patients who had creatinine 
levels outside of the range 30-1500µmol/L not included for analysis as the MDRD 
equation used was not validated for levels outside of this range (St George's University of 
London). Figure 5.1 shows the process of sample selection. 
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Figure 5.1: Process of sample selection for eGFR analysis 
Once patients who did not have the required data recorded to enable analysis had been 
excluded, there were 699 patients left for inclusion. There were only 16 patient records 
with levels recorded 2.01-5.0mmol/L so no further analysis was performed on this group 
as the small sample size is associated with a lack of statistical reliability leaving 683 
patients for the analysis. Tables 5.1 and 5.2 detail the baseline demographics of the 
patients who were included for analysis in total and split by exposure group. 
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 Gender Age 
n= Female <20 20-29 30-39 40-49 50-59 >60 
683 407 1 (0.1) 28 (4.1) 67 (9.8) 115 (16.8) 136 (19.9) 336 (49.2) 
Table 5.2: Single exposure baseline demographics (all figures are number, (%)) 
There was a higher percentage of females than males in this sample, with nearly half of 
the sample ages >60. The following table details the demographics of the sample patients 
after being separated by exposure groups. 
  Gender Age 
Exposure group n= Female <20 20-29 30-39 40-49 50-59 >60 
<0.8mmol/L 
(group 1) 
183 101 (55.2) 0 (0) 9 (4.9) 26 (14.2) 41 (22.4) 36 (19.7) 71 (38.8) 
0.81-1.0mmol/L 
(group 2) 
407 251 (61.7) 0 (0) 16 (3.9) 34 (8.4) 62 (15.2) 79 (19.4) 216 (53.1) 
1.01-1.2mmol/L 
(group 3) 
38 24 (63.2) 0 (0) 1 (2.6) 4 (10.5) 3 (7.9) 9 (23.7) 21 (55.3) 
1.21-2.0mmol/L 
(group 4) 
55 31 (56.4) 1 (1.8) 2 (3.6) 3 (5.5) 9 (16.4) 12 (21.8) 28 (50.9)  
Table 5.3: Single exposure baseline demographics by exposure group (all figures are 
number, (%)) 
In all exposure groups there were a similar number of males and females and variation 
across age groups. Those patients included aged >60 have a more uniform distribution 
across all exposure groups, whereas for those aged <60 there is more weighting towards 
the patients being in exposure groups 1 and 2.  
Using the xtmixed command which performs a multilevel mixed-effects linear regression, 
being in exposure groups three or four leads to a significant decrease in eGFR at ≤3 
months follow-up (interaction p=0.047 and p=0.040 respectively). No other main effects 
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or interactions were significant, suggesting that eGFR levels seem to recover over time. 
Table 5.4 shows the results of this analysis. 
Independent variable Coefficient (95% CI)* p  
Exposure    
0.81-1.0mmol/L (Group 2)  0.23 (-1.75 to 2.24) 0.814  
1.01-1.2mmol/L (Group 3)  2.78 (-2.11 to 7.68) 0.266  
1.21-2.0mmol/L (Group 4)  0.43 (-3.48 to 4.44) 0.834  
Time    
≤3 months (Time 1) -0.35 (-2.17 to 1.47) 0.705  
6 months (±3 months)(Time 2)  0.83 (-0.82 to 2.50) 0.322  
Exposure X Time interactions   
Group 2 X Time 1 -1.16 (-3.42 to 1.10) 0.314 
Group 2 X Time 2 -0.57 (-2.72 to 1.58) 0.603 
Group 3 X Time 1 -5.18 (-10.3 to -0.08) 0.047 
Group 3 X Time 2 -1.91 (-7.13 to 3.31) 0.473 
Group 4 X Time 1 -4.45 (-8.70 to -0.19) 0.040 
Group 4 X Time 2 -2.29 (-6.61 to 2.02) 0.298 
Wald chi2(12) = 2947.86, Prob>chi2 = < 0.001 
Table 5.4: Random effects repeated measures mixed model (using xtmixed) to predict 
eGFR, adjusting for baseline eGFR. 
 
In this analysis the Wald chi2 value has a significance of < 0.001, so we can conclude that 
the parameters associated with these variables are not zero and so should be included in 
the model. 
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5.5 Discussion 
The results from this analysis show that a single exposure to a lithium level >1.0mmol/L is 
associated with an increased risk of renal impairment in the first three months after 
exposure. However, by six months (±3 months) there is no detectable difference from the 
mean baseline eGFR. The decline in eGFR seen in the three months after the exposure is 
not likely to be clinically relevant unless this decline in eGFR is sustained. 
The results of a retrospective cohort study conducted recently showed that any exposure 
to lithium is associated with an increased risk of renal failure (Close et al., 2014). The 
Close study was a retrospective cohort study using a database examining the tsk to renal 
health for patients who had been prescribed lithium in primary care compared to non-
users of lithium. The comparison between users and non-users of lithium was not 
something that was able to be done as part of this thesis due to the nature of the data 
used for the analysis. Due to the design of the Close et al., study the role of duration of 
treatment with lithium and any variation in this risk to renal function for different serum 
levels could not be determined however they did determine that the ever use of lithium 
was associated with an increased hazard ration for renal failure when compared to non-
users of lithium with an absolute risk which was age dependent (Close et al., 2014). In this 
thesis, the comparison of different lithium level ranges compared to a reference group 
meant that any variations in the risk from single exposures in these ranges could be 
determined. Clinically being able to determine if the number of exposures the kidney has 
from different lithium levels and the duration of these exposures is relevant for continued 
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monitoring or if it is the degree of the lithium level that determines the impact on renal 
function. 
Variability in the measurement of plasma creatinine could lead to changes in GFR of up to 
5ml/min in individual patients. This is unlikely to require any action to be taken unless this 
change is sustained or there is further deterioration picked up by regular monitoring. 
The mean age of the population studied was 60, which is slightly higher than the means 
seen in previous audits or studies of 48-55 (Collins et al., 2010, Close et al., 2014). 
Compared to the rest of the UK, Norfolk has a higher percentage of the population over 
the age of 65, so this higher mean age was expected for the sample. This sample is 
representative of a group of patients at higher risk for the renal effects of lithium but one 
confounding factor is that an age-related decline in renal function may be overshadowing 
any effects of lithium. According to a review performed on previous studies by Rej et al., 
examining chronic kidney disease in lithium-treated older adults, in mixed-aged 
community samples of long-term lithium users the prevalence and incidence of severe 
renal disease varying from stage IV-V CKD, end stage renal disease or renal replacement 
therapy is 0.5–2 % and in patients aged >55 prescribed lithium the prevalence of renal 
replacement therapy is estimated to be 1.5%. These estimates suggest that results from 
previous studies in the elderly population echo findings from mixed age samples so this 
thesis data can be considered representative for UK practice populations even with the 
slightly older population that other studies (Rej et al., 2015). 
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5.5.1. Strengths and limitations 
Estimated GFR was used for this second analysis, but due to laboratory reporting 
standards this is only available routinely for patients from 2006 onwards. The eGFR was 
therefore calculated for all patients using the simplified MDRD equation. As eGFR is 
affected by age, fractional age (age in decimal years) was used in the analysis to minimise 
this impact. Well known risk factors for declines in renal function due to chronic kidney 
disease (CKD) include diabetes mellitus, hypertension and cardiac disease (NICE, 2014b). 
Data about any of these conditions and other risk factors for CKD were not reliably 
recorded on the database and could not be adjusted for in the analysis. In this analysis 
only one year post-exposure was used as a follow up period, although in on-going work 
expanding on this research a longer follow-up period will be used. Without a longer 
follow up period and the full analysis of single and multiple exposures of various lithium 
levels it is not clear whether the kidneys can fully recover from the impact of the different 
lithium level exposures. 
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5.6 Conclusion 
These analyses only looked at the impact of single exposures to a range of lithium levels 
on creatinine and then on eGFR. The short follow-up periods, further broken down in the 
eGFR analysis shows that the kidneys may be able to recover the decline in renal function. 
It is still not known, however if the associated decline in renal function is additive if there 
are multiple exposures. Determining if the number of exposures the kidney has from 
different lithium levels and the duration of these exposures or if it is the degree of the 
lithium level that determines the impact on renal function is clinically relevant for 
continued monitoring. Currently this analysis suggests that even short term exposure to 
elevated lithium levels is associated with a significant impact on glomerular renal function 
and regular monitoring of lithium levels and timely responses to these levels is important. 
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 Chapter Six     
  
152 
 
6: A longitudinal analysis of a monitoring database for the 
relationship of multiple lithium levels on estimated 
glomerular filtration rate. 
6.1 Background 
Lithium is an important treatment option for the prophylactic management of bipolar 
disorder but the effects on renal function are poorly understood. It has not as yet been 
confirmed whether the kidneys can recover from the decline in renal function shown 
after single exposures to elevated lithium levels or if the negative relationship of multiple 
or longer-term exposures on renal function are additive. 
During the course of this research national guidance has changed on the frequency of 
monitoring required for lithium. NICE now recommends six monthly lithium levels as the 
routine after the first year of treatment rather than the previously recommended three 
monthly monitoring (NICE, 2014a). This change was due to non-adherence to the three 
monthly recommendations and the cost of unnecessary investigations (Bazire, 2014, Rej 
et al., 2015). The results in the previous chapter led to a change in the new guidelines 
which recommended more frequent monitoring in certain groups of patients but now 
includes the addition of the last bullet point regarding previous lithium levels recorded: 
 older people, 
 people taking drugs that interact with lithium, 
 people who are at risk of impaired renal or thyroid function, raised calcium levels 
or other complications, 
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 people who have poor symptom control, 
 people with poor adherence, 
 people whose last plasma lithium level was 0.8 mmol/litre or higher. 
(Bazire, 2014, NICE, 2014a)  
It has been repeatedly noted in local and national audits that the recommended rates for 
serum lithium levels and eGFR monitoring are not being met which potentially puts 
patients at risk for renal adverse effects (Rej et al., 2015). At the moment patients need to 
have blood tests multiple times per year for the duration of their treatment. If knowledge 
can be solidified surrounding the relationship between lithium serum levels and kidney 
function this recommendation might be able to change for clinical reasons, and not cost 
reasons or a lack of adherence to guidelines. 
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6.2 Aims and Objectives 
6.2.1. Aim 
The aim of this analysis was to determine the relationship of double exposures of various 
lithium levels on renal function measured by eGFR. 
6.2.2. Objectives 
The objective of this analysis was to: 
- Establish the relationship on eGFR after ≤3months, six months (±3 months) and 
one year (±3 months) after exposure to two lithium levels within specified ranges. 
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6.3 Methods 
This study was limited to secondary use of information previously collected in the course 
of normal care, without an intention to use it for research at the time of collection. It is 
therefore excluded from Research Ethics Committee (REC) review, provided that the 
patients or service users are not identifiable to the research team in carrying out the 
research. Local research governance approval was received from Norfolk and Suffolk NHS 
Foundation Trust Research Governance Committee prior to commencing data collection. 
This is an extension of the initial research detailed in chapter five and so follows the same 
protocol in appendix one. The information held by SystemTDM® is detailed in the 
previous chapter. 
6.3.1. Data modelling  
The ranges of lithium levels used in this analysis were the same as those described in the 
previous chapter following the same reasoning: 0.0-0.8mmol/L (reference group), 0.81-
1.0mmol/L (group two), 1.1-1.2mmol/L (group three), 1.21-2mmol/L (group four) and 
2.01-5mmol/L (group five). The objective of this analysis was to establish the relationship 
of double exposures of different lithium levels on renal function. Lithium levels recorded 
at routine intervals and those taken immediately after an anomalous or unexpected 
result were used for the data modelling. 
From the previous analysis the level at which a significant negative association was seen 
on renal function after a single exposure was >1.0mmol/L. Due to this groups three, four 
and five were combined for this analysis. Each group was then coded with a single letter 
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or symbol: missing value = “.”, 0-0.8mmol/L = “L”, 0.81-1.0mmol/L = “S”, 1.01-5.0mmol/L 
= “H” for simplicity. 
The start of follow-up for patients in the reference group was determined by creating a 
pseudo-exposure date. This was done by adding the median duration that exposed 
patients had been registered on the database prior to their exposure event to the 
registration date for patients in the reference group. The follow-up periods of ≤3 and six 
months (±3 months) are in line with the UK guidance from 2006 for three monthly 
monitoring. As most effects occurred by six months (±3 months) this time-period was 
used as the reference group for time. 
Once patients who did not have the required data recorded to enable analysis and those 
remaining were classified by pattern of exposure there were five groups included in the 
analysis. The other pattern groups that were possible either did not occur in the sample 
at all or they had too small numbers to consider including for statistical analysis. 
6.3.2. Inclusion and exclusion criteria 
Patients were included for analysis if they were registered on SystemTDM® between 2002 
and the end of January 2013 and had at least one lithium and one creatinine reading 
recorded. The reference group was made up from patients whose lithium levels never 
exceeded 0.8mmol/L in the time they were registered on the database. Lithium levels 
remaining in the same range for the three months after the initial test result were classed 
as the same exposure. The first instance of a level within the highest group recorded was 
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classed as the point of exposure, as the previous analysis looked at single exposures the 
start of the follow-up period for this analysis starts at the second exposure. 
Readings were included following a level >1.0mmol/L up to the point at which another 
level in this range occurred. A further 12 months with all results being in the range 0.0-
0.8mmol/L was used as the time period before the recorded results for that patient could 
be used again. This was the length of time suggested as the earliest point for renal 
recovery to be consistently seen after an acute kidney injury episode (Macedo et al., 
2012). Levels above 5.0mmol/L were not included for analysis as these were likely to have 
been erroneous levels, either from mistimed sample collection, overdose or collection of 
blood samples in lithium-heparin containers (Wills et al., 2006). Patients who had 
creatinine levels outside of the range 30-1500µmol/L not included for analysis as the 
MDRD equation used was not validated for levels outside of this range (St George's 
University of London) 
6.3.3. Statistical analysis 
Estimated glomerular filtration rate (eGFR) was manually calculated using the creatinine 
levels recorded on SystemTDM® and the simplified Modification of Diet in Renal Disease 
(MDRD) equation as in the previous chapter. 
A random effects repeated measures mixed model with an interaction with time was run 
using STATA SE 12.1 to ascertain the significance of the patterns of lithium exposure and 
time-periods (StataCorp, 2011). The reference and treatment groups in this analysis are 
made up of different patients. However by using a repeated measures design for the 
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analysis each subject serves as their own control. This means that the variability between 
subjects is isolated and the analysis can focus on treatment or intervention effects which 
may otherwise have been masked by subject variability. Using the simplified MDRD 
equation gender and age are taken into consideration when calculating eGFR so no 
further adjustments were required. The data for both MDRD and residuals were normally 
distributed and were checked for outliers and heteroscedasticity. As eGFR was normally 
distributed there was no need to perform any transformations on the data. The LL 
exposure pattern (group 5) and the 1 year (±3 months) time period were used in this 
model as the reference groups.  
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6.4 Results 
Estimated glomerular filtration rate (eGFR) was manually calculated using the creatinine 
levels recorded on SystemTDM® and the simplified Modification of Diet in Renal Disease 
(MDRD) equation as detailed in the previous chapter. Tables 6.1 and 6.2 detail the 
baseline demographics of the patients who were included in the analysis and then further 
by pattern group. There are a larger number of patients included in this analysis than the 
single exposure analysis due to the fact that in the previous analysis only eGFR levels up 
to the last known lithium reading of 0.8mmol/L were included and after that the patient 
was not included in the analysis whereas those patients are able to be included in the 
different pattern groups for this analysis, including pattern groups HH and HS. 
 Gender Age 
n= Female <20 20-29 30-39 40-49 50-59 >60 
777 461 (59.3) 1 (0.1) 29 (3.7) 72 (9.3) 122 (15.7) 166 (21.4) 387 (49.8) 
Table 6.1: Double exposure baseline demographics (all figures are number, (%)) 
There was a slightly higher percentage of females than males in this sample, and nearly 
half of the sample ages >60. The following table (6.2) details the demographics of the 
sample patients after being separated by exposure groups. It would have been expected 
that the database would have reduced the number of patients with repeated exposures 
to levels >0.8mmol/L, however due to the lack of clinical information able to be provided 
to the researchers for this analysis clinical decisions and reasons for any high levels 
cannot be explained so it is not possible to know if these repeated exposures are 
intentional for example, for use in manic episodes.  
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  Gender Age 
Pattern group n= Female <20 20-29 30-39 40-49 50-59 >60 
H. 40 20 (50) 0 (0.0) 0 (0.0) 4 (10.0) 5 (12.5) 13 (32.5) 18 (45) 
HH 31 22 (71) 0 (0.0) 0 (0.0) 3 (9.7) 1 (3.2) 3 (9.7) 24 (77.4) 
HL 178 116 (65) 0 (0.0) 3 (1.7) 11 (6.2) 21 (11.8) 36 (20.2) 108 (60.7) 
HS 38 25 (66) 0 (0.0) 2 (5.3) 4 (10.5) 3 (7.9) 8 (21.1) 21 (55.2) 
LL 490 278 (57) 1 (0.2) 24 (4.9)  50 (10.2) 92 (18.8) 106 (21.6) 216 (44.1) 
Table 6.2: Double exposure baseline demographics (all figures are number, (%)) 
The pattern group refers to the following exposures: 
H. = 1.01-5.0mmol/L then missing value 
HH= 1.01-5.0 then 1.01-5.0mmol/L 
HL= 1.01-5.0 then 0-0.8mmol/L 
HS= 1.01-5.0 then 0.81-1.0mmol/L 
LL= 0-0.80 then 0-0.80mmol/L 
There was more of a difference in the percentage of males and females in this analysis at 
baseline. Three groups had a larger percentage of females than at baseline (HH, HL and 
HS) and there was also a greater variation in the ages seen in each of the pattern groups 
at baseline. However, all showed a similar trend towards the majority of patients being in 
the oldest age bracket.  
A non-significant, increase in eGFR is seen for pattern groups H., HH and HL at time period 
on and a non-significant  increase in eGFR is seen for pattern groups H. and HS for time 
period two. A non-significant decrease in eGFR is seen for pattern groups HH at time 
period two and HS at time period one. The interaction of pattern and time is significant 
only for pattern three (HL) showing a significant increase in eGFR at ≤3 months follow-up 
after the second exposure event (p=<0.001). Table 6.3 shows the results of this analysis. 
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Independent variable Coefficient (95% CI)* p  
Pattern    
1 = H. -5.11 (-8.94 to -1.28) 0.009  
2 = HH -4.93 (-10.6 to 0.72) 0.087  
3 = HL -2.66 (-4.62 to -0.71) 0.008  
4 = HS -4.22 (-8.36 to -0.09) 0.045  
Time    
≤3 months (Time 1) -1.89 (-2.73 to -1.05) <0.001  
6 months (±3 months)(Time 2) 0.39 (-0.46 to 1.23) 0.368  
Pattern X Time interactions   
Pattern 1 X Time 1 1.28 (-2.34 to 4.89)  0.489 
Pattern 1 X Time 2 2.22 (-1.14 to 5.57) 0.195 
Pattern 2 X Time 1 3.56 (-1.75 to 8.87) 0.189 
Pattern 2 X Time 2 -3.54 (-9.07 to 1.99) 0.210 
Pattern 3 X Time 1 3.30 (1.63 to 4.98) <0.001 
Pattern 3 X Time 2 -1.56 (-3.21 to 0.08) 0.062 
Pattern 4 X Time 1 -0.01 (-3.60 to 3.59) 0.998 
Pattern 4 X Time 2 0.02 (-3.60 to 3.65) 0.989 
Wald chi2(15) = 3536.14, Prob>chi2 = < 0.001 
Table 6.3: Random effects repeated measures mixed model to predict eGFR, adjusting for 
baseline eGFR. 
 
In this analysis the Wald chi2 value has a significance of < 0.001, so we can conclude that 
the parameters associated with these variables are not zero and so should be included in 
the model. 
6.4.1. Findings from individual cases 
To see what was happening for individual cases, where significant changes may have 
been hidden by the amalgamation into the large data set a selection of cases were pulled 
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from the raw data (5 patients, as an arbitrary figure, from each pattern group). Table 6.4 
shows the data for these patients. 
Patient 
I.D 
Pattern 
group 
Patient 
Age at 
exposure  
Gender Lithium 
level for 
‘H’ value 
eGFR 
baseline 
eGFR 
time 1 
eGFR 
Time 2 
126 H. 61 M 1.02 90.6 113.0 102.1 
452 H. 47 F 2.56 45.7 38.3 46.4 
1057 H. 49 M 1.4 103.9 94.6 84.7 
2886 H. 79 F 1.09 56.6 67.5 79.3 
3163 H. 63 F 1.09 59.9 74.1 77.7 
308 HH 70 F 1.09 50.9 51.8 55.8 
492 HH 59 M 1.2 70.5 76.6 71.8 
1562 HH 55 F 2.67 69.3 69.6 63.9 
2542 HH 68 M 1.3 90.3 100.5 96.8 
3374 HH 65 F 1.15 76.1 82.7 84.0 
18 HL 62 F 1.18 76.3 71.9 67.7 
48 HL 84 F 1.35 27.1 20.1 20.1 
1482 HL 61 M 1.12 79.9 65.3 61.8 
2800 HL 41 M 1.4 122.4 122.7 126.9 
3418 HL 37 M 2.89 89.8 110.9 112.5 
109 HS 95 F 1.13 38.3 33.8 37.6 
458 HS 62 M 1.02 27.9 30.0 30.9 
1547 HS 48 F 1.48 65.1 73.6 69.3 
2989 HS 55 F 1.02 88.3 91.9 88.5 
3370 HS 73 F 1.2 64.9 66.2 61.1 
Table 6.4: Individual case data for selection of patients in each pattern group 
The average effect seen for the pattern group H., HH and HL from the statistical analysis 
was a non-significant increase in eGFR at time period one a non-significant increase in 
eGFR at time period two for pattern groups H. and HS. For the five cases for each pattern 
group pulled out to look at individually a variation in increases and decrease in eGFR was 
seen which would explain why there was not a statistically significant effect as there was 
variability in the effect for individual cases. This effect was not explained by gender, age 
at exposure or lithium level at exposure.  
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The interaction of pattern and time is significant only for pattern three (HL) showing a 
significant increase in eGFR at time period one. For the five cases for this pattern group 
pulled out to look at individually a variation in increases and decrease in eGFR was seen 
however the increase was only seen in the younger group of patients with a decrease 
seen in all three patients aged over 60 looked at individually.  
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6.5 Discussion 
For patients within this sample, having the lithium level pattern of 1.01-5.0 then 0-
0.8mmol/L (HL), there appears to be a short term positive association on renal function 
≤3 months follow-up after the second exposure event (L) and a borderline decline at 6 
months (±3 months). All groups except 1.01-5.0 then 0.81-1.0mmol/L (HS) showed an 
increase in eGFR after exposure at time one with two levels between 1.01-5.0mml/L (HH) 
and 1.01-5.0 then 0-0.8mmol/L (HL) showing a decrease in eGFR at time two. However 
the interaction between pattern and time was only significant for 1.01-5.0 then 0-
0.8mmol/L (HL) at the first time period. This correlates with recent research from Clos et 
al who concluded that long-term lithium therapy is not associated with changes in renal 
function, demonstrated by changes in eGFR, in the absence of episodes of acute toxicity 
(Clos et al., 2015). Our results also seem to suggest that there may be more to investigate 
surrounding changes in lithium levels, as well as cumulative doses or just exposures to 
levels thought to be out of the therapeutic range. 
As detailed in chapter five, variability in the measurement of plasma creatinine could lead 
to changes in GFR of up to 5ml/min in individual patients. This is unlikely to require any 
action to be taken unless this change is sustained or there is further deterioration picked 
up by regular monitoring variability in plasma creatinine.  
No additive effects were shown in this analysis although one major limitation was the 
sample size of the relevant groups. Currently this suggests that close monitoring is 
needed for lithium levels to prevent them from, as much as is practically and clinically 
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possible, from reaching a level of 1.01-5.0mml/L (H), as this single exposure still shows an 
association as was initially reported in the previous analysis of single exposures. 
6.5.1. Strengths and limitations 
Estimated GFR was used for this analysis but as in the previous chapter, this is only 
available routinely for patients from 2006 onwards. The eGFR was therefore calculated 
for all patients using the simplified MDRD equation using calculated creatinine levels 
recorded on SystemTDM®. As eGFR is affected by age, fractional age was used in the 
analysis to minimise this impact.  
Well known risk factors for declining renal function include diabetes mellitus, 
hypertension and cardiac disease. Data about any of these conditions was not reliably 
recorded on the database and could not be adjusted for in the analysis. Due to the way 
the data was recorded on the database there was no reliable information about other 
medications the registered patients were taking which may have included nephrotoxic 
drugs, these could have caused an impact on renal function separate to any relationship 
to lithium exposure which could not be accounted for in our analysis.  
The mean age of the population studied was 60, which is slightly higher than the means 
seen in previous audits or studies of 48-55 (Collins et al., 2010, Close et al., 2014). 
Compared to the rest of the UK, Norfolk has a higher percentage of the population over 
the age of 65, so this higher mean age was expected for the sample. The relationship 
between age and lithium level was not analysed in this thesis and with the age groups of 
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the sample having a significant proportion of patients aged >60 this could be considered a 
limitation of the analysis. 
The sample sizes for all groups apart from 1.01-5.0 then 0-0.8mmol/L (HL) were relatively 
small and would benefit from a collaborative research project to expand on these results 
and this analysis. It is therefore still unclear from this analysis if two levels between 1.01-
5.0mml/L (HH) have an additive negative relationship on renal function.  
In this analysis two exposures were analysed due to the complexities of the data. 
Clinically this allows a determination of the relationship of two different lithium levels on 
renal function over time. One main limitation of this analysis is the small sample size of 
most of the exposure groups, with only group three having a large sample size. 
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6.6 Conclusion 
The results from this analysis still suggest that close monitoring of lithium levels still 
needs to occur to prevent a single level between 1.01-5.0mmol/L (H) exposure as 
previously discussed in chapter five. These results raise the discussion point that it could 
possibly be changes in lithium levels which lead to the longer-term association with a 
decline in renal function with the results not clearly showing a difference between high 
and lower levels of exposure. With only small sample sizes this is not a definitive 
conclusion from this work but something to be considered in future, larger, analyses. 
Currently, although there are still unanswered questions about multiple exposures to 
lithium levels which have not been answered from this analysis, recommendations would 
be to continue monitoring lithium levels more frequently, not less frequently as has 
recently been recommended until the additional question of whether changes in the level 
also have an association with renal function, not just the level itself (NICE, 2014a). 
There is a need for collaborative research to expand the sample sizes of pattern groups 
either not seen in this sample or those that were too small. All pattern groups apart from 
1.01-5.0 then 0-0.8mmol/L (HL) have less than 40 patients in them. This means that 
statistically they are viable for analysis but may not be large enough to infer suggested 
changes in current practice. 
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7: Discussion and Conclusion. 
7.1 Overall discussion 
The original aim for this PhD was to determine the relationship between various lithium 
levels on renal function, however, as the research has progressed this expanded into a 
more comprehensive research question. The eventual focus of the PhD encompasses not 
only work to quantify the association of lithium levels with declines in renal function at 
different lithium serum levels and multiple exposures, but also whether the use of the 
systematic aid to help with the monitoring of lithium has any impact on prescribing 
decisions or if there are other factors at play as shown in prescribing research focussed on 
newer drugs (Ljungberg et al., 2007, Schumock et al., 2004, Prosser and Walley, 2006, 
Perlis, 2007). There has been a surge in research in lithium over the past couple of years 
alongside the work conducted for this thesis, suggesting that there are still numerous 
unanswered questions about lithium prescribing, monitoring and long-term effects.  
From the literature review conducted the current guidelines for the frequency of lithium 
level monitoring have not veered far from original customs, which were based on 
common practice, so this was clearly an area where the work from this thesis would add 
to the evidence-base for practice recommendations in the UK. This is reflected in the 
change in NICE guidelines on lithium monitoring that occurred part way through this 
thesis, a change apparently based on what is, or is not, performed in practice rather than 
what may be needed for patient safety (Bazire, 2014). Concerns have been raised prior to 
this work about the consistency of lithium monitoring across the UK, with the results of 
the POMH-UK audit leading to a NPSA patient safety alert (Collins et al., 2010, NPSA, 
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2009).The first part of this thesis was to establish the impact of the local computerised 
monitoring system on lithium monitoring to see if there was a difference seen from the 
poor compliance reported in the national POMH-UK audit (Collins et al., 2010). The 
results suggest that an actively managed database such as SystemTDM®, which was the 
system evaluated within Norfolk, aids more effective monitoring of lithium by not only 
ensuring that the majority of patients receive the recommended number of monitoring 
tests per annum but also appears to be associated with improved response rates to out-
of-range results received. One major limitation of this data is that we were not able to 
control for other external factors that could have impacted on this increase in lithium 
level monitoring in the years since the database implementation such as an increase in 
training and awareness of lithium and the introduction of QoF in 2004. The reasons for 
the high lithium levels and any actions taken by the clinical team are also not known from 
the information on the database. 
The qualitative work in this thesis evolved from the results in the service evaluation and 
prescribing information (Anderson, 2012, Powell-Smith and Goldacre, 2015). 
Consideration was being made at the time of the work for SystemTDM® to be rolled out 
to Suffolk from the neighbouring county of Norfolk particularly as the two counties are 
covered by the same Mental Health Trust. There was a disparity in prescribing of lithium 
seen between the two counties and so it was felt that by interviewing prescribers, in this 
case consultants who hold overall responsibility for patients, before SystemTDM® was 
rolled out it, what the influential factors were on prescribing decisions could be 
investigated. Work in this area had previously been conducted on newer drugs or 
comparing different areas of practice and not on older drugs such as lithium or comparing 
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two areas that shouldn’t display such disparity in prescribing (Schumock et al., 2004, 
Ljungberg et al., 2007). This study adds to the current evidence in these areas by 
supporting that the application of knowledge and discussions with colleagues, patient 
symptom and severity and diagnosis, patients past experience with medications, 
medication side effects, concurrent physical health problems, medication interactions, 
patient preferences and beliefs and the prescriber’s familiarity with certain drugs and 
practical experiences with drugs are all influential factors for prescribing of drugs such as 
lithium as well as drugs studied previously (Chow et al., 2014, Hajjaj et al., 2010, 
Rajendran et al., 2012, Shepherd et al., 2014, Denig et al., 2002b, Ljungberg et al., 2007, 
McGettigan et al., 2001, Tan et al., 2009, Hedenrud et al., 2013). 
However, the idea of prescribing based on the competence of the doctor rather than 
based on their grade was discussed, which ties in with issues of the knowledge and 
experience of prescribers. The idea that there needs to be more of an emphasis on 
teaching of older drugs such as lithium to ensure that generational differences are not 
seen in prescribing practices for newer doctors was also raised from this study. The 
emphasis on competence, education and training is not only relevant for lithium but for 
any drugs requiring therapeutic drug monitoring (TDM). With computerised systems in 
place any negative factors from the added complexities of prescribing drugs requiring 
TDM is partially negated alongside good communication between areas of practice. 
Unlike other studies the cost of drugs themselves was not raised as an issue, more so the 
cost of wasted services or clinics with a lack of robust communication or electronic 
systems to aid communication between areas of practice (Higgins and Tully, 2005, 
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Anderson, 2015). There are issues surrounding this raised in this study due to the recent 
changes in service configuration for mental health services whereby the consultant 
responsible for the long-term care of the patient is no longer likely to be the consultant 
who sees the patient as an inpatient, and may even be in a different geographical area 
(Begum et al., 2013). This leads to issues around initiating complex and long-term 
medications as the person who would be initiating the drugs, such as lithium, is not able 
to have a full discussion around the considerations needed from the patient’s perspective 
about their long-term treatment. This correlates with the previously raised factor that 
interacting with the patients (and relatives where relevant) along the journey to 
prescribing in a shared-decision making process is important in the prescribing decision. If 
the prescriber is not able to be involved after the initiation of a drug this process cannot 
be followed. At some points the idea of a lithium clinic was raised as a way to aid in the 
long-term care of patients prescribed lithium, and to bridge any issues from the change in 
structure of mental health services where the initial consultant initiating a treatment 
option is not the consultant following the patient up in the long-term. However where 
there was a computerised system in place to aid the prescribing and monitoring of 
patients prescribed lithium, concerns raised about its prescribing were negated along 
with the cost implication of missed or repeated clinic visits and blood tests. 
As early on in the thesis work the effectiveness of a computerised system has been 
evaluated, a logical next step was to further investigate the relationship of lithium levels 
on renal function using the data collected by this robust system. This had been an area 
where there was inconsistent research conducted previously and an area where there 
  
173 
 
were still uncertainties about the definite effects of lithium on long-term renal function 
(McKnight et al., 2012).  
As part of a systematic approach to analyse the patient data collected by SystemTDM® 
since its inception, the impact of one lithium level, of varying degrees, was explored 
initially. Serum creatinine was used as the initial marker for renal function as this was 
recorded on the system. However, although this is an endogenous marker of kidney 
disease, it has its limitations as a marker of renal function (NICE, 2008). Estimated GFR 
was therefore used for the final analysis as reported in the thesis. There are also still 
limitations to using this marker of renal function as not all factors that can affect the 
calculated eGFR were recorded on the database. These factors include race, other current 
medications, or diseases (NICE, 2014b). 
This showed that exposure to one lithium level >1.0mmol/L had a statistically significant 
negative association on renal function in the first three months after exposure but with 
no other high levels the kidneys appeared to be able to recover this function. In practice 
however, lithium is a long-term treatment and it is therefore likely that lithium levels will 
change over time for patients potentially leading to multiple or further exposures to 
levels >1.0mmol/L. This data adds to previous research which was not able to determine 
variations in this risk to renal function for different serum levels, due to the comparison 
of different lithium level ranges compared to a reference group (Close et al., 2014). 
The next step for the progression of the thesis was to look at multiple exposures to 
various lithium levels. The NICE guidance on lithium monitoring changed since the first 
analysis was run on single lithium levels, and was amended in part due to the results 
  
174 
 
presented. The guidance at the time of this analysis therefore only recommended six 
monthly lithium level testing for patients after their first year, except for certain groups. 
Patterns including missing values at the second exposure point (three months) were of 
interest as well as those with a level recorded then as this would reflect a change to the 
six monthly testing. However, due to the impact of SystemTDM® on ensuring that 
patients received lithium levels and other testing parameters in line with the previous 
national guidance of three monthly testing, we found that there were very few patients in 
our sample with missing values.  
With the results from the double exposure analysis showing mainly non-significant 
increases in eGFR apart in all pattern groups apart from HH which showed a non-
significant decrease in eGFR at time period two i.e. six months after the second exposure 
and HS at time period one i.e. three months after the second exposure. This correlates 
with recent research from Clos et al who concluded that long-term lithium therapy is not 
associated with changes in renal function, demonstrated by changes in eGFR, in the 
absence of episodes of acute toxicity (Clos et al., 2015). 
When evaluating these results it started to be considered whether in fact the change in 
the lithium levels was a factor to be considered on the impact on renal function not just 
the level itself due to the variation in increases and decreases in eGFR and the fact that 
the interaction of pattern and time was significant only for pattern three (HL) showing a 
significant increase in eGFR at ≤3 months follow-up after the second exposure event. This 
was evidenced in the variation in the effects shown in the individual results for various 
patients pulled out as examples, when looking at these examples there was no correlation 
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between lithium level at exposure, age or gender that could explain the variation apart 
from the three patients aged >60 in the HL pattern group who all showed a decline in 
eGFR. The sample sizes of the pattern groups in this analysis were too small to be 
statistically reliable for most of the groups apart from 1.01-5.0 then 0-0.8mmol/L (HL) so 
not much reliance should be placed on these results. There were also multiple tests run 
for the analysis on the data on single and multiple exposures to lithium which does limit 
the robustness of the results presented. However this was thought to be an appropriate 
limitation to the analysis due to the way the data was presented for analysis. 
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7.2 Conclusions 
Mental health disorders for which treatment with lithium is appropriate are long-term, 
chronic conditions and require a long-term treatment. Therapeutic ranges of lithium for 
the treatment of the various disorders for which it is licensed to treat have been well 
established. Evidence, however, to support recommended monitoring frequencies is 
lacking. The use of a computerised, actively managed database for the monitoring of 
lithium has, within Norfolk, been associated with a steady increase in the numbers of 
patients receiving tests at the recommended frequencies, and a quicker response to 
levels outside of the recommended range reducing patient exposure to the potentially 
toxic effects of lithium. However this increase could also be partly explained by an 
increase in education about lithium levels and the implementation of QoF. 
The evidence contained within this thesis provides a backbone on which to conduct 
further research for multiple exposures to various lithium levels on a larger scale with the 
potential for collaborative research across the UK. So far the evidence is suggestive of a 
short-term negative association on renal function after exposures to single, high lithium 
levels but due to the small patient groups in the multiple exposures analysis the results 
from this are not statistically reliable so we cannot draw robust conclusions from them. 
These results did, however, raise the considerations that changes in lithium levels, not 
just the level itself, may impact on renal function. This lends itself to further research in 
order to investigate further to see if this hypothesis is correct or if the level of lithium is 
the principal factor contributing to the statistical increase in renal function seen for some 
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groups at follow-up after multiple exposures and the non-significant decrease seen for 
other groups. 
In terms of the factors affecting prescribing decisions many factors mentioned correlate 
with previous studies researching newer medications and other healthcare settings. 
However, the new themes bought up added to the idea of knowledge, learning and 
competence of prescribers with concerns around a lack of knowledge of older drugs seen 
in newer doctors. There needs to be focus maintained on older drugs so that knowledge 
about their use and how to prescribe them is not lost with newer generations of 
prescribers. 
Although the idea of a lithium clinic was raised as an option for the ongoing prescribing of 
lithium, the feasibility of this was outside of the remit of this thesis. However the 
prescribers who used a computerised system such as SystemTDM® for the monitoring of 
their lithium patients were less concerned about setting up a specific clinic as they were 
confident in the long-term monitoring process. The initial prescribing of lithium and other 
drugs for the longer term treatment of patients was still an area of debate with 
prescribers not wanting to commit their colleagues to a specific course of action, and all 
prescribers had a reluctance to completely ‘let go’ of patients, wanting to still oversee 
their lithium treatment. 
This suggests that a clearer, structured way of lithium being prescribed, with guidance 
surrounding at what points during the patient’s journey the initial prescribing choice 
should be discussed and a decision made is needed. This would help overcome the barrier 
of split services within mental health and give clearer roles to the various consultants 
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involved in a patient’s care. In addition the wider roll out of a system which could act as a 
centralised lithium monitoring system with access for all those involved in the patients 
care along their journey should be considered to aid in the long-term monitoring of 
lithium. This would help to maintain levels within acceptable ranges consistently and 
avoid any exposures to levels outside of these ranges, or multiple changes in lithium 
levels to minimise the potential detrimental effects on renal function. This sort of system 
would also allow for all those involved being able to retain some sort of oversight over 
patients whether or not they are still directly under their care. It would also allow for 
greater research to be conducted to address the additional research questions raised by 
this thesis. 
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7.3 Publications and conferenced proceedings arising from the thesis 
Peer-reviewed Journals 
Kirkham E, Skinner J, Anderson T, Bazire S, Twigg MJ, Desborough JA; One lithium level 
>1.0mmol/L causes an acute decline in eGFR: findings from a retrospective analysis of a 
monitoring database. (BMJ Open 2014;4:11 e006020 doi:10.1136/bmjopen-2014-006020) 
Kirkham E, Bazire S, Anderson T, Wood J, Grassby P and Desborough JA; Impact of active 
monitoring on lithium management in Norfolk; Therapeutic Advances in 
Psychopharmacology; 2013;(5):260-265 
Published Conference Abstracts and presentations 
Kirkham E, Desborough JA, Skinner J, Bazire S, Anderson T, Wood J, Grassby P (2013) The 
effects of computerised standardisation on lithium monitoring (Oral Presentation at 
College of Mental Health Pharmacy Conference 2013) 
Kirkham E, Desborough JA, Skinner J, Bazire S, Anderson T (2013) What happens if you go 
‘high’ on lithium. (Poster at College of Mental Health Pharmacy Conference 2013) 
Kirkham E, Desborough JA, Skinner J, Bazire S, Anderson T (2013) Does the ‘active’ part of 
an actively managed database for lithium have an effect? International Journal of 
Pharmacy Practice 21 (Suppl. 2) 30-137 (Poster at Royal Pharmaceutical Society 
Conference 2013) 
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Kirkham E, Skinner J, Anderson T, Bazire S, Twigg MJ, Desborough JA. 'What does lithium 
do to your creatinine?' European Neuropsychopharmacology. 2014;24(Supplement 
2):S410 (Poster at European Congress of Neuropsychopharmacology 2014) 
Kirkham E, Bazire S, Twigg MJ, Anderson T, Desborough JA (2015) Factors which influence 
prescribing of lithium: views and perceptions of consultant psychiatrists (Poster at Health 
Services Research and Pharmacy Practice Conference 2015) 
Kirkham E, Bazire S, Twigg MJ, Anderson T, Desborough JA (2015) Robustness of 
monitoring systems influential in decisions to prescribe lithium. (Poster at British 
Association of Psychopharmacology Summer meeting 2015) 
Planned publications 
Final PhD Project: Factors affecting lithium prescribing: views and perceptions of 
consultants on current practice. 
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7.4 Recommendations for future work 
- Collaborative work with other areas of the UK, and possibly internationally, where 
lithium is prescribed and initiated to expand on the statistical analysis of multiple 
exposures of various lithium levels. By collaborating with other areas which have 
similar data to that recorded on the SystemTDM® may mean a more reliable 
interpretation could be gained from the results. Specific patterns of exposure 
which were not present in the Norfolk cohort may also be available to be 
analysed. This work could also be expanded to look at three, four, five and so on 
different lithium level exposures and expand on the pattern groups evidenced in 
the Norfolk data where significant conclusions could not be drawn from the 
results. The population in Norfolk is also not the most diverse and so additional 
collaborations would enable any demographics which may have an additional 
impact on renal function. 
- The relationship between age and lithium level was not fully explored in this 
thesis, this is an area where there is scope for future work focussing on the >60 
age group of patients which are prevalent within Norfolk. 
- Further interviews could also be conducted across the UK within different Trusts 
to see if there are other factors at play in other areas of the UK where per head of 
population there are disparately different rates of lithium prescribing as recorded 
from Openprescribing.net (Powell-Smith and Goldacre, 2015). 
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1. Introduction 
Since the early 1970s lithium carbonate has been approved in the US for long-term 
prophylactic use in bipolar disorder with approval in the UK occurring by 1985 (Sanofi-
Aventis, 2011, FDA, 2012 (a)). Lithium has since been licensed for the treatment and 
prophylaxis of mania and hypomania, prophylactic treatment of recurrent affective 
disorders, treatment of recurrent bipolar depression where the use of alternative 
antidepressants has been ineffective and the treatment of aggressive or self-mutilating 
behaviour (Sanofi-Aventis, 2012, Norgine, 2011, Rosemont, 2011). During the 1950s the 
narrow therapeutic range of lithium was determined and ad-hoc monitoring for signs of 
toxicity including gastric disturbances, motor disturbances such as muscular weakness 
and ataxia and slurred speech occurred (Ashburner, 1950, Noack and Trautner, 1951). 
Until 2003, with the publication of the British Association for Psychopharmacology (BAP) 
guidelines and later in 2006 with the National Institute for Health and Clinical Excellence 
(NICE) bipolar guidance, there were no nationally recognised guidelines in the UK for 
lithium monitoring outside of the recommendations in the British National Formulary 
(BNF) (NICE, 2006, BAP, 2009). By the 1980s these BNF recommendations were limited to 
adjusting the dose to achieve plasma concentrations between 0.6 and 1.2mmol/L (Joint 
Formulary Committee, 1988). However renal toxicity and side effects had been associated 
with higher levels (>0.8mmol/L) suggesting that tolerability may be problematic with the 
higher levels recommended even if further benefits are gained in symptom control 
(Gelenberg et al., 1989, Severus et al., 2008). Long-term use of lithium has been 
associated with thyroid disorders and effects on renal function. Lithium has been 
associated with a nephrogenic diabetes insipidus and a speculative description of specific 
lithium nephropathy (McKnight et al., 2012, Joint Formulary Committee, 2012). 
NICE guidelines on the management of bipolar disorder developed in 2006 state that 
during maintenance treatment with lithium, a serum lithium level should be taken every 3 
months, renal and thyroid function tests should be completed every 6 months (more 
often if there is evidence of impaired renal function), and weight, BMI or waist 
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circumference should be done annually (NICE, 2006). The BAP guideline recommends that 
kidney and thyroid function are tested every 12 months, with lithium levels checked every 
3-6 months in people on a stable dose (BAP, 2009). 
In December 2009 the National Patient Safety Agency (NPSA) released an alert to improve 
the safety of lithium therapy due in part to concerns that guidelines were not being 
followed (NPSA, 2009). This focussed on regular monitoring in line with NICE guidance, 
reliable communication systems for blood test results, appropriate verbal and written 
information provided to patients and systems are in place to identify and deal with 
potential interactions with lithium therapy (NPSA, 2009). Seven years before this alert a 
lithium database and register (System TDM®) had been implemented across Norfolk 
following a clinical incident in primary care. The main objectives of this database were to 
ensure that all patients on lithium have access to adequate information, education and 
specialist advice and receive regular blood tests following an agreed protocol (Holmes, 
2005). 
In a recent meta-analysis and systematic review the toxicity profile of lithium was 
investigated showing little evidence for a clinically significant reduction in renal function 
in most patients and an association with an increased risk of reduced urinary 
concentrating ability, hypothyroidism, hyperparathyroidism, and weight gain. The quality 
and quantity of the primary evidence available was a main limitation of this study. High 
quality data from long-term randomised or controlled cohort studies were sparse and the 
sample size of most included observational studies was quite small (McKnight et al., 
2012). 
The Norfolk based database (System TDM®) now has ten years’ worth of data collected 
during routine clinical practice allowing a retrospective single cohort study to be 
performed with a large sample size. Both renal function (from urea, creatinine and eGFR) 
and thyroid function (from TSH and T4) are recorded for all patients along with lithium 
levels, and other risk factors. 
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2.  Aims 
 To investigate the importance of lithium monitoring 
3.  Objectives  
 To determine the impact of an active management system on lithium monitoring 
 To determine the effects of lithium control on renal function 
 To determine the effects of lithium control on thyroid function 
 To determine the relationship between lithium control and other significant variables 
4. Method 
Data analysis will not commence until all relevant approvals are in place. As the research 
is limited to secondary use of information previously collected in the course of normal 
care (without an intention to use it for research at the time of collection) it is excluded 
from REC review, provided that the patients or service users are not identifiable to the 
research team in carrying out the research as in this case, therefore only requiring NHS 
R&D approval. 
The database currently holds the following information about those patients registered 
on it: 
Database ID, NHS number, alternative ID, full name, address and registered GP practice of 
each patient 
Date of registration 
Date of test results and results for: lithium, urea, creatinine, eGFR, TSH, T4 
Risk factor: ACE inhibitor, Age >70, Diuretic, Impaired renal function, NSAID 
Patient DoB 
Gender 
Diagnosis  
Past and future addresses 
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Letters sent 
Notes relating to patient 
Uploaded documents 
Any alerts relating to patient 
 
The clinical pharmacy team will then anonymise this data removing NHS number, 
alternative ID, full name, address and registered GP practice of each patient, past and 
future addresses, letters sent, notes relating to patient, uploaded documents, any alerts 
relating to patient. 
4.1 Participant Identification 
All patients registered on the data base have data collected in routine clinical care which 
will be accessed for analysis. The patients will be identified by the clinical team who have 
access to the full data stored on the database. 
4.1.1. Inclusion Criteria 
 Patients who have been prescribed lithium for any indication and whose results were 
collected in routine clinical care and entered onto the database. 
 Patients over the age of 18 years. 
4.1.2. Exclusion Criteria 
 Nil specific exclusion criteria due to the data being collected in routine clinical practice 
4.2 Sample size  
At the time of writing the clinical pharmacy team have informed the researchers that 
there are 1730 patients on the database (active, inactive, suspended or deceased). All 
patients who meet the inclusion criteria are expected to be included for analysis. 
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4.3 Data collection 
The anonymised data from the clinical team will be locally encrypted using AES-256 
encryption and then saved to cloud based storage for backup prior to analysis. This 
analysis will be performed at the University of East Anglia using computers which require 
a password log-in. All anonymised, locally encrypted data on the database from the sql 
server management studio will be stored electronically with direct access only for the 
principal researcher. 
Data extraction and analysis will be repeated six monthly to ensure that the most 
comprehensive and current data is being used for analysis.  
4.4 Data analysis  
Data gained from the study will be analysed using STATA. The tests to be used will be 
determined by the distribution of the data and the different relationships between the 
monitoring parameters and lithium levels to be analysed. Assuming that the test results 
or a transformation of them (e.g. log) are approximately normally distributed, regression 
methods will be used to model each of the results and the risk factors above, together 
with age, sex and diagnosis. Otherwise, non-parametric methods (Mann-Whitney, 
Kruskal–Wallis) will be used to examine the effect of the risk factors. 
Only anonymised data will be analysed by the researcher and their supervisors using 
password protected computers. All anonymised data will be destroyed five years after 
completion of the study. 
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1 Introduction 
Lithium is licensed in the UK for the treatment and prophylaxis of mania and hypomania, 
prophylactic treatment of recurrent affective disorders, treatment of recurrent bipolar depression 
where the use of alternative antidepressants has been ineffective and the treatment of aggressive 
or self-mutilating behaviour (Sanofi-Aventis, 2012, Norgine, 2011, Rosemont, 2011). Lithium is 
considered to be effective when its serum level is maintained between 0.6 and 0.8mmol/L in 
newly initiated patients. Few patients will benefit from higher serum levels above 1.0mol/L as 
these are associated with an increase in signs and symptoms of lithium toxicity. Since lithium has 
a narrow therapeutic window the National Institute for Health and Clinical Excellence (NICE) 
guidance currently recommends that the serum lithium level is checked every 3 months whilst the 
British Association for Psychopharmacology (BAP) guidelines recommend every 3-6 months. Renal 
and thyroid function tests are also recommended at baseline and routinely throughout treatment. 
These additional monitoring requirements are because lithium is almost entirely renally excreted, 
so any change in renal function or fluid balance can potentially lead to lithium accumulation. 
Treatment with lithium has also been associated with an increased risk of clinical hypothyroidism 
(BAP, 2009, NICE, 2006). 
Despite these guidelines there remain a number of concerns regarding adherence to monitoring 
recommendations which is a cause for concern in relation to patient safety (Collins et al., 2010, 
Eagles, 2000). Between the years 2005-2009 there were 567 patient safety incidents reported to 
the National Reporting and Learning System (NRLS) relating to lithium therapy. A key theme in 
these incident reports was lack of patient monitoring which holds a risk of litigation (NPSA, 2009). 
In a ten year review the Medical Defence Union found that there were 102 cases of litigation 
involving lithium prescribing and monitoring. Out of these, poor monitoring was cited in 59 cases, 
13 of which involved deaths (excluding suicides) and 44 cases of toxicity (Holmes, 2005). In 2009 
the Prescribing Observatory for Mental Health UK (POMH-UK) audit of lithium prescribing 
identified that only 30%, 55% and 50% of patients met monitoring standards for serum lithium, 
renal and thyroid function respectively (Collins et al., 2010). In December 2009 the National 
Patient Safety Agency (NPSA) released a patient safety alert partially due to the results of the 
POMH-UK audit as well as concerns about patient safety incident reports (NPSA, 2009). The alert 
focussed on regular monitoring in line with NICE guidance, reliable communication systems for 
blood test results, appropriate verbal and written information provided to patients and systems 
to be developed to identify and deal with potential interactions with lithium therapy (NPSA, 
2009). 
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Although the NPSA alert was released in 2009 a unique Norfolk-wide lithium register and 
database (SystemTDM®) has been in operation since 2002. This database was developed by a 
local prescribing group and is currently only used in Norfolk. Recently, there has been interest in 
providing this service to other Mental Health Trusts across the country. The main objectives of 
this database are to ensure that all those on lithium have access to adequate information, 
education and specialist advice and receive regular blood tests following an agreed protocol. The 
database incorporates a reminder service for blood tests to patients together with alerts to 
prescribers of lithium results that are out of the specified range or overdue blood tests, both of 
which require action. In January 2012 individual Norfolk and Suffolk Mental Health Trusts merged 
to form Norfolk and Suffolk NHS Foundation Trust (NSFT). The intention of NSFT is to roll out 
SystemTDM® to Suffolk, however, to date only one area in Suffolk has been approached and 
registered patients on the database. 
Nationally (where lithium prescribing is hospital initiated), there are shared care agreements in 
place allowing secondary care initiation and prescribing until the patient is stabilised and then 
transferred to primary care for continued treatment. These shared care agreements have been in 
place in both Norfolk and Suffolk for some years. However, anecdotal prescribing information 
suggests that lithium appears to be prescribed twice as often in Norfolk as in Suffolk, despite the 
similarity in their current shared care agreements, population size and age distribution (Anderson, 
2012, ONS, 2011). Therefore, we want to explore the factors which affect the decision to 
prescribe lithium by interviewing consultants within NSFT to determine potential reasons why this 
difference is observed. For those consultants based within Suffolk this will be done before the 
database becomes normal practice as it currently is within Norfolk. 
There is a dearth of research on the factors which influence prescribing decisions for established 
treatments, most focusses on new drugs and comparisons between primary and secondary care 
or different healthcare professionals within secondary care (Ljungberg et al., 2007, Schumock et 
al., 2004). The aim of this project is to build on this limited research to ascertain the key factors 
which influence consultants prescribing choices relating specifically to lithium. Semi-structured 
interviews will be used to ascertain the views and perceptions of consultants currently working 
across NSFT. 
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2. Aims and Objectives 
2.1 Aim 
The aim of this project is to understand the factors affecting lithium prescribing by eliciting the 
views and perceptions of consultants on current practice through semi-structured interviews. 
 
2.2 Objectives 
The objectives of the semi-structured interviews will be to: 
 Explore consultants’ views on lithium as a medicine. 
 Explore what factors consultants consider as influential in decisions to prescribe lithium or 
another medicine in current practice 
 Describe the effect of current guidance on the prescribing of lithium. 
 Describe the effect of current shared care agreement and the procedure for transfer of 
prescribing to primary care 
 Compare the views and perceptions of Norfolk and Suffolk based consultants on the 
prescribing of lithium i.e. comparing the views of those experienced with the database and 
those who are not 
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3. Methodology, Procedure and Analysis 
3.1 Method 
This has been reviewed and approved by the Faculty of Medicine and Health Sciences Research 
Ethics Committee and the relevant NHS research governance committee. Semi-structured 
interviews will be undertaken with mental health consultants within NSFT. Interviews were 
chosen because the strengths of this method are well suited to our study in that they will 
facilitate a depth of focus and understanding of perspectives and experiences. The aim of this 
study is to capture the current practices of consultants within the trust; therefore interviews 
provide the opportunity for them to describe these without external influences as would be 
present in a focus group situation. In addition, semi-structured interviews should be more 
accessible to the population studied, which is made up of busy professionals, compared to focus 
groups (Ritchie and Lewis, 2003). 
3.2 Participant Recruitment 
As part of regular research meetings (involving NSFT consultants) potential participants will be 
alerted to the project. This is routine practice within these meetings and will be conducted by the 
NSFT Research and Development (R&D) lead in conjunction with the primary researcher (EK). The 
R&D lead will ask attendees if they are happy for the primary researcher to be present for the 
appropriate portion of the meeting. If consultants express an interest at any of these meetings 
they will be given a covering letter (Appendix 1) inviting them to participate in this study on behalf 
of the researchers. The letter will be accompanied by a participant information sheet (Appendix 
2), expression of interest form (Appendix 3) and a pre-paid envelope addressed to the primary 
researcher. Potential participants will be able to complete the appropriate documentation at the 
meeting and return directly to the researcher or take it away to allow them time to think about 
their participation. As the attendance of consultants in the research forums varies across localities 
contact via letter and email will however be the main method of recruitment as described below. 
The work contact details of all consultants working within Suffolk will be obtained by the primary 
researcher from research and development or the Trust e-mail group ‘consultants’ in order to 
contact them for this project. The primary researcher will then send out a covering letter 
(Appendix 1) inviting them to participate in this study. The letter will be accompanied by a 
participant information sheet (Appendix 2), expression of interest form (Appendix 3), decline to 
participate postcard (Appendix 4) and a pre-paid envelope addressed to the primary researcher. 
The e-mail (Appendix 5) will have attached a participant information sheet (Appendix 2) and will 
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encourage respondents to reply via e-mail with the information required on the expression of 
interest (Appendix 3). After two weeks, consultants that have not responded will be sent a second 
letter (Appendix 6) and email (Appendix 7). 
During the process of recruitment an encryption form (Appendix 12) will be kept allowing for each 
potential participant to be allocated a study reference number. When either an expression of 
interest form decline to participate postcard is returned these will be recorded to keep track of 
who has replied and the dates on which reminders are due to be sent out. 
Once participants have agreed to be involved with the research and have suggested times and 
locations that are suitable for them they will be contacted to confirm a time and date for the 
interview. Once this has been agreed an email or letter will be sent to them with confirmation of 
the date, time and location of the interview (Appendix 8). A reminder will be sent one week 
before the interview date. If more consultants are willing to be interviewed than it is feasible to 
conduct then the demographic data collected will be used to ensure that the two groups of 
interviewees from Norfolk and Suffolk are as similar as possible. The remainder of the consultants 
who expressed interest in participating will be send a regret email/letter (Appendix 9) 
To contextualise results, potential participants will be asked to detail whether they have worked 
for Norfolk and Waveney Mental Health Trust (the predecessor organisation to NSFT in Norfolk) in 
the previous ten years. They will also be asked if they have been employed in Norfolk or Suffolk 
for less than a year. This will capture those participants who are likely to be less experienced with 
the database (if based in Norfolk), and is due to the need to understand whether they have 
worked with SystemTDM® in the past. The only inclusion criteria for the project are that potential 
participants all consultants currently employed by NSFT, there are no specific exclusion criteria. 
3.3 Data Collection 
The interviews will take place at a venue and time that is suitable for the interviewees and will be 
conducted by the primary researcher. As a risk reduction measure these details will be shared 
with the supervisory team, and telephone contact made at the end of each interview. All 
participants will need to sign a consent form (Appendix 10) on the day of the interview in order to 
participate and a copy will be given to participants for their records. Refreshments will be 
provided for all participants by the researcher. 
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A pilot interview will be conducted by the primary researcher with a second researcher (MT) 
present for quality and assurance purposes of the primary researcher, not for interaction with the 
participant. This pilot interview will be transcribed by the primary researcher and will be reviewed 
by the supervisory team. Data collected during this interview will not be included in analysis and 
amendments will be made to the interview topic guide if required.  
The interviews are expected to last up to one hour and the participant will be free to leave at any 
point. If they choose to leave due to time constraints then the data up to the point of them 
leaving will be used in the analysis, if they choose to leave for other reasons then the participant 
will be asked if they consent to their data up to that point being included in the analysis or if they 
want it to be removed. The topics expected to be covered in the interviews are:  
- Introduction and background to the project 
- What are your views on lithium as a medicine? 
- When and for what type of patients would you consider prescribing 
lithium?  
- What influences your choice to prescribe lithium rather than other 
medicines?  
- Do you routinely use any treatment guidelines to influence choice of 
medicine? 
- Do you think it matters who prescribes/initiates lithium? 
- Conclusion 
The interviews will be audio recorded using two voice recording devices. The interviews will be 
transcribed confidentially by the primary researcher and checked for accuracy by another 
member of the research team. Alternatively, depending on finances, an option would be to 
outsource the transcribing to a reputable company such as Clayton Research Support, 54 
Chapmans Drive, Old Stratford, Northamptonshire, MK19 6NT, who have been used for such 
projects previously and then the verbatim transcripts will be checked for accuracy by the 
researcher. If transcribing is outsourced a confidentiality agreement will be signed before they 
undertake any transcribing (Appendix 11). 
In order to encourage the participants to be open and honest the interview recordings will only be 
accessed by the principal researcher and the member of the research team checking accuracy. 
Once transcribed and checked for accuracy the interview recordings will be deleted. The consent, 
and expression of interest forms and the decline to participate postcards in hard copy will be 
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stored in lockable storage at the University of East Anglia and will all be destroyed within five 
years of completion of the study. An encrypted memory stick will be used to hold the data and 
analysis after completion of the study and this will stored in a locked environment for five years 
and then destroyed. The encryption form will be destroyed within six months of completion of 
the study. 
3.4 Data Analysis 
A thematic analysis will be undertaken of the anonymous transcripts which will be performed at 
the University of East Anglia using computers which require a password log-in. These transcripts 
will be analysed by two researchers independently and consensus reached if disagreements 
occur. Manual coding, using a ‘scissors and paste’ technique, will be undertaken by the primary 
researcher who has attended a course in interviewing skills and received training on qualitative 
data analysis. The supervisory team will be involved in the coding process and advise as required. 
Thematic analysis will be used allowing for identification and analysis of themes or patterns that 
that are elicited from the data. Due to the nature of this research we will aim to produce a rich 
thematic account of the whole data set in order to get a sense of the predominant or important 
themes (Braun and Clarke, 2006). The process of thematic analysis as described by Braun and 
Clarke: 
1. Familiarise yourself with your data e.g. transcription and reading 
2. Generating initial codes 
3. Searching for themes e.g. organising codes into groups, starting to identify themes 
4. Reviewing themes e.g. checking themes match with the originally generated codes 
5. Defining and naming themes 
6. Producing the report 
There will be constant reference at all stages to the original transcript as this will help the 
researcher determine the level of themes and subthemes and confirm that these are relevant to 
what was said in the transcript and have not been taken out of context during the coding process. 
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School of Pharmacy 
University of East Anglia 
Norwich 
NR4 7TJ 
Tel. 01603 591973 
 
Pharmacy Department 
Hellesdon Hospital 
Norwich 
NR6 5BE 
Tel. 01603 421480 
Dear [Name] 
 
Invite to participate in research - local interviews with consultants to get their views 
and perceptions on the factors affecting lithium prescribing in current practice 
 
The pharmacy department at Hellesdon Hospital is currently working with the University of 
East Anglia on a project to evaluate the role of lithium monitoring. As part of this project we 
would like to learn about factors which affect lithium prescribing, focussing on the views and 
perceptions of consultants on their current practice. To facilitate this we would like to invite 
you to be a part of the project and arrange an interview with Emma Kirkham (the primary 
researcher), of approximately 1 hour with you as a consultant currently working within NSFT. 
You will also receive this invitation via email. 
 
This work is being conducted as part of a research project and therefore we intend to publish 
the results in a peer-reviewed journal, albeit in an anonymised format. The data collected will 
be kept in an anonymised format within the School of Pharmacy and all raw data from the 
project will be destroyed within one year of the study’s completion. Relevant approvals have 
been obtained for the project. 
 
Please read the enclosed participant information sheet and if you are happy to participate 
please return the expression of interest form using the pre-paid envelope or reply via email to 
Emma Kirkham on e.kirkham@uea.ac.uk or emma.kirkham@nsft.nhs.uk with the following 
information: 
 
- Year of qualification   
- Gender  
- Age group: 20-35, 36-50, 51-65, 66+  
- Whether you have worked within mental health in Norfolk or Suffolk for less than one 
year.  
- In the last 10 years have you ever worked for Norfolk and Waveney Mental Health 
Trust? 
- Your speciality e.g. Adult Services, Forensics, Older Age, CAMHS 
- Preferred contact details 
 Chair: Gary Page 
Deputy Chief Executive: Andrew Hopkins  
Trust Headquarters: Hellesdon Hospital, Drayton High Road, Norwich, NR6 5BE 
Tel: 01603 421421    Fax: 01603 421440    www.nsft.nhs.uk 
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- If possible suitable times/locations for interviews or details for best person to contact 
for this 
 
If after two weeks no response has been received we will contact you again to confirm 
whether you wish to participate in this project. If at any point you have any questions about 
the project please feel free to contact Emma Kirkham by email or on 01603 591973 and I will 
endeavour to answer them for you. 
 
Thank you in anticipation of your help. 
 
Yours sincerely, 
 
Emma Kirkham 
Research Pharmacist   and 
School of Pharmacy 
University of East Anglia 
Norwich, NR4 7TJ 
 
 
Tim Anderson 
Lead Clinical Pharmacist 
Hellesdon Hospital 
Norwich, NR6 5BE  
 
Enclosures (3) 
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Participant Information Sheet
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Version 3, December 2013 
 
 
Factors affecting lithium prescribing: views 
and perceptions of consultants on current 
practice 
  
Research funded by the Pharmacy department at Hellesdon Hospital 
Participant Information Sheet 
This information sheet is designed to be read by you, the potential participant, to help you 
understand this project and what it will involve. It is set out as a series of questions and 
answers. If any question that you would like to ask is not provided for then please feel free to 
contact the primary researcher via telephone or email. 
What is the project about? 
The aim of this project is to better understand the views and perceptions of consultants who 
prescribe lithium on factors which influence their prescribing decisions.  
What are the benefits of becoming involved in this project? 
The results of this project will be used to evaluate and influence the way in which lithium is 
monitored within Norfolk and Suffolk NHS Foundation Trust. Additionally, the preliminary 
findings from this project will be shared with you, verbatim quotes from the interviews may be 
published but personally identifiable information will be removed. Participants will only be 
identifiable by their study numbers in written documentation and any quotes will be attributed 
to the study number allocated to that participant. 
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What does the project involve? 
The project will involve a face to face interview of approximately 1 hour with the primary 
researcher (EK), refreshments will be provided for you. You will be free to leave at any point 
with no ill effects. If you choose to leave due to time constraints then the data up to the 
point of leaving will be used in the analysis, if you choose to leave for other reasons then you 
will be asked if you consent to your data up to that point being included in the analysis or if 
you want it to be removed. You will be asked questions on the following topics: 
What are your views on lithium as a medicine? 
When and for what type of patients would you consider prescribing lithium?  
What influences your choice to prescribe lithium rather than other medicines?  
Do you routinely use any treatment guidelines to influence choice of medicine? 
Do you think it matters who prescribes/initiates lithium? 
Do I have to take part? 
Participation is entirely voluntary. If we do not hear from your two weeks after sending out 
this invitation pack (via email and letter) we will send out a second pack to you. If you do not 
wish to participate please return the decline to participate postcard and you will received no 
further correspondence from us. 
Will information need to be provided on individual patients under my care? 
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No, the interviewer will not ask for any data which identifies individual patients. Additionally, 
you will be able to decline to answer questions if you wish. However, if an issue raising a 
concern of professional misconduct or negligence is disclosed as part of the research study 
then this will be passed onto the Research Integrity Officer as per Trust policy. 
 What happens next? 
If you would like to participate then please contact the primary researcher Emma Kirkham on 
e.kirkham@uea.ac.uk or emma.kirkham@nsft.nhs.uk or return the expression of interest 
form in the pre-paid envelope provided to confirm your participation. You will then be 
contacted to arrange a time and location for the interview to take place convenient for you. 
Complaints 
If you have a complaint about how you were approached or how the interviews were 
conducted please contact the Research and Development office at Hellesdon Hospital on 
01603 421340 or RDofficemailbox@nsft.nhs.uk . They will be able to answer any concerns 
you may have. 
For further information please contact: 
Primary Researcher: 
Miss Emma Kirkham 
School of Pharmacy, 
University of East Anglia, 
Norwich, NR4 7TJ 
Tel: 01603 591973 
Research Supervisor: 
Dr. James Desborough 
School of Pharmacy, 
University of East Anglia, 
Norwich, NR4 7TJ 
Tel: 01603 593413 
Thank you for taking the time to read this information sheet 
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Expression of Interest form 
Name:  
 
 
Year of qualification   
Gender  
Age group (please circle) 20-35  
36-50  
51-65  
66+  
Speciality e.g. Adult Mental 
Health, CAMHS, Older adult 
 
In the last 10 years have 
you ever worked for Norfolk 
and Waveney Mental Health 
Trust? 
 
Have you been employed 
within mental health in 
Norfolk or Suffolk for less 
than a year? 
 
Preferred contact number:  
Email address:  
If possible please suggest 
suitable times/locations for 
interview: 
 
 
 
 
 
 
Please return this form to the research team in the pre-paid envelope supplied. No stamp is required 
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Decline to Participate Postcard 
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Decline to Participate Postcard 
 If you do not want wish to 
participate in this research, 
please return this postcard (no 
stamp needed) and you will not 
be contacted again. If you do 
not return this postcard or 
expression of interest /reply via 
email we will contact you in 2 
weeks’ time to check whether 
you are interested in 
participating.  
 
 
I do not wish to take part in this 
research  (Please tick) 
 
 
Thank you for your time 
 
REF NO: _____ 
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Covering email 
 234 
Version 2, August 2013                                
Subject: Invite to participate in research - local interviews with consultants to get their views 
and perceptions on the factors affecting lithium prescribing in current practice 
__________________________________________________________________________ 
Dear [Name] 
 
The pharmacy department at Hellesdon Hospital is currently working with the University of 
East Anglia on a project to evaluate the role of lithium monitoring. As part of this project we 
would like to learn about factors which affect lithium prescribing, focussing on the views and 
perceptions of consultants on their current practice. To facilitate this we would like to invite 
you to be a part of the project and arrange an interview with Emma Kirkham (the primary 
researcher), of approximately 1 hour with you as a consultant currently working within NSFT. 
You will also receive this invitation via letter. 
 
This work is being conducted as part of a research project and therefore we intend to publish 
the results, albeit in an anonymised format, in a peer-reviewed journal. The data collected will 
be kept in an anonymised format within the School of Pharmacy and all raw data from the 
project will be destroyed within one year of the study’s completion. Relevant approvals have 
been obtained for the project. 
 
Please read the attached participant information sheet and if you are happy to participate 
please reply via email to Emma Kirkham on e.kirkham@uea.ac.uk or 
emma.kirkham@nsft.nhs.uk with the following information: 
 
- Year of qualification   
- Gender  
- Age group: 20-35, 36-50, 51-65, 66+  
- Whether you have worked within mental health in Norfolk or Suffolk for less than one 
year.  
- In the last 10 years have you ever worked for Norfolk and Waveney Mental Health 
Trust? 
- Your speciality e.g. Adult Services, Forensics, Older Age, CAMHS 
- Preferred contact details 
- If possible suitable times/locations for interviews or details for best person to contact 
for this 
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If after two weeks no response has been received we will contact you to confirm whether you 
wish to participate in this project. If at any point you have any questions about the project 
please feel free to contact Emma Kirkham by email or on 01603 591973 and I will endeavour 
to answer them for you. 
 
Thank you in anticipation of your help with the project. 
 
Yours sincerely, 
 
Emma Kirkham      Tim Anderson 
Research Pharmacist   and   Lead Clinical Pharmacist 
School of Pharmacy      Hellesdon Hospital 
University of East Anglia     Norwich,  
Norwich       NR6 5BE  
NR4 7TJ 
 
Attachments (1)      REF NO: _____ 
 
========================================================= 
Miss Emma Kirkham MRPharmS    Tel: 01603 591973 
Research Pharmacist      Mob: 07841702776 
School of Pharmacy      E-mail: e.kirkham@uea.ac.uk 
University of East Anglia     emma.kirkham@nsft.nhs.uk 
Norwich Research Park 
Norwich, NR4 7TJ, UK 
=========================================================
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 Chair: Gary Page 
Chief Executive: Aidan Thomas  
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School of Pharmacy      Pharmacy Department 
University of East Anglia      Hellesdon Hospital 
Norwich        Norwich 
NR4 7TJ       NR6 5BE 
Tel. 01603 591973      Tel. 01603 421480 
 
Dear [Name] 
 
Re: Invite to participate in research - local interviews with consultants to get their 
views and perceptions on the factors affecting lithium prescribing in current practice 
 
You were recently contacted to see if you would like to be involved in the above research 
project being run by the Pharmacy Department in conjunction with the University of East 
Anglia. As yet we have not received any response to our invite and would like to see if you 
are interested in participating. If you have already responded then please ignore this letter.  
 
Please read the enclosed participant information sheet and if you are happy to participate 
please return the expression of interest form using the pre-paid envelope or reply via email to 
Emma Kirkham on e.kirkham@uea.ac.uk or emma.kirkham@nsft.nhs.uk with the following 
information: 
 
- Year of qualification   
 Chair: Gary Page 
Chief Executive: Aidan Thomas  
Trust Headquarters: Hellesdon Hospital, Drayton High Road, Norwich, NR6 5BE 
Tel: 01603 421421    Fax: 01603 421440    www.nsft.nhs.uk 
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- Gender  
- Age group: 20-35, 36-50, 51-65, 66+  
- Whether you have worked within mental health in Norfolk or Suffolk for less than one 
year.  
- In the last 10 years have you ever worked for Norfolk and Waveney Mental Health 
Trust? 
- Your speciality e.g. Adult Services, Forensics, Older Age, CAMHS 
- Preferred contact details 
- If possible suitable times/locations for interviews or details for best person to contact 
for this 
 
If at any point you have any questions about the project please feel free to contact Emma 
Kirkham by email or on 01603 591973 and I will endeavour to answer them for you. 
 
Thank you in anticipation of your help with the project. 
 
Yours sincerely, 
 
Emma Kirkham      Tim Anderson 
Research Pharmacist   and   Lead Clinical Pharmacist 
School of Pharmacy      Hellesdon Hospital 
University of East Anglia     Norwich,  
Norwich       NR6 5BE  
NR4 7TJ 
Enclosures (2)
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Second email
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Version 2, August 2013                                
Subject: Re: Invite to participate in research - local interviews with consultants to get their 
views and perceptions on the factors affecting lithium prescribing in current practice 
__________________________________________________________________________ 
Dear [Name] 
 
You were recently contacted to see if you would like to be involved in the above research 
project being run by the Pharmacy Department in conjunction with the University of East 
Anglia. As yet we have not received any response to our invite and would like to see if you 
are interested in participating. If you have already responded then please ignore this email.  
 
Please read the attached participant information sheet and if you are happy to participate 
please reply via email to Emma Kirkham on e.kirkham@uea.ac.uk or 
emma.kirkham@nsft.nhs.uk with the following information: 
 
- Year of qualification   
- Gender  
- Age group: 20-35, 36-50, 51-65, 66+  
- Whether you have worked within mental health in Norfolk or Suffolk for less than one 
year.  
- In the last 10 years have you ever worked for Norfolk and Waveney Mental Health 
Trust? 
- Your speciality e.g. Adult Services, Forensics, Older Age, CAMHS 
- Preferred contact details 
- If possible suitable times/locations for interviews or details for best person to contact 
for this 
 
If at any point you have any questions about the project please feel free to contact Emma 
Kirkham by email or on 01603 591973 and she will endeavour to answer them for you. 
 
Thank you in anticipation of your help with the project. 
 
Yours sincerely, 
 
 
 241 
Version 2, August 2013                                
Emma Kirkham      Tim Anderson 
Research Pharmacist   and   Lead Clinical Pharmacist 
School of Pharmacy      Hellesdon Hospital 
University of East Anglia     Norwich,  
Norwich       NR6 5BE  
NR4 7TJ 
Attachments (1)      REF NO: _____ 
 
========================================================= 
Miss Emma Kirkham MRPharmS    Tel: 01603 591973 
Research Pharmacist      Mob: 07841702776 
School of Pharmacy      E-mail: e.kirkham@uea.ac.uk 
University of East Anglia     emma.kirkham@nsft.nhs.uk 
Norwich Research Park 
Norwich, NR4 7TJ, UK 
========================================================= 
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Confirmation letter/email
 Chair: Gary Page 
Chief Executive: Aidan Thomas  
Trust Headquarters: Hellesdon Hospital, Drayton High Road, Norwich, NR6 5BE 
Tel: 01603 421421    Fax: 01603 421440    www.nsft.nhs.uk 
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School of Pharmacy      Pharmacy Department 
University of East Anglia      Hellesdon Hospital 
Norwich        Norwich 
NR4 7TJ       NR6 5BE 
Tel. 01603 591973      Tel. 01603 421480 
Dear [Name] 
 
Confirmation of participation in research: local interviews with consultants to get their 
views and perceptions on the factors affecting lithium prescribing in current practice 
 
This letter confirms our arrangements for your involvement in the above project. As previously 
noted your involvement will consist of an interview of approximately one hour in length. 
Refreshments will be provided. 
 
Time: 
 
Location: 
 
If at any point you have any questions about the project please feel free to contact Emma 
Kirkham by email or on 01603 591973 and I will endeavour to answer them for you. 
 
Thank you in anticipation of your help with the project. 
 
Yours sincerely, 
 
Emma Kirkham      Tim Anderson 
Research Pharmacist   and   Lead Clinical Pharmacist 
School of Pharmacy      Hellesdon Hospital 
University of East Anglia     Norwich,  
Norwich       NR6 5BE  
NR4 7TJ  
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Subject: Re: Confirmation of participation in research - local interviews with consultants to 
get their views and perceptions on the factors affecting lithium prescribing in current practice 
__________________________________________________________________________ 
Dear [Name] 
 
This email confirms our arrangements for your involvement in the above project. As 
previously noted your involvement will consist of an interview of approximately one hour in 
length. Refreshments will be provided. 
 
Time: 
 
Location: 
 
If at any point you have any questions about the project please feel free to contact Emma 
Kirkham by email or on 01603 591973 and I will endeavour to answer them for you. 
 
Thank you in anticipation of your help with the project. 
 
Yours sincerely, 
 
Emma Kirkham      Tim Anderson 
Research Pharmacist   and   Lead Clinical Pharmacist 
School of Pharmacy      Hellesdon Hospital 
University of East Anglia     Norwich,  
Norwich       NR6 5BE  
NR4 7TJ 
 
========================================================= 
Miss Emma Kirkham MRPharmS    Tel: 01603 591973 
Research Pharmacist      Mob: 07841702776 
School of Pharmacy      E-mail: e.kirkham@uea.ac.uk 
University of East Anglia     emma.kirkham@nsft.nhs.uk 
Norwich Research Park 
Norwich, NR4 7TJ, UK 
=========================================================
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Regret letter/email 
 
 Chair: Gary Page 
Deputy Chief Executive: Andrew Hopkins 
Trust Headquarters: Hellesdon Hospital, Drayton High Road, Norwich, NR6 5BE 
Tel: 01603 421421    Fax: 01603 421440    www.nsft.nhs.uk 
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School of Pharmacy      Pharmacy Department 
University of East Anglia      Hellesdon Hospital 
Norwich        Norwich 
NR4 7TJ       NR6 5BE 
Tel. 01603 591973      Tel. 01603 421480 
Dear [Name] 
 
Re: Invite to participate in research - local interviews with consultants to get their 
views and perceptions on the factors affecting lithium prescribing in current practice 
 
Thank you for your response agreeing to participate in the above research project. 
Unfortunately at this time we have more participants than needed so we will not need to 
arrange an interview with you at this time. 
 
Once again many thanks for your willingness to participate in this research project. 
 
Yours sincerely, 
 
 
Emma Kirkham       Tim Anderson 
Research Pharmacist   and    Lead Clinical Pharmacist 
School of Pharmacy       Hellesdon Hospuital 
University of East Anglia      Norwich, NR6 5BE 
Norwich, NR4 7TJ  
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Subject: Invite to participate in research - local interviews with consultants to get their views 
and perceptions on the factors affecting lithium prescribing in current practice 
_________________________________________________________________________ 
 
Dear [Name] 
 
Re: Invite to participate in research - local interviews with consultants to get their 
views and perceptions on the factors affecting lithium prescribing in current practice 
 
Thank you for your response agreeing to participate in the above research project. 
Unfortunately at this time we have more participants than needed so we will not need to 
arrange an interview with you at this time. 
 
Once again many thanks for your willingness to participate in this research project. 
 
Yours sincerely, 
 
 
Emma Kirkham      Tim Anderson 
Research Pharmacist   and   Lead Clinical Pharmacist 
School of Pharmacy      Hellesdon Hospital 
University of East Anglia     Norwich 
Norwich       NR6 5BE 
NR4 7TJ 
 
====================================================================== 
Miss Emma Kirkham MRPharmS    Tel: 01603 591973 
Research Pharmacist      Mob: 07841702776 
School of Pharmacy      E-mail: e.kirkham@uea.ac.uk 
University of East Anglia     emma.kirkham@nsft.nhs.uk 
Norwich Research Park 
Norwich, NR4 7TJ, UK 
====================================================================== 
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Factors affecting lithium prescribing: 
views and perceptions of consultants 
on current practice 
 
Interview consent form 
If you wish to take part, please initial each box and complete the details at the bottom of the 
form. 
1. I agree to participate in the above study to investigate my views and 
perceptions of factors affecting lithium prescribing in current practice. 
2. I confirm that I have read and understood the participant information sheet 
dated 12/13, version 3 for the above interview and have had the opportunity 
to ask questions.  
 
3. I am willing to allow the interview to be audio-recorded for the purposes of 
analysis and possible publication. 
 
4. I understand that everything I say will be anonymised and will be kept 
securely at the UEA. 
 
5. I agree to be interviewed and understand that my consent to participate 
can be withdrawn up until the point when the interviews are transcribed and 
analysed. 
 
 
_________________________ _______________________ ____________________________ 
Name of participant   Date    Signature 
 
_________________________ _______________________ ____________________________ 
Name of person taking consent  Date    Signature  
Address of participant: 
_________________________________________________________________________________ 
_________________________________________________________________________________ 
When completed: 1 copy for participant 
1 copy for research team 
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Confidentiality Form between University of East Anglia, Norfolk and Suffolk 
NHS Foundation Trust and [name of transcribing company] 
 
Project title: Factors affecting lithium prescribing: views and perceptions of 
consultants on current practice 
 
Name of researcher: Emma Kirkham 
 
The digital recordings you are transcribing have been collected as part of a research 
project. Digital recordings may contain information of a very personal nature, which 
should be kept confidential and not disclosed to others. Maintaining this confidentiality 
is of utmost importance. 
 
We would like you to agree: 
 
- Not to disclose any information you may hear on the digital recording to 
others 
- When using the digital recording to ensure it cannot be heard by other 
people 
- To show your transcription only to the relevant individual (named above) 
who is involved in the research project. 
 
If you find that anyone speaking on a digital recording is known to you, we would like 
you to stop transcription work on that digital recording immediately and inform the 
person who has commissioned the work (Emma Kirkham). 
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Declaration 
 
I have read the above information and I understand that: 
 
1. I will discuss the content of the digital recording only with the individual(s) involved 
in the research project. 
 
2. I will keep the digital recording in a secure place where it cannot be heard by 
others. 
 
3. I will treat the transcription of the digital recording as confidential information. 
 
4. If the person being interviewed on the digital recordings is known to me I will 
undertake no further transcription work on the digital recording. 
 
 
I (and my team) agree to act according to the above constraints 
 
Your name __________________________     on behalf of [name of transcribing 
company] 
 
Signature __________________________     Date ___________________________ 
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Interview Topic Guide (summary version) 
 
 Introduction and background 
o Aims and objectives of project 
o Area of speciality of participant 
o Provide assurances about confidentiality and timing, and 
confirm consent 
 
 What are you views on lithium as a drug? 
 
 When and for what type of patients would you consider prescribing 
lithium for? 
o Prompts: 
 Process of prescribing 
 Where initiated – outpatient or inpatient 
 
 What influences your choice to prescribe lithium rather than other 
drugs? 
o Prompts: 
 Compliance of patient – patient information 
 Medical history 
 Social history 
 Blood results – what happens if patients go 
toxic/actions taken 
 Monitoring – why important or that looked at 
o …and reasons for not prescribing lithium? – what are the alternatives 
 
 Do you routinely use any treatment guidelines to influence your 
choice of drug? 
 
 Do you think it matters who prescribes/initiates lithium? 
o Prompts: 
 What influences this?  
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 Experience of doctor 
 Experience with lithium 
 
 Conclusion 
o Is there anything you would like to add? 
  
 276 
2
7
6
 
B A Z I R E ,  S .  2 0 1 4 .  R E :  N I C E  B i p o l a r  G u i d e l i n e s  c o m m e n t .  T y p e  t o  B A Z I R E ,  S . 
M
A
C E D O ,  E . ,  Z A N E T T A ,  D .  M .  &  A B D U L K A D E R ,  R .  C .  2 0 1 2 .  L o n g - t e r m  f o l l o w - u p  o f  p a t i e n t s  a f t e r  a c u t e  k i d n e y  i n j u r y :  p a t t e r n s  o f  r e n a l  f u n c t i o n a l  r e c o v e r y .  P l o S  o
2
7
6
 
B A Z I R E ,  S .  2 0 1 4 .  R E :  N I C E  B i p o l a r  G u i d e l i n e s  c o m m e n t .  T y p e  t o  B A Z I R E ,  S . 
M
A
C E D O ,  E . ,  Z A N E T T A ,  D .  M .  &  A B D U L K A D E R ,  R .  C .  2 0 1 2 .  L o n g - t e r m  f o l l o w - u p  o f  p a t i e n t s  a f t e r  a c u t e  k i d n e y  i n j u r y :  p a t t e r n s  o f  r e n a l  f u n c t i o n a l  r e c o v e r y .  P l o S  o
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix Twelve 
  
 277 
 
2
7
7
 
B A Z I R E ,  S .  2 0 1 4 .  R E :  N I C E  B i p o l a r  G u i d e l i n e s  c o m m e n t .  T y p e  t o  B A Z I R E ,  S . 
M
A
C E D O ,  E . ,  Z A N E T T A ,  D .  M .  &  A B D U L K A D E R ,  R .  C .  2 0 1 2 .  L o n g - t e r m  f o l l o w - u p  o f  p a t i e n t s  a f t e r  a c u t e  k i d n e y  i n j u r y :  p a t t e r n s  o f  r e n a l  f u n c t i o n a l  r e c o v e r y .  P l o S  o
2
7
7
 
B A Z I R E ,  S .  2 0 1 4 .  R E :  N I C E  B i p o l a r  G u i d e l i n e s  c o m m e n t .  T y p e  t o  B A Z I R E ,  S . 
M
A
C E D O ,  E . ,  Z A N E T T A ,  D .  M .  &  A B D U L K A D E R ,  R .  C .  2 0 1 2 .  L o n g - t e r m  f o l l o w - u p  o f  p a t i e n t s  a f t e r  a c u t e  k i d n e y  i n j u r y :  p a t t e r n s  o f  r e n a l  f u n c t i o n a l  r e c o v e r y .  P l o S  o
Participant: 7, Location: N, Age/Gender: 51-65/M, Type of practice: CRHTT 
 
Line numbers Raw text Initial code 
10 it’s a challenging drug Challenging drug 
11 it is both quite effective and quite flawed at the same time Effective and flawed 
12 serious side effects Serious side effects 
12-13 if you use lithium continuously you will get renal failure Inevitable renal failure 
22 monitor for routinely Routine monitoring 
23 my understanding of what I have read Read about S/E 
23 that’s what happens if you use it long enough Duration of tx  
24-25 severe enough to mean you have to stop taking it Severity of side effects and 
stop tx 
26 if I needed lithium would I use it myself? Well I’m not sure actually Not use on self 
27-28 if I had an acute condition and use it as a short term medication Use on self as acute/short 
term 
28 tends to be used longer term Long-term tx 
29 I’d also inject personal experience into this because this is how prescribing works Personal experience 
30 what you learn and get taught Teaching and learning 
30 and what you read in scientific literature Read in literature 
31-32 then you also have stuff that your friends say that you meet somewhere you know, you  
professional colleagues you know and that influences  
Friends/colleagues and 
prescribing 
32-33 if they’ve had really good results or whatever Good experiences 
33-35 the first patient I ever prescribed lithium for, who I still remember, developed a complete heart block within a couple 
of days of starting it which is an irreversible side effect of lithium 
Bad 1st experience 
37-38 So after that I didn’t prescribe lithium for another couple of years Stopped prescribing lithium 
38-39 the second patient I prescribed for it then took an overdose of lithium Bad second experience 
41 took quite a large overdose Overdose 
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42-43 it took the ------------- 32 hours to measure their lithium level after being admitted 
for a lithium overdose  
Long time to measure level 
after overdose 
44-45 so these things colour one’s use so I am not a high prescriber of lithium Experiences affect Rxing 
45-47 I do prescribe it sometimes erm it’s most often in the context of continuing someone else’s prescription and less often 
in terms of me initiating it myself 
Continues prescriptions not 
initiate 
48 big advantages are its cheap Cheap = advantage 
48-49 because its subject to monitoring process I suspect that erm the reliability of someone taking it as prescribed is 
probably slightly better  
Monitoring process 
increases reliability of taking 
50-51 because at least psychologically if you know you have blood tests and so on it means you’re more likely to do the 
thing you’re supposed to be doing 
Monitoring process 
increases reliability of taking 
56-57 people with a bipolar disorder and people with severe depression Use for bipolar and severe 
depression 
61-62 people with existing renal damage or thyroid problems, people with perhaps with cardiac problems Factors - not prescribe for 
62-65 I would want to prescribe it for someone who I thought would be reasonably likely to take it and umm you know do 
the tests and and stuff and if I thought someone was unreliable and they wouldn’t do it then I probably wouldn’t 
prescribe it because that’s not going to help anyone 
Reliability of patient taking it 
66-68 Interviewer: so the monitoring and getting those blood tests done (PARTICIPANT 7: Yeah) is something that quite 
important 
PARTICIPANT 7: yeah sure (INTERVIEWER: you) I mean you don’t want to waste everyone’s time 
Monitoring important 
69-70 it’s more damaging almost as far as I know with almost any psychotropic medication to chop and change from 
medication to medication than it is to you know stick on one medication 
More damaging to chop and 
change 
70-72 so someone who that you know is not going to use it properly because of whatever factors then that would be less 
likely 
Reliability of patient taking it 
72 but then I think other factors I don’t know err you know polypharmacy or something Factors - not prescribe for 
73 if there was an increased risk of renal damage or drugs that would interact in some way Factors - not prescribe for 
76-79 Do you think the speed at which people respond to maybe a lithium level or getting that test done is something that’s 
important? 
Speed of response to levels 
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PARTICIPANT 7: umm well in that patients case it is important because the person’s taken an potentially lethal 
overdose of lithium 
79-80 in order to treat it they need to have some idea of what the toxicity level Toxicity levels and overdose 
80-82 so if the level’s normal despite them having allegedly taken 35 tablets or something you’re going to treat it very 
differently to if you do the level and its 25 point something you know  
Treat overdose on levels 
83-84 how closely you support and scrutinise to monitor the patient will be very influenced by what the result is Treat overdose on levels 
88 lithium’s got a relatively narrow therapeutic window Narrow therapeutic range 
89-90 I was at a conference recently where people were talking about information on lithium People talking – conferences 
91-92 he was talking about the results from the lithium database Results from database 
93-96 having a level over around point eight was about right and that more than that was more toxic which is interesting 
because for instance in America its accepted therapeutic level might even be 1 or 1.2 
Intercontinental differences 
in practice 
97 it’s within the realm of acceptable practice Acceptable practice 
99-102 you want to start the person on it and then because individuals metabolise it differently you want to stabilise them 
and to do that you need to do a series of tests and then at some point they’ll get to kind of equilibrium state and then 
you’ll do tests from time to time just to check that nothing’s changed 
Stabilise patient, reduce 
monitoring 
107-109 I work in the acute service which is defined as people who would normally be admitted to hospital but they are 
treated either in hospital or in a home treatment service 
Acute service 
111-113 technically I’m supposed to see people out of hospital but because I’m part of the acute service in fact I see both 
because I cover for colleagues who work on the wards  
See I/P and O/P 
119 in hospital everything that happens is usually more symbolically important In hospital – more important 
120-121 because you’re in hospital and its more dramatic and you know psychologically you know it is just more important In hospital – more important 
123-125 INTERVIEWER: so it wouldn’t influence your choice to choose to prescribe lithium or another drug if they were an 
inpatient compared to if they were an outpatients or under the home treatment team 
PARTICIPANT 7: not hugely, not by itself no  
I/P or O/P alone not 
influence choice 
125-127 I mean you can get someone who’s an inpatient who’s completely unreliable and someone who’s at home who is 
completely reliable  
Reliability of patient taking it 
128-129 INTERVIEWER: so it’s much more based on each patient individually? Based on individual patients 
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PARTICIPANT 7: yeah 
132-135 there’s a symbolism you know err, consultants…errr……, consultants are perceived as having a certain status now that 
might be a rubbish status for some people and a high status for others but erm they’re perceived in that way and 
essentially patients view consultants as the person who will have the answer you know 
Symbolism of consultants 
135-137 so if a consultant prescribes it I guess its symbolically going to be more important or more powerful than if someone 
else does 
More important if consultant 
prescribes 
139-140 you just have to think of one’s own experience or one’s families experience if my mother in law’s unwell then I’d like 
her to see the consultant...it’s just how people… 
Personal experience 
145-147 I think patients generally speaking, not always, but generally speaking want to have information about the treatments Patients want information 
147-148 erm I think that’s perfectly appropriate a lot of them research it themselves now Patients self-research 
148-149 some will use the doctors or nurses or pharmacists or whatever it is to to get information Sources of information 
149-151 I think you know it’s it’s it should be a kind of human right in a sense that you should have as much information as you 
want about it 
As much information as 
want 
152-153 how much the information do patients actually understand is a completely different question and people tend to get 
what they want from the information 
Understanding and 
interpreting information 
155-156 you know, people see what they want to see erm and that happens to everybody cause we’re all coloured by our life 
experience 
Understanding and 
interpreting information 
158-160 how they’ve perceived it is that it is a completely hit and miss things you know errrrr what they will take from the 
information is not necessarily what I would take from it 
Understanding and 
interpreting information 
160-161 yes it’s a really good thing to give information and at the same time yes the information’s frequently misunderstood Understanding and 
interpreting information 
161-163 it’s kind of hard really hard to get that right so you give people all the information they want and in a way that they 
really do understand it  
Understanding and 
interpreting information 
163-164 so I think what happens at the moment is people effectively have the ability to get information overload Information overload 
164-165 they can use the internet and so on even if the doctor doesn’t want to talk to them they can just look it up on google Sources of information 
166-167 that they have information overload and they don’t necessarily have the skills or the training to interpret all 
information 
Information overload 
Understanding and 
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interpreting information 
170-173 medico-legal because if you prescribe something and you fail to inform the patient of risk X,Y,Z and they then develop 
a complete heart block or whatever in theory then they can sue you because you didn’t give them the information  
Medico-legal issues – 
protecting self 
173 informed consent Informed consent 
173-174 so it’s very hard and it’s even more hard when you know that they don’t understand the information necessarily Understanding and 
interpreting information 
177 I think people understand more than they used to Increased understanding 
178 because they can look it up at their leisure on google Sources of information 
179-180 I think it’s really positive that people have the information can use it Provision of information 
182-184 I just think we need to acknowledge that having all the information doesn’t necessarily mean the patient becomes an 
expert on it and has a balanced view on it 
Understanding and 
interpreting information 
188-189 you can read about lithium from someone else and have a different view and it’s all in the scientific literature Differing views in literature 
193-194 do I practice broadly in accordance with treatment guidelines I think yes, erm but do I consciously try and do it as in 
step one, step two…probably not erm 
Broadly follow guidelines 
194-196 but that’s not because I’m opposed to the guidelines it’s because I’m hopefully good at what I do so I do that 
automatically without having to check it 
Experience 
196-198 when I’m not following the guideline it would be because there are particular circumstances for that patient that 
justify a deviation from the guideline cause the guideline is a guideline it’s not you know … 
Justify deviation 
201-208 the guidelines I’d use myself would be NICE guidelines erm …errr in terms of prescribing I would look at ---- ---‘s book 
[PDD], I would look at the Maudsley book erm …every now and then I’ve actually got err have I got it here yes I have 
I’ve got a Martindale[…]other guidelines I’d look at less often so for instance in Scotland they have the SIGN, S.I.G.N a 
whole variety of international ones erm but I would tend to look at more guidelines if there was a particular problem I 
wasn’t sure about 
Guidelines 
210-211 there are loads of guidelines so it’s not possible to practice in accordance with the guidance because they all say 
slightly different things so 
Difference in guidelines 
216 I think it should be according to the competence of the person doing it Initiation on competence 
219-223 so if someone works in primary care but they are competent to do it because they have had the relevant training and Competence and experience 
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experience then that’s great and if it’s in secondary care and you walk in here as a patient and the first person you see 
is my junior doctor who started yesterday and has never seen a psychiatric patient then you know so the setting isn’t 
as important as the competence  
- initiation 
229-230 in the crisis team we often work quite closely with GPs so they might prescribe while we’re managing the patient Primary care prescribe, 
secondary care manage 
230-231 for example sometimes we do the prescribing sometimes they do it just depends Setting for prescribing varies 
232-234 there are other instances that I’m aware of where we might prescribe a certain drug and GPs wont prescribe it erm or 
even where we’re told its double red whatever that means as though its illegal 
Conflict over certain drugs 
236-237 there are case where GPs will refuse to continue medication because they claim they haven’t had the training or 
something like that 
Training issue in primary 
care 
241-243 but I think that if you’re a GP you should give yourself the training, get the training, you know if you’re your patients 
need a certain drug you should make yourself aware of what you need to be aware of 
Doctors take responsibility 
for relevant training 
248-250 lithium because of the toxicity issue and the narrow therapeutic index and so on that’s window it’s erm really useful 
to have a system in place that helps make managing all of that easier 
Systems to manage 
monitoring 
251-252 and I’m very keen on, in medicine, using systems to improve safety rather than relying on the individual person being 
able to remember something  
Systems to improve safety 
253-256 I so I think the lithium database has been a fantastic thing to have happened and I think its hugely improved the 
quality of care and I suspect that’s measurable and demonstrable possibly even including the number of side effects 
and so on that we have seen I would expect has probably reduced as a result of the database. 
Database improved quality 
of care 
258-259 INTERVIEWER: So systems like that you think help improve quality and... 
PARTICIPANT 7: Yep sure they make it easier for me to do my job properly 
Systems help do job properly 
261-262 I think that erm it’s an interesting observation about whether medications are promoted or not and how that affects 
their use and so on 
Promotion or lack of meds 
265-268 I think that’s an interesting question because what should society do about the drugs that are not marketed but that 
should be used, should the government have a responsibility to promote them you know and if so how?  
Responsibility to promote all 
drugs 
 
 
